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Abstract
Latent tuberculosis infection (LTBI), a product of exposure to Mycobacterium
tuberculosis (Mtb), can lead to tuberculosis (TB) and further cause death if untreated.
Fortunately, TB can be prevented with LTBI treatment. Targeting newly arrived visa
holders for LTBI screening and treatment is an effective strategy for decreasing future
TB burden. However, LTBI treatment completion rates are low, and researches had
primarily focused on the nonrural U.S. setting. This study, using a retrospective cohort
design under the epidemiological disease triangle framework evaluated (a) the treatment
completion rates for 2 cohorts of visa holders (i.e., immigrants, N = 31 and refugees, N =
109) with LTBI residing in the rural setting using Pearson’s chi-square analysis, (b) mean
times on LTBI treatment using Kaplan-Meier survival analysis, and (c) predictors of time
on treatment using Cox proportional hazard regression. Study findings revealed
immigrants had higher treatment noncompletion rates over refugees (25.6% and 19.3%).
The potential risk factors for noncompletion were being older than 24 years of age (HR =
0.18, p = 0.01). There were also significant interactions for the time on treatment between
(a) being < 25 years old and visa type (HR = 0.23, p = 0.04), (b) being < 25 years and
traveling longer (miles) to treatment facility (HR = 0.25, p = 0.03), or (c) being < 25
years and Mtb blood-test positive (HR = 0.35, p = 0.05). These findings suggest
interventions targeting visa holders older than 24 years may increase the rate of treatment
completion and decrease the future TB cases. Therefore, the study promotes social
change by providing actionable, rural-population-specific information for the
prioritization of visa holders at increased risk of experiencing LTBI treatment
noncompletion.
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Chapter 1: Introduction to the Study
Introduction
Tuberculosis (TB), an infectious disease caused by the bacteria Mycobacterium
tuberculosis (Mtb), is most commonly associated with the lungs but can be found in other
parts of the body causing long term sequellae such as airway constriction, neural deficits,
infertility, or death (Shah & Reed, 2014). Hypothesized to have killed more persons than
any other microbe by causing tuberculosis, Mtb has long been a burden to humanity
(Daniel, 2006; Hartman-Adams, Clark, & Juckett, 2014; World Health Organization
[WHO], 2016a). Although infection with Mtb exists on a spectrum of noninfectious
latency to active disease, TB remains a leading global source of morbidity and mortality,
joining the human immunodeficiency virus (HIV) in 2014 as the top cause of death
despite its curableness (Nahid et al., 2016; Shah & Reed, 2014; WHO, 2015).
It is estimated that nearly one quarter to one third of the global population is
asymptomatically infected with Mtb with an additional 1% newly infected each year
(Campbell, Chen et al., 2015; Cardona, 2010; Houben & Dodd, 2016; Hartman-Adams et
al., 2014; Moghaddam, Moghadam, Khademi, Bahreini, & Saeidi, 2016; Subedi et al.,
2015; WHO, 2016a). Active, transmissible TB disease develops in 2% to 10% of persons
infected with Mtb who fail to receive and complete preventive treatment, while others
remain latently infected or naturally clear the infection (Campbell, Chen et al., 2015;
Cardona, 2010; Houben & Dodd, 2016; Kahwati, Feltner, & Halpern, 2016; Lewinsohn
et al., 2016; Raviglione & Sulis, 2016; Subedi et al., 2015; WHO, 2016a). In 2015, over
10 million incident cases of active TB were identified, with India, Indonesia, China,
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Nigeria, Pakistan, and South Africa representing 60% of the global burden (WHO,
2016a). Annually, more than one million TB related deaths are recorded globally
resulting in a mortality rate of 19 per 100,000 persons (Subedi et al., 2015). An estimated
three million persons annually with infectious TB are never reported to officials and thus
contribute significantly, yet silently, to the global spread of disease (Kamal, Suleman,
Raza, Abassi, & Ayub, 2016; Raviglione & Sulis, 2016;).
Latent tuberculosis infection (LTBI), as a noncommunicable form of TB, is
readily cured with up to 9 months of treatment but can reactivate to overcome the host
immune system at an unpredictable point in time when left untreated. This reactivation
can cause individual harm and spread disease to others (Hartman-Adams et al., 2014;
Kahwati et al., 2016; Lewinsohn et al., 2016; Moghaddam et al., 2016). In the United
States, foreign-born new migratory arrivals from TB endemic regions are at increased
risk of being infected with Mtb and account for a high proportion of persons with active
disease annually, which is thought to be the product of reactivation from exposure before
migration (Dara, Gushulak, Posey, Zellweger, & Migliori, 2013). Often, these migrants at
greatest risk of having LTBI hale from countries with poor sanitation, from congregate
housing settings, from having poor housing in general, or possibly from temporary,
overcrowded relocation camps that increase the likelihood of spread (Lim, Jarand, Field,
& Fisher, 2016; Yun et al., 2015). If these persons migrate while infected with the Mtb
pathogen, reactivation and spread years later may sustain the cycle of disease
transmission. Research from the high-incidence and urban TB setting reveal that treating
LTBI before reactivation can be a successful control strategy, can be the most cost-
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effective strategy for preventing active TB disease, and for potentially reducing future TB
rates (Association of State and Territorial Health Official, 2015; Centers for Disease
Control and Prevention [CDC], 2013; Nuzzo, Golub, Chaulk, & Shah, 2015). Ensuring
high rates of LTBI treatment completion is now regarded as a critical component to
preventing future cases of TB disease and decreasing global morbidity and mortality.
A more comprehensive understanding of the epidemiology of treatment
completion for foreign-born persons diagnosed with LTBI as well as the factors
associated with treatment completion or noncompletion may assist TB control programs
to more appropriately deploy resources to improve treatment completion rates and
subsequently improve population health. Many of the identified predictors of treatment
completion from studies in the international, high-incidence, and urban TB setting have
been inconsistent, suggesting that geography and other regionally specific characteristics
may play a role in influencing completion rates (Johnson et al., 2016; Malangu &
Yamutamba, 2016). These inconsistencies further highlight the need for research across
all settings with particular emphasis on the rural setting where TB resources may be
scarce, as this setting is significantly underrepresented in published literature. Treatment
completion research in the rural setting may better position public health institutions to
organize interventions to improve completion rates in the most appropriate population
and in the most effective manner, leading to a reduction in future disease burden and
improving morbidity and mortality.
The contents of the following chapter outline the retrospective cohort study that
aimed to determine LTBI treatment completion rates in the rural Idaho-based visa-
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holding population as well as the potential predicting variables of completion or
noncompletion. This chapter includes a brief description of TB and LTBI treatment, the
known epidemiology of TB and LTBI in Idaho, the significance of this work for the rural
setting, the assumptions, and the limitations of this study. Information submitted to the
Idaho state TB Program from postmigration health evaluations on refugees, immigrants,
and other visa holders completing LTBI therapy between 2011 and 2016 were analyzed
to determine completion rates. This data was also used to determine at what point after
initiating treatment visa holders were likely to fail and what factors were predictive of
completion or noncompletion. The results of this study have the potential to influence
public health practice in the rural environment by documenting LTBI treatment
completion rates in the population most influenced by TB in the United States. Also, this
research highlighted variables that could become targets of interventions to improve
overall LTBI treatment completion rates in the rural foreign-born population.
Background of Tuberculosis and its Management
Mycobacterium tuberculosis is thought to have coevolved with humans prior to
migration from the African continent and is now found globally (Esmail, Barry, Young,
& Wilkinson, 2014). Historians suspect Mtb evolved from a low-pathogenic form with
prolonged latency to the more pathogenic form currently challenging public health
(Esmail et al., 2014). Persons at elevated risk of having LTBI include recent migrants
from high-incident TB settings, persons currently or formally homeless, persons who live
or work in congregate settings, and health care workers (Bibbins-Domingo et al., 2016;
Fox, Dobler, Marais, & Denholm, 2016; Oren et al., 2016; Raviglione & Sulis, 2016;
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Severi, Maguire, Ihekweazu, Bickler, & Abubakar, 2016). If undetected and untreated,
persons with LTBI are at risk of developing active TB disease (Pareek, Greenaway,
Noori, Munoz, & Zennet, 2016). The progression from latency to active TB has the
potential to cause individual death, requires a significant amount of health care and
public-sector resources to prevent transmission and ensure disease is cured, and can also
leave long term lung tissue damage or other more severe consequences. Reducing the risk
of reactivation by treating LTBI can prevent death, saves health care and public
resources, and ensures those infected suffer minimal to no lifelong penalties from disease.
Assuming up to 10% of those infected with Mtb develop active disease, the
current untreated LTBI reservoir in the United States could produce an additional 1.3
million cases of active TB in the future (CDC, 2013; Diel, Loddenkemper, & Nienhaus,
2016; Houben & Dodd, 2016; LoBue & Mermin, 2017). Additionally, and on average,
three persons could be infected per each reported active case annually, adding to the 11 to
13 million estimated to already be latently infected and establishing a cycle of disease
transmission that could be disrupted using preventive LTBI therapy (CDC, 2013; Houben
& Dodd, 2016; Diel et al., 2016). With recent migrants being at high risk for exposure to
Mtb and for having reactivation within 2 to 5 years after relocating, the consistent flow of
new foreign-born arrivals (Migration Policy Institute, 2015) further supports the need to
rapidly ensure the complete treatment of the infected at high rates (Pareek et al., 2016).
Treatment Regimens
Tuberculosis disease. The prompt recognition of signs and symptoms consistent
with TB disease minimizes transmission and leads to more rapid cure of the individual
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via treatment (Nahid et al., 2016). The combination of rifampin (RIF), isoniazid (INH),
pyrazinamide, and ethambutol, collectively referred to as RIPE, are recommended for
administration in one of four different regimens and over two distinct phases for at least 6
months in persons with active TB (CDC, 2013b; Nahid et al., 2016). For patients with
newly diagnosed pulmonary tuberculosis, the preferred regimen consists of daily RIPE
for a duration of 8 weeks or 56 doses (intensive phase) followed by RIF and INH for an
additional 18 weeks or 126 doses (continuation phase) (Nahid et al., 2016). In most parts
of the world, including Idaho, this regimen is delivered under directly observed therapy
(DOT), or under the supervision of the managing provider or public health official to
improve compliance and ensure no adverse events take place. Under most circumstances,
treatment of active TB spans 6 months; however, complicated disease or drug resistance
can extend the treatment time drastically (Nahid et al., 2016).
Latent tuberculosis infection. The treatment of LTBI has generally spanned 9
consecutive months; however, shorter regimens have more recently been developed
(CDC, 2013a). Presently, 6 to 9 months of daily or twice weekly INH is the preferred
treatment regimen as clinical trials have demonstrated this regimen to be the most
efficacious (CDC, 2013a). Due to low adherence rates, the use of 4 months of daily RIF
has also become popular (CDC, 2013a). This regimen is also appropriate for persons
exposed to INH-resistant TB but cannot be used with HIV-positive persons. The most
recent treatment advancement involves an intermittent combination dose of weekly INH
and rifapentine (RPT) spanning 12 weeks. Shown to be noninferior to 6 or 9 months of
INH, the INH and RPT combination is the shortest available regimen and may contribute
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to improved overall treatment completion rates once widely used (CDC, 2013a; Stagg et
al., 2014). Most frequently used to treat recently arrived visa holders in the United States
with LTBI, recent known contacts to someone with TB disease infected with Mtb, and
persons in congregate settings with LTBI, the more standardized, targeted use of LTBI
treatment is expanding in the United States as a strategy to prevent future cases of active
TB (Bibbins-Domingo et al., 2016).
Idaho Epidemiology
Tuberculosis. In Idaho, reflecting national trends, rates of TB disease have been
on a steady decline. With an incidence rate of 1.1 per 100,000 persons in 2016, rates of
TB in Idaho are consistently below the national rate of 3.0 per 100,000 persons (Idaho
Department of Health and Welfare [IDHW], 2016). Those less than 5 years of age
diagnosed with TB in Idaho have a 5-year average incidence rate for the period 2012 to
2016 of 1.44 per 100,000 persons, which is higher than adults at 0.75 per 100,000 persons
(CDC, 2017a). Comparable to national trends, men in Idaho are diagnosed with TB
disease twice as often as their female counterparts. The foreign-born are
disproportionately impacted by TB in Idaho with a 5-year average (2012 to 2016)
incidence rate of 9.5 per 100,000 persons, far exceeding that of the U.S.-born 5-year
average (2012 to 2016) rate at 0.26 per 100,000 persons (IDHW, 2016). Of these foreignborn persons with TB, from 2012-2016, one quarter were refugees, over one tenth were
immigrants, and nearly two tenths were other visa holders with the total foreign-born
representing 73% of Idaho’s TB burden (CDC, 2017a; IDHW, 2016).
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Latent tuberculosis infection. Although a precursor to TB disease and a marker
for future burden, rates of LTBI in both the U.S.-born and foreign-born in Idaho are not
known, although estimates can be drawn. Using the prevalence of LTBI estimated from
tuberculin-skin-test (TST) and interferon gamma release assay (IGRA) positivity reported
by Miramontes et al. (2015) in the analysis of the 2011-2012 National Health and
Nutrition Examination Survey, over 16,400 foreign-born persons in Idaho may be
infected with Mtb. Although the foreign-born represent a small fraction of the overall
Idaho population, infection is likely concentrated in this high-risk group, with many
being a current or former visa holder. Although not directly reported on for the foreignborn in Idaho, visa holders are likely at heightened risk of being infected with LTBI if
they have migrated from a region with high TB burden, have resided in a high-risk
congregate setting such as a shelter or correctional facility, or have had known recent
exposure to TB (Bibbins-Domingo et al., 2016; Lewinsohn et al., 2016). Additionally,
with the foreign-born being at higher risk of progression from infection to disease within
2 to 5 years after arrival, targeting visa holders in Idaho for prophylactic LTBI treatment
upon arrival may reduce future active TB burden (Lewinsohn et al., 2016).
Patient management. Persons suspected of having or diagnosed with active TB
should promptly be placed on four-drug therapy. Generally, once identified, persons
suspected of having or diagnosed with TB are assigned a TB case manager, often from
the public sector. These case managers are responsible for ensuring transmission is
controlled, contact investigations are carried out, treatment is adhered to, and the patient
is free from adverse medication events. From 2012 to 2016, persons with TB reported to
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Idaho public health officials initiated treatment within 7 days of being suspected of
having disease or being diagnosed with disease 93.2% of the time (CDC, 2017a). This
remains very close to the national target of 95% (CDC, 2017b). Furthermore, of persons
initiating TB treatment during this time, 91% complete treatment within 12 months
(CDC, 2017b). These high rates of treatment initiation and completion for active TB are
critical to preventing transmission and protecting the population’s health.
Contact tracing. Identifying persons exposed to Mtb is a core TB control
function. This activity assists in the identification of persons potentially infected after
exposure and can assist with the promotion of preventive treatment initiation. In Idaho,
only persons with infectious TB disease (e.g., pulmonary or laryngeal disease, acid-fast
bacilli positive lab results) receive contact investigations. Children under the age of 5 also
receive a type of contact investigation, termed a source case investigation, to identify
their source of exposure. Contact investigations initially focus on the immediate
household and expand until all potential contacts have been identified, notified, and
offered testing. Identified contacts are prioritized for follow-up by proximity to the index
during exposure, age (with emphasis being given to those less than 5 years), and the
presence of underlying medical conditions (Taylor, 2005). These contacts are offered
testing and, if infected, LTBI treatment at no cost. In Idaho, from 2012 to 2016, 100% of
TB cases reported to public health officials had contacts elicited.
LTBI treatment completion in contacts. Known contacts to infectious TB are
given special attention in United States as these persons were likely infected within U.S.
borders. Aiming to minimize transmission within the United States, information about
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contacts to persons with infectious TB is gathered by local public health officials and
aggregate treatment completion data are reported to the CDC. When a contact to an
infectious TB case is identified and is diagnosed with LTBI, preventive treatment is
recommended to ensure the contact does not develop future transmissible disease (Taylor,
2005). From 2012 to 2016, 441 contacts to persons with infectious TB were identified by
public health officials in Idaho (CDC, 2017a). Of those, 10% were found to have LTBI
with less than 48% successfully completing treatment (CDC, 2017a). This low rate of
treatment completion in identified contacts indicates that a select number of infected
persons known to public health officials may be at continued risk of developing active
disease. In the resource limited setting, the small number of persons not completing LTBI
treatment completion after being involved in a contact investigation may be deprioritized
to the much larger pool of foreign-born persons entering jurisdictions as these individuals
are more likely to accept treatment. During this same 2012-2016 time period, 5,030 visa
holders arrived in Idaho representing a much higher potential pool of preventive LTBI
treatment candidates. Additionally, with community transmission from a U.S.-born case
being rare in Idaho, many of the contacts identified are members of the foreign-born
population, further highlighting the need to prioritize treatment completion in this group.
Treatment Completion
Completion rates for persons diagnosed with active TB disease globally and in the
United States are generally higher than those of persons diagnosed with LTBI (CDC,
2016a; WHO, 2016a). Worldwide in 2014, 83% of persons prescribed RIPE for active
TB disease completed therapy (WHO, 2016a) compared to nearly 90% in the United
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States (CDC, 2016a). The developed TB infrastructure in the United States promotes
treatment completion as a priority strategy for reducing exposures and moving the
country toward TB elimination. Additionally, the labor-intensive DOT strategies
deployed by jurisdictions in the United States contribute significantly to the overall
treatment completion success rate. In 2015, 92.1% of persons in the United States
diagnosed with TB completed therapy under DOT (CDC, 2016a).
Successful completion of LTBI treatment, under most circumstances, cures the
infected individual and prevents the development of active disease, can prevent future
active TB complications and hospitalizations, and can improve long term tuberculosis
morbidity and mortality (Denholm & McBryde, 2010; Nuzzo et al., 2015; Sandgren et al.,
2016). However, LTBI treatment completion rates in the urban, high-incidence, or
resource-rich setting in the United States reportedly range from 24% to over 90% (Cook,
Maldonado, Yarnell, & Holbert, 2006; Spyridis et al., 2007; Young, Wessolossky, Ellis,
Kaminski, & Daly, 2009). In specific populations, like those recently exposed to Mtb, the
homeless, and IV drug users, completion rates vary but are frequently low. There are no
published data on the treatment completion rates in rural, low-incidence settings with
large immigrant populations, such as in Idaho. Treatment completion rates must remain
consistently high in all groups and improve annually to move the United States toward
elimination of TB risk, a task that requires a more comprehensive analysis of completion
and noncompletion trends (Masini et al., 2016) from settings beyond the urban and highincidence locales.
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The U.S. foreign-born person typically achieves LTBI treatment completion rates
less than the national elimination target of 85% (Sandgren et al., 2016). Presently, some
research outlining factors associated with LTBI treatment noncompletion in U.S. foreignborn persons exists; however, study settings are limited to the urban, high-incidence,
often TB resource-robust settings, leaving rural TB control programs to extrapolate
findings to their settings (Cegolon et al., 2010; Codecasa et al., 2013; Coly & Morisky,
2004; Jiménez-Fuentes, de Souza-Galvao, Mila Augé, Solsona, Peiró, & Altet-Gómez,
2013; Li, Munsiff, Taratino, & Dorsinville, 2009; Stennis, Burzynski, Herbert, Nilsen, &
Macaraig, 2016). This extrapolation may be a dangerous practice leading to assumptions
that influence the distribution of scarce resources to an inaccurate target. With the
prevention of reactivated TB through the treatment of LTBI becoming a highly favorable
TB control strategy, a better understanding of the epidemiology of LTBI in every setting
is needed. In the rural setting, where refugees, immigrants, and other visa holders may
relocate and in whom LTBI and TB disease may be concentrated, the scarcity of TB
resources likely indicates that recommendations from urban, high-incidence settings may
be only tangentially relatable. By studying the LTBI treatment completion rates in the
rural low-incidence setting, appropriately tailored recommendations for ensuring
completion can be made.
Problem Statement
Since 1992, rates of TB in the United States have been on a steady decline.
However, recent year-to-year decreases have begun to slow (CDC, 2015a; Miramontes et
al., 2015; Salinas et al., 2016). Although well below the over 26,000 cases reported in
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1992 at the height of the TB resurgence in the United States, the 9,557 cases reported in
2015 represent a 1.6% increase from the previous reporting year (CDC, 2016a). There
must be strong efforts to understand the epidemiology of LTBI and preventive treatment
completion trends in high-risk populations as these individuals act as a future reservoir
for transmissible disease and contribute to the slowing of progress toward TB elimination
(Salinas et al., 2016). Preventive treatment is the most cost-effective control strategy for
low-incidence countries for averting future TB disease with some jurisdictions estimating
that nearly 40% of cases of active TB are preventable (Blount et al., 2016; Campbell,
Marra, Cook, & Johnston, 2014; CDC, 2013; Varkey, Jerath, Bagniewski, & Lesnick,
2007;). Hirsch-Moverman, Daftary, Franks, and Colson (2008) estimated that the
291,000 to 433,000 persons treated for LTBI in 2002 prevented 4,000 to 11,000 future
cases of TB. High rates of completion of preventive therapy have the potential to reduce
overall health care costs associated with TB control, improve immediate and future
individual health outcomes, and dampen the potential future spread of drug-resistant
strains of Mtb (Hirsch-Moverman et al., 2008).
Review of U.S. immigration surveillance data consistently indicates that a clear
majority of the reported TB cases in the United States stem from reactivation in foreignborn persons. This reactivation frequently occurs within 2 to 5 years of entering the
country after overseas exposure (Menzies, Winston, Holtz, Cain, & Mac Kenzie, 2010;
Campbell, Chen et al., 2015; CDC, 2016a; Houben & Dodd, 2016). The increasingly
important role foreign-born persons play in influencing TB trends in the United States
indicates that this group should be a target of interventions that aim to increase LTBI
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detection, treatment, and completion (CDC, 2013; CDC, 2016a). Although national TB
control targets aim for 85% LTBI preventive treatment completion rates for foreign-born
persons to reduce future rates of reactivation, this threshold is inconsistently met (HirschMoverman et al., 2008). With LTBI treatment initiation rates below 70% for refugees and
immigrants and completion rates below 55% nationally (CDC, 2016b), a significant pool
of potential future reactivated cases of TB exists. In Idaho, a state that resettles more
refugees per year than the 26 per 100,000 national average, foreign-born persons account
for more than 65% of the reported TB cases (CDC, 2016b; Radford & Connor, 2016).
Annually, a variable number of Idaho-arriving refugees, immigrants, and other permanent
visa holders are diagnosed with LTBI, but it is unknown of those initiating therapy how
many will complete prescribed regimens (CDC, 2016b). The undescribed LTBI treatment
completion rates in Idaho may indicate there exists a large pool of persons at risk of
experiencing reactivated TB who could spread disease to others and require costly health
care interventions to address future advanced disease. It is unknown what factors may
contribute to rates of completion or noncompletion in this rural setting.
Some published literature from the international, urban, and high-incidence TB
settings inconsistently indicate a variety of host, environmental, and agent factors
influence treatment completion rates for persons with LTBI (Campbell, Chen et al., 2015;
Hirsch-Moverman et al., 2008; Johnson et al., 2016; Parsyan, Saukkonen, Barry,
Sharnprapai, & Horsburgh, 2007; Sandgren et al., 2016;). What remains to be studied are
the trends in treatment completion in the rural setting and what potential interactive host,
agent, and environmental factors may be associated with treatment completion or
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noncompletion. These invariable research findings highlight the importance that
geographical setting may have on visa holder LTBI treatment completion rates, but the
limited settings in which the epidemiology of LTBI completion rates has been studied do
not ensure generalization. In Idaho, where geography can pose a significant barrier to
accessing the limited TB resources, TB control program metrics aim for a LTBI treatment
completion rate at or above the national 2020 target of 85% for persons initiating LTBI
therapy (CDC, 2015b; CDC, 2016b), but the mean duration Idaho visa holders actually
remain on therapy is unknown and may be critical to recommending when to intervene to
improve completion. Understanding LTBI treatment completion rates in Idaho may also
assist with identifying when visa holders are at greatest risk for not completing therapy
(Vozoris & Batt, 2016). This gap in knowledge potentially prevents reductions to future
TB-related morbidity and mortality in the rural setting (Li et al., 2009).
Studies are needed in the low-incidence rural setting to allow TB control
programs serving high-risk populations in this landscape to identify the factors associated
with treatment completion or noncompletion. Findings from such studies may promote
the more appropriate use of interventions, considering the limited resources available.
The Idaho State Tuberculosis Program is the entity responsible for coordinating and
reporting on the medical evaluations of new foreign-born arrivals, so using data gathered
and submitted to the program on refugees, immigrants, and other permanent visa holders
requiring follow-up for medical conditions including TB and LTBI, the epidemiology of
treatment completion for LTBI in this population can be better understood and a response
appropriately tailored (IDHW, 2016; Lönnroth et al., 2015).
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Purpose of the Study
If high LTBI treatment completion rates have the potential to reduce future
disease burden and improve health, current research from the high-incidence and urban
setting may not be adequate to guide the development of programs to improve
completion rate interventions in the rural setting. The purpose of this study was to
examine in depth the LTBI treatment completion and noncompletion rates in Idaho visa
holders diagnosed with LTBI and to determine what factors were associated with
treatment completion or noncompletion using time-to-event-based analytic techniques. A
retrospective cohort was used to address the current gap in what is known about LTBI
treatment completion and noncompletion in the rural U.S. setting. Event-based analysis
was essential in determining how many months Idaho visa holders with LTBI remained
on therapy, the probability that visa holders experienced the event (e.g., treatment
noncompletion), as well as in determining which covariates were potentially associated
with the outcome of interest. This analysis was particularly useful for identifying those
potential covariates that may be host-, environment-, or agent-specific. Published
research findings from the urban, high-incidence TB setting inconsistently indicate host
factors such as age, gender, and country of origin, and environmental factors such as area
of resettlement, influence treatment completion rates for persons with LTBI (HirschMoverman et al., 2008; Sandgren et al., 2016). This research was essential for exploring
whether these covariates consistently influence treatment completion in the rural setting,
which is a phenomenon currently rarely explored in the United States and never explored
in Idaho.
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Research Questions and Hypotheses
The main research questions of this study were designed to explore the LTBI
treatment completion rate in Idaho refugees, immigrants, and other visa holders and what
host (i.e., gender, age, country of origin, smoking status, race/ethnicity), environment
(i.e., distance to the health department/TB clinic and area of resettlement in Idaho [urban
vs. rural]), and agent (i.e., TST or IGRA positivity) factors may be predictive of time on
treatment until completion or noncompletion. The specific research questions for this
study are outlined below.
RQ1: Is visa type (refugee, immigrant, parolee, asylee, or fiancé) associated with
LTBI treatment completion among permanent visa holders initiating LTBI
treatment in Idaho?
H01: There is no association between visa type and LTBI treatment
completion among permanent visa holders initiating LTBI treatment in Idaho.
Ha1: There is an association between visa type and LTBI treatment
completion among permanent visa holders initiating LTBI treatment in Idaho.
RQ2: Is the mean time distribution to last treatment for LTBI between permanent
visa holders initiating LTBI treatment in Idaho significantly different?
H02: The mean time distribution to last treatment for LTBI between
permanent visa holders initiating treatment in Idaho is not statistically
difference.
Ha2: The mean time distribution to last treatment for LTBI between
permanent visa holders initiating treatment in Idaho is statistically different.
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RQ3: Is time on LTBI treatment in permanent visa holders initiating treatment in
Idaho affected by sex, age, country of origin, visa type, smoking status, distance
between residence and treatment facility, area of resettlement, time between
arrival and initial medical evaluation, TST positivity, or IGRA positivity?
H03: Time on LTBI treatment in permanent visa holders initiating treatment in
Idaho is not affected by sex, age, country of origin, visa-type, smoking status,
distance between residence and treatment facility, area of resettlement, time
between arrival and initial medical evaluation, TST positivity, or IGRA
positivity.
Ha3: Time on LTBI treatment in permanent visa holders initiating treatment in
Idaho is affected by sex, age, country of origin, visa-type, smoking status,
distance between residence and treatment facility, area of resettlement, time
between arrival and initial medical evaluation, TST positivity, or IGRA
positivity.
Theoretical Framework for the Study
At the foundation of this current research lies the epidemiologic triangle, a model
traditionally employed for disease causation, which outlines how agent-, host-, and
environment-related factors influence the development of disease (Gordon, 1953). The
epidemiologic triangle has been further applied to non-communicable disease and
prevention research where the outcome of interest may be a behavior or health condition
however, extremely complex relationships may not be appropriately described by this
framework (Egger, Swinburn, & Rossner, 2003; Nganwa et al., 2010; Swinburn & Egger,
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2002; Uzoigwe, Khaitsa, & Gibbs, 2007). Latent tuberculosis infection, although a
noncommunicable state of disease, requires exposure to and the implantation of the
microorganism Mycobacterium tuberculosis. The reactivation to active, transmissible
disease is a product of a complex interaction between multiple factors. Successful LTBI
treatment completion to prevent reactivation may be influenced by an interaction between
factors making the epidemiologic triangle the main framework in which this research is
constructed. In this context and for this research, although the epidemiologic triangle is
most known for exploring disease causation, it is suspected that the host-, environment-,
and agent-related factors discussed in detail in chapter 3 may play a critical role in
influencing LTBI treatment completion. In this sense, the epidemiological triangle
continues to be relevant framework for understanding what host, environment, and agent
factors may influence preventive treatment outcomes as a potential precursor to exploring
more behavior related factors in the future.
Epidemiologic Triangle Constructs
In the epidemiologic triangle, the bidirectional relationship and the intersection
between the host, the agent, and the environment can result in the spread of infectious
disease (Egger, Swinburn, & Rossner, 2003). Targeting and manipulating each of the
points has historically led to the control of epidemics. The constructs of the model consist
of the host, or the individual at risk of disease, whom interacts with the agent, or the
necessary and disease causing component, but also with the environment in such a way
that all three determine the timing, severity, and characteristics of disease (Haddon,
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1980). By disrupting the agent, destabilizing the transmission promoting environment,
and protecting or altering the host, disease eradication can be achieved.
This research employed these tenets in the context that high rates of LTBI
preventive therapy completion disrupts progression to reactivated disease and that factors
within each of the constructs of the epidemiologic triangle play a vital role in influencing
completion. Additionally, the constructs were critical to interpreting the findings of this
research to help explain what factors may be important to treatment noncompletion. Visa
holders in Idaho infected with Mtb (the agent) and diagnosed with LTBI, may not
complete LTBI preventive therapy due to the interaction or imbalance between personal
(host) factors such as gender, age, and country of origin and their area of Idaho
resettlement (the environment) in terms of urban versus rural or distance from their
treating facility. By investigating host, agent, and environmental factors related to
treatment completion and noncompletion, the epidemiologic triangle can be utilized to
support the notion that a high rate of treatment completion is critical to preventing future
disease by disrupting noncompletion through public health intervention.
This study expanded upon the epidemiologic triangle by analyzing host,
environment, and agent data as independent study variables to better understand the
relationship to the treatment completion outcome. Although more behavior oriented
frameworks exist and could too be useful for exploring LTBI treatment noncompletion,
the epidemiologic triangle was more appropriate for this research due to the extremely
limited information available surrounding this phenomenon. As a starting point, it is
expected that this framework will be essential to exploring the basic components of LTBI
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treatment noncompletion in the rural setting. However, this research, constructed using
the epidemiologic triangle, highlighted relationships potentially requiring additional
exploration through a more behavior-oriented lens, such as the ecological perspective.
This research employing the tenets of the epidemiologic triangle may be the first step in
describing LTBI treatment completion and noncompletion influencing factors in the rural
setting.
Nature of the Study
This was a retrospective epidemiological study using a secondary database to
determine LTBI treatment completion rates and what factors influenced the likelihood
visa holders fail treatment. Such a design is consistent with research grounded by Koch’s
germ theory of disease (1882) and the epidemiologic model (Gordon, 1953) as LTBI and
TB treatment completion has been well documented as a disease of social context
influenced by host, environment, and agent-related factors (Hirsch-Moverman, Bethel,
Colson, Franks, & El-Sador, 2010; Raviglione & Sulis, 2016; Venkatraman, Morris, &
Wiselka, 2013). The main dependent variable in this retrospective cohort research was
treatment noncompletion while independent variables included demographic factors,
smoking status, TST or IGRA positivity, distance to health department/TB clinic, time
between arrival and medical evaluation, and area of resettlement in Idaho (urban versus
rural). Any subsequently developed intervention should be based on altering the
bidirectional interaction between these factors to improve LTBI treatment completion. To
determine the mean survival time as well as the characteristics related to treatment
failure, a retrospective cohort of Idaho refugees, immigrants, and other visa holders
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attending Idaho TB clinics was used spanning five years. Treatment start and stop times
for Idaho visa holders initiating LTBI therapy were converted to months on therapy to
standardize these times for event analysis. This quantitative analysis should help in
determining if survival time, again, in terms of treatment failure, are different in the ruralstate setting when compared to the literature available for the urban setting, and if
specific factors influence rates of completion.
Definitions
The definitions outlined below are referenced consistently throughout this
research or may be unique to this research. The terms and phrases defined below were
derived from Merriam-Webster’s Online Dictionary and Medical Dictionary (2017) or A
Dictionary of Epidemiology (Porta, 2014).
Definitions of Variables Used in the Study to Describe Participants
Birth country: The country in which a migrant (visa-holder) was born.
Immigrant: (I) An individual seeking permanent residence in a country. Includes
“Immigrant” visa designation in the dataset. Does not include persons with temporary
visas such as international students, temporary visitors, or persons working in the United
States under a temporary work visa.
Other visa-holder: (OVH) Non-immigrant and non-refugee visas issued to U.S.
migrants. Includes “Parolee” (P), “Fiancé” (K1, V1), and “Asylee” (A) visa designations
in the dataset.
Refugee: (R) A person who has fled another country or power to the United States
to escape danger or persecution. Includes “Refugee” visa designations in the dataset.
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Definition of Key Terms Used in the Study
“A” classification: Inadmissible health condition found during predeparture
medical examination including: 1) a communicable disease of public health significance;
2) a physical or mental disorder and behavior associated with violence; 3) a drug abuser
or addict.
Active tuberculosis: A diseased state in which Mtb has overcome the host immune
response generally causing: unexplained weight loss, anorexia, night sweats, fever,
fatigue, and chills. If disease occurs in the lungs, persons with cough may transmit the
pathogen to susceptible hosts.
Agent: A component of the Epidemiologic Triangle Model and factor (e.g.
microorganism) essential for the establishment of disease.
“B” TB classification: Subset of B Classifications including: 1) B1 tuberculosis,
pulmonary; 2) B2 tuberculosis, extrapulmonary; and 3) B3 tuberculosis, latent
tuberculosis infection evaluation.
Case: A person having a disease or condition; in this research, TB or LTBI.
Censor: An observation of an unknown value likely the cause of a participant
being lost to follow-up or not experiencing the event prior to study completion or event
completion.
Elimination: WHO goal of <1 case of TB per one million population.
Environment: Physical, biological, social, cultural and other dimensional factors
that interact to influence the health status of the individual.
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Event/failure: Not completing LTBI treatment due to self-withdrawal or at the
advice of a health care provider but having a documented date in which treatment was
last taken after initiation.
Host: An individual affording lodgment to the infectious Mycobacterium
tuberculosis agent after exposure.
Infectious tuberculosis: A clinical diagnosis made due to the presence of Mtb in
respiratory specimens, signs and symptoms consistent with TB disease, and radiographic
evidence of disease.
Interferon gamma release assay (IGRA): Whole-blood tests used to assist in
diagnosing infection with Mtb. In the United States, refers to only two licensed products:
1) QuantiFERON®-TB Gold In-Tube or QuantiFERON® Plus; and 2) T-SPOT®.TB
test.
Latent tuberculosis infection: The presence of Mtb in the body in a noninfectious
state without the clinical signs and symptoms of disease.
Public health district (PHD): Primary outlets for public health services in Idaho
(IDHW, 2017) with seven PHDs serving all 44 Idaho counties: Panhandle Health District,
North Central Health District, Southwest District Health, Central District Health, South
Central District Health, Southeastern Idaho Public Health, and Eastern Idaho Public
Health.
Reservoir: A potential habitat of an infectious agent.
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Rural residence: A census tract classification area that is not urban (see Urban
residence definition). Includes 32 of Idaho’s 44 counties classified by the U.S. Office of
Management and Budget.
Survival/success: Completion of ≥90% of prescribed dosages of LTBI treatment.
Survival time: Length of time on LTBI treatment until completion or censoring
recorded in months.
Treatment completion: Documented completion of ≥90% of prescribed LTBI
treatment.
Treatment noncompletion: Documented completion of <90% of prescribed LTBI
treatment, being censored as LTFU, or experiencing an adverse event that leads to the
discontinuation of LTBI treatment.
TB control program: A public health entity charged with preventing the
transmission of TB, ensuring the rapid detection of those with disease, and the
appropriate treatment of those with disease and their contacts.
Tuberculin skin test (TST): An intradermal injection of tuberculin purified protein
derivative that is useful in determining if an individual is infected with Mtb.
Urban residence: A census tract classification area that has 50,000 or more
population. Refers to 12 metropolitan counties of Idaho’s 44 total counties: BoiseNampa-Caldwell (five counties); Idaho Falls (three counties); Pocatello (two counties);
Coeur d’Alene (one county), and Lewiston (one county).
Assumptions
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Consistent with survival analyses, it was assumed that for this research, censoring
was independent of survival time. Additionally, no underlying probability distribution
was used as a basis for the analysis however it was assumed that the hazard remained
constant over time, which is also a standard assumption of survival analysis (Bewick,
Cheek, & Ball, 2004). It was also assumed that all prearrival B TB classifications were
accurate and that any post-arrival diagnoses were appropriate. The administration and
interpretation of TST post-arrival, as well as the interpretation of IGRA results, was
assumed to be accurate and consistent throughout the study timeframe. Lastly, it was
assumed that the recommendation to initiate LTBI treatment regardless of PHD of
residence was consistent and that ability to pay was not a contributing factor to not
completing treatment since state-supplied free medications were available and frequently
used.
Scope and Delimitations
This quantitative retrospective cohort study aimed to determine what the LTBI
treatment completion rate was in Idaho refugees, immigrants, and other visa holders as
well as what variables may have been predictive of noncompletion in this rural-based
population. Annually and consistently, Idaho refugees, immigrants, and other visa holders
account for a majority of the state’s confirmed TB cases and thus, the completion of
preventive therapy upon arrival may be critical to decreasing future rates of TB disease in
the state and improving community health by preventing the risk of future transmission.
Present research on this phenomenon has focused on the high-incidence, urban setting,
leaving rural-based TB Control Programs to generalize findings to situations that may not
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be relatable. This research and the subsequent focus on rural populations may help ensure
TB Control Program interventions aimed at improving LTBI treatment completion rates
are developed from conducting research in the appropriate setting but may also provide
insight into the urban versus rural dichotomy of TB control.
The sample included in this study was limited to refugees, immigrants, and other
permanent visa holders identified as possibly having LTBI during predeparture medical
screening and categorized as a “Class B2 TB” or “Class B3 TB” migrant in the CDC’s
Electronic Disease Notification (EDN) system before relocation to Idaho. These visa
holders had initiated LTBI treatment after being diagnosed in the United States. All
migrants with the appropriate Class B TB notifications used in this research had initiated
therapy after January 1, 2012 and completed LTBI treatment in Idaho before December
31, 2016. Non-permanent visa holders (e.g. student visas) were excluded from this cohort
as these visas do not require extensive predeparture or post-arrival medical follow-up
prior to entering the United States. The CDC’s EDN system is the most robust source of
both predeparture and post-arrival migrant medical screening information for Idaho.
Those entities responsible for visa-holder evaluation have a contractual obligation to
submit follow-up evaluation forms to the Idaho state TB Program to be reimbursed for
performing these medical screenings. All contractor submitted data are entered into EDN.
Additionally, this population is likely representative of much of the burden of disease in
Idaho, which is a low-incidence TB state that rarely experiences verified TB
transmission. Even in the most populated metropolitan centers where disease is
concentrated, transmission rarely occurs. However, cases of TB disease have been
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reported in domestic-born Idahoans indicating that LTBI may exist in a low level in this
group as well, potentially limiting the broad generalization of this research. Independent
variables used in this research were frequently deployed in other LTBI treatment research
however, never in Idaho, rarely in the rural setting, and few consistent associations had
been found. The results of this study may be applicable to rural, low-TB incidence
jurisdictions with similar public health and health care structures as well as TB and LTBI
epidemiology.
Limitations
This study may be limited by inconsistencies in predeparture medical practices,
although overseas panel physicians should be abiding by the same CDC Technical
Instructions (Dara et al., 2013; Lee et al., 2013). Also, post-arrival medical evaluation
provider interpretation of diagnostic results may contribute to misclassification bias.
These differences in practice may produce varying rates of data completeness but may
also influence the overall rate in which migrants are recommended preventive LTBI
therapy. In Idaho, the medical evaluation of migrants with Class B TB notifications
suggestive of LTBI is often carried out by one of seven agencies that are different in
terms of structure, resource, and mission which results in different degrees of care and
could lead to differences in whether provider recommendations to treat are made.
Additionally, some migrants arriving in Idaho do not come directly to the state; most
arrive in urban U.S. areas with international airports designated to receive them and as
such, may be at risk of TB exposure during any prolonged periods of time spent in these
metropolitan areas prior to leaving for Idaho. This risk blurs whether exposure happened
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overseas or domestically, however, as a low-incidence TB country, the United States
rarely experiences widespread community transmission so the impact of this limitation
should be relatively small.
An additional concern of this research involves the potential to underestimate the
true rates of treatment completion due to migrants being lost to follow-up (LTFU) but
also due to the interval in which medication adherence and completion is measured in
Idaho. Visa holders may move out of state and complete therapy in the new jurisdiction
or, since many are sent home with an entire month’s worth of medication, may actually
finish all required doses but not present back to the health department or TB clinic
managing their care resulting in records indicating LTFU or noncompletion when
preventive therapy may have actually been completed. Furthermore, government
personnel responsible for dispensing LTBI treatment medications may only know if a
patient does not complete treatment if they do not show up for monthly clinic visits or fill
monthly prescriptions, limiting the level of data analysis that can be performed and the
conclusions that can be drawn related to the number of days from initiation to failure. A
more accurate and detailed log of actual dates medication is observed being ingested
would be ideal however, would be logistically taxing in Idaho. Lastly, it is possible that
some migrants seek care in the private sector and thus, could be excluded in this research
if the provider does not submit follow-up TB data to the state.
Significance
Quantifying the completion rate and understanding the associated risk factors for
treatment noncompletion in the rural U.S. setting will help bring the importance of the
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low completion rate problem to the attention of public officials and the population in this
setting. Additionally, this research may produce social change by providing a foundation
for the deployment of more appropriate public health interventions in the rural setting.
Early interventions may improve LTBI treatment completion rates in Idaho and lessen the
future burden of TB disease in the state thus improving the community’s overall health
and reducing the strain on already limited TB resources in the state. These potential
improvements in health may also be long term since the risk of re-exposure to Mtb in the
low-incidence setting is small.
The results of this study may provide the Idaho state TB Control Program and the
health care community with greater insight into LTBI treatment completion and
noncompletion rates as well as into which visa holders have the greatest risk for not
completing therapy. This study may also show which specific host, or environment, or
agent factors influence treatment noncompletion and if made the target of an intervention,
could improve completion rates. The findings of this research may also benefit similar
communities facing treatment completion issues. Understanding of this phenomenon is
paramount to eliminating the risk of reactivated and transmissible TB disease in Idaho
visa holders and to potentially decreasing morbidity and improving mortality, and thus
health, in all Idahoans. National TB stakeholders are increasingly calling for
improvements in LTBI treatment completion rates and at the conclusion of this study
critical information will be available to better understand how the Idaho TB Control
Program may successfully reduce that state’s future burden of TB disease by curing a
majority of the current pool of those infected with Mtb.
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Summary
The focus of Tuberculosis Control Programs in the United States is changing from
narrowly concentrating on minimizing transmission to preventing active TB likely
because of the recent year-to-year slowing in moving the country toward elimination.
Although greater emphasis is being placed on preventing the large pool of persons in the
United States with LTBI, most of whom are foreign-born, from developing active TB
through prophylaxis, LTBI treatment completion rates remain low. Additionally, the
research surrounding what factors may be associated with treatment completion or
noncompletion is inconclusive and factors may be geographically unique. Increasingly,
the foreign-born are being targeted upon entry to the United States for preventive therapy
if infected with Mtb, but the rural setting is often overlooked in the treatment completion
research and may be reliant upon implementing interventions that derived from nongeneralizable research findings from the urban, high-incidence, TB resource-rich setting.
The limited amount of rural-based LTBI treatment completion research may delay
programs that serve this setting in reaching elimination, may lead to the misguided use of
already strained resources, and may lead to sustained population TB morbidity and
mortality.
In Idaho, a rural-state that frequently resettles more refugees per capita than the
nation’s 26 refugees per 100,000 residents average, accurate LTBI treatment completion
rates for the foreign-born refugee, immigrant, and other visa-holding population are
unknown as are the potential factors that may contribute to completion or noncompletion.
This gap in knowledge if not filled could potentially indicate a sustained reservoir for
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future disease transmission, sustained or increased morbidity and mortality, and a
decreased ability to eliminate TB in the state. Interventions in the non-rural setting that
aim to improve migrant LTBI treatment completion rates have successfully demonstrated
a reduction in future TB disease trends. These findings emphasize the need for all
jurisdictions serving a high volume of foreigners to ensure LTBI treatment completion
does not fall below national standards. Idaho’s high rate of migrant resettlement implies a
greater risk for future TB disease transmission. This heightened risk calls for research
into LTBI treatment completion and the potential predictors of noncompletion to guide
treatment completion improving public health intervention development and deployment.
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Chapter 2: Literature Review
Introduction
In the low-incidence tuberculosis setting such as the United States, the large LTBI
reserve is the most immediate obstacle for achieving elimination of tuberculosis. To
prevent future transmission if reactivation occurs, persons with LTBI may benefit from
the 60% to 90% efficacy of eradicating Mtb by completing preventive treatment (Dobler
& Marks, 2012; Getahun et al., 2015; Menzies, Jahdali, & Otaibi, 2011). With the
foreign-born in the United States more likely to be infected with Mtb, targeting this highrisk group for preventive treatment could decrease the current pool of persons at risk of
developing active TB (Blount et al., 2016; Pareek et al., 2016). Unfortunately, poor
adherence to the LTBI regimen reduces effectiveness. Research from urban-based and
high-incidence TB settings indicate that elimination in the United States will not be
achieved until LTBI treatment completion rates are improved (Cook et al., 2006; Dobler
& Marks, 2012; Sandgren et al., 2016). However, there is little published research about
the epidemiology of LTBI treatment completion in foreign-born persons residing in the
rural U.S. setting, which often has limited resources. A study of this type may help
potentially reduce disease burden by preventing future transmission through interventions
that improve LTBI treatment completion.
Predicting the risk of LTBI treatment noncompletion can be a successful approach
to improving poor completion rates in high-risk populations (Shieh et al., 2006). Studies
surrounding this phenomenon in various urban, high-incidence TB settings have
produced inconsistencies in identifying the variables associated with preventive treatment
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completion and noncompletion (Hirsch-Moverman et al., 2008; Johnson et al., 2016; Lin
& Melendez-Torres, 2016). This gap highlights the potential role that geography and TB
resource availability may play in ensuring high completion rates (Hirsch-Moverman et
al., 2008; Johnson et al., 2016; Lin & Melendez-Torres, 2016). It has been determined
that host, agent, and environmental factors associated with treatment completion may
interact and influence treatment outcomes, making these factors appropriate targets for
study (Coly & Morisky, 2004; Hirsch-Moverman, et al., 2008; Malangu & Yamutamba,
2016; Parsyan et al., 2007).
In Idaho, a frontier state in the top 10 for resettling persons of foreign-birth per
capita (Radford & Connor, 2016), the future threat of LTBI reactivation will remain
constant unless treatment completion rates can be better achieved. Identifying potential
host, agent, and environmental predictors of failure for visa holders in Idaho will also
assist with intervention development aiming to improve completion rates. The sporadic
TB resources, limited availability of those with clinical expertise, and the vast geography
of Idaho can pose significant barriers to high treatment completion rates. Early
identification of noncompletion predisposing factors may help better target interventions,
improve completion rates and community health, and have a positive social impact on the
Idaho populace.
This chapter functions as a review of literature surrounding the known history of
TB and LTBI, screening practices in the United States for TB and LTBI, the known
epidemiology of TB and LTBI in the United States, the impact of and risk factors
associated with having LTBI, and the documented predictors of LTBI treatment
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completion in certain nonrural populations. The literature search and review focused on
publications related to LTBI treatment completion and the specific associations
ascertained between participants and completion rates in various, although infrequently
rural, U.S. and international settings.
Literature Search Strategy
For this research, I identified the literature reviewed by querying electronic
databases using Boolean searches including the phrases LTBI or latent tuberculosis
infection and treatment or treatment completion or treatment completion rates or
preventive therapy or completion predictors and foreign-born or migrants or immigrants.
I carried out alternative searches, also using electronic databases, using LTBI or latent
tuberculosis infection and treatment adherence or predictors of adherence. I utilized
Google Scholar in early searching to gain more familiarity with the terminology of
similar research. I relied heavily on MEDLINE, CINAHL, ProQuest Nursing and Allied
Health Source, ProQuest Health and Medical Collection, PubMed, ScienceDirect, and
EBSCO electronic databases to identify the peer reviewed studies informing this
dissertation research. I also employed a Thoreau Multi-Database search to ensure any
previously unsearched databases were identified. Initial broad searches were critical to
the process of better defining future search terminology and strategies, but also in
identifying authors and publications likely influential to LTBI treatment completion
research.
The longstanding history of TB research indicated some prioritization of
published works was necessary for this literature review. Seminal publications on the
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history of Mycobacterium tuberculosis and tuberculosis as a disease are frequently
referenced throughout this research; however, most peer-reviewed works critical to
forming an understanding of LTBI, LTBI treatment initiation, LTBI treatment
completion, and predictors of completion or noncompletion were limited to publication
within the most recent 6 years (2012-2017). Summaries and critiques of the identified,
applicable, peer-reviewed literature are found throughout this chapter. Additionally,
references cited in the reviewed literature were also essential to identifying more
potentially related publications. Lastly, I queried the ProQuest Dissertation database
using the aforementioned search phrases in order to assist in identifying publications
cited in dissertation research and sources possibly previously missed.
Methods Used in Latent Tuberculosis Infection Treatment Completion Research
I performed a literature review of 181 LTBI treatment completion or related
published studies to determine what was known about predicting LTBI treatment
completion or noncompletion in the United States, internationally, and in the rural
setting. Most identified studies used the cohort design, but I also identified crosssectional studies, systematic literature reviews, and randomized control trials. Few case
control studies were deployed that aimed to compare treatment completion rates for
different regimens assigned to different groups. Thirty-eight studies using cohort samples
included an analysis of LTBI treatment completion and predicting variables compared to
11 observational studies, one randomized control trial, and nine systematic literature
reviews. Of these, 22 were performed in low-incidence countries including the United
States, Canada, United Kingdom, and Australia, 23 were from urban United States, nine
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were from urban international settings, four were from rural international settings with a
high-incidence of TB, and one covered urban and rural international high-incidence
settings. Few identified studies included samples drawn from the rural U.S. setting.
Brief History of Tuberculosis and Latent Tuberculosis Infection
A significant cause of mortality globally, tuberculosis has long been a scourge to
civilization. Advancements in science and technology have led to the discovery of Mtb at
pre-Neolithic sites, but TB disease was also well documented in Greek and Biblical
writing (Daniel, 2006; Herzog, 1998). Specifically, bony processes from 8,000 BCE have
been found to be suggestive of Pott’s Disease, or TB disease of the spine, while a bone
unearthed from 5,000 BCE shows the changes that are consistent with tuberculosis
disease (Daniel, 2006; Herzog, 1998). Acid-fast bacilli have also been isolated from a
psoas abscess discovered in an Incan child well-preserved in a mummified state (Herzog,
1998). Together, these archaic discoveries demonstrate that TB has a long history.
Both Hippocrates and Aristotle described TB and its varying presentation in
animals in 460 BCE and 384 BCE, respectively (Herzog, 1998). Efforts to describe the
pathogenesis of Mtb emerged more consistently in the early 19th century in documented
work by Théophile Laennec. The tubercle bacillus was identified as the cause of
tuberculosis in 1882 by Heinrich and Koch, establishing a turning point in TB control and
microbial science. During this time, consumption, the term used to describe persons with
tuberculosis, was influencing multiple realms of life from science to fashion. The pale,
gaunt, rose-colored cheeks of consumption sufferers brought into popularity the use of
the corset as society responded to the high rates of TB by romanticizing the diseased state

38
(Daniel, 2006). In 1909, shortly after the infective nature of TB became the predominant
theory regarding transmission, Clemens Freiherr von Piquet introduced the term “latent
tuberculosis” from findings of a study in children involving Koch’s 1907 discovery of the
TST. It was at this time that the notion that TB existed on a spectrum of latency to
transmissibility became widely accepted.
In 1943, the advent of streptomycin, the only effective medication against TB at
the time, brought TB control into the modern era (Daniel, 2006; Herzog, 1998). Shortly
thereafter, the discovery of streptomycin-resistant strains prompted development of new
drugs such as INH, pyrazinamide, ethambutol, and RIF in 1952, 1954, 1962, and 1963,
respectively. These four drugs are still critical to treating TB disease today (Herzog,
1998; Nahid et al., 2016).
Characteristics of Mycobacterium Tuberculosis
Latent tuberculosis infection and tuberculosis disease are caused by Mtb.
Although TB disease and LTBI are different manifestations of infection with Mtb, the
organismal characteristics are critical to understanding the progression from infection to
disease. The control of TB in the low-incidence setting has focused on identifying
persons with active TB but has recently transitioned to targeting Mtb in its latent state.
Cell Biology
Described as a facultative intracellular parasite, the tubercle bacillus has evolved
alongside its host to heighten immune system evading techniques (Daffé & Etienne,
1999; Vergne, Chua, Singh, & Deretic, 2004). The construction of Mtb likely contributes
significantly to this success (Daffé & Etienne, 1999). The outermost structure, the
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capsule, consists of a complicated mixture of polypeptides that ultimately aid in ensuring
the biogenesis of any Mtb engulfing phagocyte is disrupted. This disruption prevents the
human host immune cell from eliminating the tubercle bacilli and allows Mtb to quietly
spread and suppress immunological detection (Daffé & Etienne, 1999; Vergne et al.,
2004).
Reservoir
Humans are the only known reservoir of M. tuberculosis (Heymann, 2015). TB
disease in humans is known to be caused by M. tuberculosis, M. bovis, M. africanum, M.
canetti, and M. microti, collectively referred to as Mtb complex, with various animals
acting as reservoirs for these other non-Mtb pathogens in the complex (Heymann, 2015).
Particularly, M. bovis is known to be endemic in many cattle populations outside of the
United States but can also be found in other animals such as deer, caribou, elk, or moose
(Heymann, 2015). Transmission of Mtb between human and nonhuman hosts is possible.
Transmission
The primary means of transmission of the tubercle bacillus are the coughing,
singing, or sneezing of an individual with infectious pulmonary disease. Transmissibility
is assumed as long as the viable organism is present in sputum. Infection after mucous
membrane exposure or exposure through broken skin is possible but rare. Consumption
of M. bovis through unpasteurized milk can also cause TB disease in humans (Heymann,
2015).
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Pathogenesis of Latent Tuberculosis Infection and Tuberculosis
Latent tuberculosis infection occurs in persons exposed to Mtb but in whom
clinical signs and symptoms of active TB are absent. A susceptible host can become
infected after inhalation of a single droplet nucleus expelled from an infectious contact
with active pulmonary TB (Cardona, 2010; Getahun et al., 2015). An estimated 30 to
50% of those exposed to Mtb will become infected. The size of the inhaled droplet nuclei
influences the site of implantation in the respiratory tract but once detected by the host
immune system, alveolar macrophages engulf the Mtb bacilli allowing the pathogen to
evade the immune defense systems and multiply (Cardona, 2010; Esmail et al., 2014;
Ling Lin & Flynn, 2010). The immunologic response may produce a granuloma at the
site of infection in which the bacteria may continue to multiply while evading a more
pronounced host immune response. At this point, the host remains infected however Mtb
dissemination is held off by the body’s natural immune system. For some, bacterial
eradication may never be achieved (Ling Lin & Flynn, 2010). In healthy individuals, the
granulomas that may develop after inoculation with Mtb are thought to be the body’s
attempt to contain the infection. This containment prompts the latency stage in the cycle
of the tubercle bacillus in its efforts to establish active TB (Ling Lin & Flynn, 2010).
Two to 10 weeks after inoculation diagnostic tools can be used to detect
immunologic sensitization to Mtb (Ling Lin & Flynn, 2010). These tools have limitations
in their usability and result interpretation due to varied sensitivity and specificity (Esmail
et al., 2014; Leung, Lange, & Zhang, 2013; Ling Lin & Flynn, 2010). Clinicians and
other health care providers use these diagnostic tools, the interpretation of a chest x-ray,
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and an exposure risk profile to help support a diagnosis of LTBI as there is no technique
to detect Mtb in the latent stage (Leung, Lange, & Zhang, 2013).
In settings where transmission of Mtb is limited, the lifetime risk of LTBI
becoming active disease is estimated at 12% and most develop active disease within the
first year after exposure (Esmail et al., 2014; Oren et al., 2016). For those whose
reactivation does not occur within the first year, reactivation at longer time intervals is
possible, but difficult to predict due to the limited number of studies on this phenomenon.
TB activation may be the result of a weakened host immune system that allows Mtb to
rupture the macrophages that were initially responsible for consuming the invader and
either spreading Mtb to other body sites via lymphatic system or develop cavities in the
lungs (Esmail et al., 2014). Under these circumstances the host is no longer considered to
have LTBI, but instead active TB and respiratory tract expulsion could transmit Mtb to
others. Active disease may progress rapidly and can be accompanied with fever, night
sweats, weight loss, cough lasting greater than two weeks, and hemoptysis.
Tuberculosis Screening in the United States
The United States has a comprehensive system for evaluating migratory persons
for medical conditions of public health concern. Since the late 1800’s, the U.S. Public
Health Service has been responsible for providing recommendations for the overseas
medical examination of persons intending to relocate to the United States, including the
requirement to test for LTBI and treat active TB, if identified during predeparture
screening. These efforts are an attempt to reduce the incidence of imported disease (Lee
et al., 2013; Liu, Posey, Cetron, & Painter, 2015). Panel physicians, U.S. Embassy
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appointed health care providers, following strict CDC Technical Instructions, classify
medically evaluated individuals into health categories after evaluation. Those identified
as having Class A conditions, which include communicable diseases of public health
significance, a lack of vaccine documentation (or associated waiver), a physical or mental
illness associated with harmful action, and drug abuse, are permitted to enter the United
States only under rare circumstances. Those with Class B conditions, which include
sexually transmitted diseases, mental illness, and noninfectious TB, are allowed to enter
but may require extensive medical follow-up once in the United States.
Evaluated individuals identified as having active, infectious TB are not permitted
to enter the United States and are given a Class A condition categorization. Those with
abnormal chest x-rays but negative sputum analyses, those with extrapulmonary TB,
those suspected of having LTBI, and those with documented recent contact to an active
case of TB receive a Class B TB designation and are permitted to enter the United States
without treatment documentation (Lee et al., 2013; Liu, Posey, Cetron, & Painter, 2015).
The results of these prearrival medical screenings are electronically submitted to state
public health agencies prior to the migrant’s arrival in the new host-country (Lee et al.,
2013).
Annually, about 450,000 immigrants enter the United States along with an
additional 75,000 refugees (Lee et al., 2013). Each entrant is subject to the screening of
admissible and inadmissible diseases or conditions prior to entry (Blount et al., 2016; Lee
et al., 2013; Liu, Posey, Cetron, & Painter, 2015; Varkey et al., 2007; Wingate et al.,
2015). In 2009, a total of 104,954 refugees, immigrants, and other visa holders entered
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the United States after clearing overseas medical examinations and receiving a medical
condition classification. Of these arrivals with medical classifications, 99% were for noninadmissible medical conditions, including non-infectious TB. All 50 states received
refugees, immigrants, or other visa holders with a Class B TB however California, Texas,
and New York consistently receive nearly 50% of these new arrivals. Nearly 57% of
those arriving with a TB classification were thought to have non-infectious TB or LTBI
(Lee et al., 2013). This persistently high rate of LTBI positivity in new arrivals
emphasizes the sustained health threat to high-income countries, like the United States,
will endure if LTBI is not addressed in this vulnerable population (Lönnroth et al., 2015).
Epidemiology of Tuberculosis and Latent Tuberculosis Infection
Risk Factors for Tuberculosis and Latent Tuberculosis Infection
Various persons are at increased risk of becoming infected with Mtb. In the lowincidence setting, persons at greatest risk of having LTBI include children under the age
of five that have known contact to someone with infectious TB, people living with HIV
and other immunocompromising conditions, persons starting anti-tumor necrosis factor
therapy, health care workers, the homeless, persons residing or working in congregate
settings, and those migrating from an intermediate- or high-incidence TB setting (WHO,
2016a). Persons at highest risk for progressing from LTBI to TB disease include people
living with HIV, residents of correctional facilities, and children under five years of age.
Comorbidities such as diabetes mellitus, smoking and the overuse of alcohol also place
persons with LTBI at greater risk of progressing from latency to active disease
(Raviglione & Sulis, 2016). Regardless which of the aforementioned risk categories are
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concerned, LTBI treatment may be an effective control strategy for preventing disease in
these persons (Lee et al., 2014; Martinez-Aguilar et al., 2015; Mirtskhulava et al., 2008;
WHO, 2016a).
Incidence, Prevalence, and Mortality in the Pretreatment Era
With limited historical record keeping, geographical spread of tuberculosis
overtime is not fully understood. Molecular analysis of identified ancestral stains of TB
suggests that humans began spreading Mtb as the migration out of Africa to Europe and
Asia took place (Gagneux, 2012; Levy, 2012; Pruitt, 2013). Additional limited historic
documentation further supports that Mtb was introduced to the European and Asian
populations through Indo-European cattle herders whilst nomadic from the ancestral
lands in the Indian and Africa regions (Niemi, 2014). As the concentration of humans
increased and villages were established, the proximity to cattle decreased, spread was
sustained. In Northern America, tuberculosis swept through Indian communities after
introduction from French-Canadian fur traders in the late 19th century. By this time, TB
was well known in sub-Saharan Africa, India, and China. As global populations began to
surge and travel across oceans was feasible, Mtb found its way to every country (Levy,
2012).
Although skeletal remains, depictions in art, and historical relics illustrate TB as a
scourge on humanity for millennia, accurate counts of disease burden are not available
until the early 17th century when the London Bills of Mortality were used to record the
causes of death in the city. During this time, tuberculosis, or phthisis, was among the
most common listed causes of death however, with no diagnostic tools available at that
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time, misclassification was likely (Davies, 1994). A successful treatment for TB was
unknown at this time.
In the early 20th century but still before the advent of treatment, improved
housing standards dismantled slums and dispersed what were historically crowded
centers for TB transmission. In developing countries, TB mortality began to decline
roughly 1.7% per year in the pre-treatment era as sanitation improved (Davies, 1994)
although Mtb continued to spread globally through colonization and the industrial
revolution (Bates & Stead, 1993). For many centuries, TB was likely the cause of up to
half of all human mortality events in Europe and North America (Gagneux, 2012). In
many countries, the TB mortality decline lasted only until the 1980’s before increases
continued globally with over 10 million incident cases recorded in 2014 by the WHO
(Chaisson, 2007). In the United States, consistent and accurate nationwide tracking of TB
and TB mortality began in 1786 where 300 persons out of every 100,000 persons would
die from tuberculosis (Wegner, 2013).
Incidence, Prevalence, and Mortality in the Posttreatment Era
Post-advent of successful treatment for TB around 1945, TB-related mortality
rates in developed countries fell. From a high of 1,600 deaths per 100,000 people in
1800, the United States has seen a drastic decrease in TB mortality to less than 500
persons in 2015 (Centers for Disease Control and Prevention [CDC], 2016; Wegner,
2013). Although a significant improvement, these lower mortality rates are still not
enough to rid the country of this disease (Al-Tawfiq & Memish, 2014). From 1985 to
1992, the average age of a TB sufferer in developed countries dropped from 49 years to
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43 with much of TB disease burden in persons 25 to 44 years. Infants and children less
than four years old experienced increasing incidence rates during this time. Disease was
and continues to be concentrated in urban, minority populations (Chadha, 1997). In
developing countries, the available data suggests a much slower decline in TB mortality.
In 2015, an estimated 10.4 million persons had TB disease with an additional
three to four million thought to not have been reported contributing to sustained
transmission (Kamal et al., 2016; Raviglione & Sulis, 2016; WHO, 2016a). Although
accurately quantifying the incidence of TB globally has been a focus of public health for
decades, the epidemic is larger than previously estimated (WHO, 2016a). In 1993, the
WHO declared tuberculosis a global public health emergency, prompting the
development of the global TB Elimination Strategy, after decades of soaring morbidity
and mortality (WHO, 2014; WHO, 2016a). Twenty nine out of every 100,000 people
died of tuberculosis in 2015 (WHO, 2016b). On the global scale, nearly two thirds of TB
sufferers in 2015 were male, 90% were adult, and India, Indonesia, China, Nigeria,
Pakistan, and South Africa consumed 60% of the burden (WHO, 2016a). As a disease of
poverty, regression analysis has been used to estimate that more than seven million new
cases occur annually in the under-developed and developing world (CDC, 1990).
Latent tuberculosis infection. TB infection is a global problem with an unequal
distribution of burden. The WHO estimates 2 to 3 billion people are infected with Mtb
with most residing in developing or under-developed nations (2016a). Similar to trends of
TB disease, the foreign-born residing in the United States are more likely to be infected
with Mtb, with an estimated 85% of TB disease cases being the product of longstanding
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untreated LTBI (CDC, 2016; Miramontes et al., 2015). Approximations of LTBI
prevalence in the United States are based off population screening research. In lieu of
general population screening, populations at high risk of having LTBI may act as a proxy
for establishing baseline estimates of burden. Using survey methodology, researchers
with the 2011-2012 National Health and Nutrition Examination Survey (NHANES)
identified participants eligible and willing to be tested for LTBI (Miramontes et al.,
2015). The researchers determined that 4.7% of the U.S. population is likely latently
infected with Mtb (Miramontes et al., 2015). This percentage escalates to over 20% for
foreign-born residents in the United States (Kahwati et al., 2016). Based off this study,
the 13,276,000 persons estimated to be infected are likely to be a majority male, aged 45
to 64 years, non-Hispanic Asian, and foreign-born (Miramontes et al., 2015). These
persons remain at risk of reactivation without preventive treatment.
TB and LTBI trends. Globally, since 1997, the average change in incidence rate
of TB in high-income countries was -2.2% compared to +1.8% in sub-Saharan Africa and
other low-income countries (Dye, Lönnroth, Jaramillo, Williams, & Raviglione, 2009). In
the era prior to treatment, TB incidence did decrease in most developed and developing
countries by as much as 58% (Chadha, 1997). TB incidence is highly correlated with
higher human development indexed countries, with lower child mortality, and with
countries where access to improved sanitation is broad (Dye, Lönnroth, Jaramillo,
Williams, & Raviglione, 2009). Although globally TB mortality has declined 22% from
2000 to 2015, significant reductions of TB and LTBI rates in high-income countries alone
will not shift the global population toward TB elimination (WHO, 2016a).
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Of the 10.4 million cases of TB in 2015, 6.3% were under the age of 15 years
old. Persons living HIV accounted for 1.2 million of the total reported TB burden and the
WHO reports that most persons living with HIV who subsequently develop TB reside in
Africa, with more than 50% coming from Southern Africa (2016a).
Like global trends, 60% of the incident cases reported in the United States were
men in 2015 and 66% were foreign-born (CDC, 2016). In 2015, nearly two thirds of TB
cases reported occurred in those aged 15 years to 64 years. Those greater than 65 years
accounted for 24% of the TB disease burden, while those aged zero to 15 represented
only a fraction of reports. Asians have consistently had the highest rate of TB in the
United States but have recently been joined by Native Hawaiians/Other Pacific Islanders.
Of the foreign-born TB cases residing in the U.S. in 2015, Mexico, the Philippines, and
India were reported to be the top three countries of origin. Less than 500 deaths were
attributed to TB in the United States, representing a decrease of 71% when compared to
the 1992 resurgence peak in the country (CDC, 2016). The overrepresentation of certain
age groups, race/ethnicities, and persons from selected high-incidence countries
demonstrates how TB becomes concentrated in specific populations in the low-incidence
setting and how targeted LTBI treatment interventions may prove beneficial.
Latent tuberculosis infection trends are less well documented. In 1993, the first
significant attempt to estimate the global burden of LTBI was performed resulting in a
total of 1.86 billion (32%) of the world’s population thought to be infected (Dye, Scheele,
Dolin, Pathania, & Raviglione, 1999). Statistical analysis of these estimates indicated that
the Africa, Eastern Mediterranean, and the Southeast Asian WHO regions had the highest

49
prevalence rate with over 995,000 persons thought to be infected (Dye, Scheele, Dolin,
Pathania, & Raviglione, 1999). Currently, it is believed that 1.7 billion persons, or nearly
a quarter of the global population, have LTBI. Six percent of those infected are thought to
be less than fifteen years old, with 13% of those hailing from Africa. It is estimated that
56 million persons of the 1.7 billion infected had been inoculated within the two most
recent years (Houben & Dodd, 2014).
Screening for and the administration of preventive LTBI therapy can act as a
safeguard against eventual TB transmission with new emphasis being placed on
decreasing the LTBI reservoir in the United States as a technique for moving the nation
toward elimination and improving the year-to-year case reporting decreases (Houben &
Dodd, 2016; Kahwati et al., 2016; Raviglione et al., 2016; Salinas et al., 2016). The
elevated risk and rate of reactivation TB in U.S. foreign-born residents underscores the
need to comprehensively understand the role various factors may play in preventive LTBI
treatment completion since successful completion has a 90% efficacy rate in bacillary
removal (Lin & Melendez-Torres, 2016; Malangu & Yamutamba, 2016).
Latent Tuberculosis Infection Treatment
For LTBI, provider-based decisions to initiate treatment are supported by
diagnostic results, radiographic studies, clinical history, and the potential risk of exposure
(Nahid et al., 2016). In some instances, empiric treatment for LTBI is warranted if
suspicion of infection is high, yet diagnostic evidence is limited (Nahid et al., 2016).
Tuberculosis Control Programs collaborate with the health care sector to identify persons
suspected of being infected with Mtb to initiate curative treatment and prevent potential
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future transmission (Nahid et al., 2016); a strategy that amplifies individual and
community-level benefits (Menzies et al., 2004; Nahid et al., 2016). Latent tuberculosis
infection is commonly treated with six, nine, or 12 months of INH with the latter duration
of treatment having an efficacy of over 90% in killing Mtb (Dobler & Marks, 2012;
Menzies et al., 2011; Nahid et al., 2016).
In response to low treatment completion rates with the six, nine and 12 month
regimens, shorter courses of INH containing regimens are being deployed to treat LTBI
with high efficacy rates consistently over 80% in the United States (Menzies et al., 2011;
Nahid et al., 2016). Alternative regimens are still needed with the aim to reduce duration
and improve treatment completion (Getahun et al., 2015). Innovative uses of three
months of INH and RPT weekly are being utilized in various parts of the United States to
treat LTBI and improve completion, as is four months daily of RIF (Denholm &
McBryde, 2010; Menzies et al., 2004; Menzies et al., 2011; Page et al., 2006; Spyridis et
al., 2007; Stennis, Burzynsk, Herbert, Nilsen, & Macaraig, 2016). Typically, successful
completion of LTBI therapy cures the individual and barring no future exposures, may be
protective for 19 years (Getahun et al., 2015).
Impact on Public’s Health
Tuberculosis
Although some persons cured of active TB disease may have minimal negative
health impacts, others not receiving treatment may develop chronic obstructive
pulmonary disease, fibrotic scarring, fistulas, or tracheal stenosis. Each of these can be
prevented with early detection and treatment of latent disease and without, can be life
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threatening (Chakaya, Kirenga, & Getahun, 2016; Larson, 2000). The effects of untreated
extrapulmonary tuberculosis may include permanent spinal pain, irreversible joint
damage, meningitis, hepatic and renal insufficiencies, or heart disorders (Shah & Reed,
2014). As the single largest infectious disease killer of young persons and adults globally,
untreated tuberculosis has health care, community, and economic impacts (Larson, 2000).
With many of those suffering from TB making up a large portion of the global workforce,
if diagnosed with TB, three to four months of productivity could be lost due to the
requirements for isolation, frequent medical checkups, and the need to take medication
often in front of a health care provider. On average, this temporary gap in employment
caused by having TB may result in earnings losses of 20 to 30%. Persons diagnosed with
TB may also experience social rejection, discrimination, or other psychological
consequences (Larson, 2000). Combined, these factors emphasize the need to identify
persons infected with TB before symptoms develop to reduce the likelihood of
transmission, long term sequellae, and negative societal impacts.
Treatment. Effective tuberculosis treatment was announced in 1944 with the
discovery of Streptomycin. Acquired resistance developed rapidly which promoted the
development of INH as well as the concept of dual-therapy (Davies, 1994; TB Alert,
n.d.). Over the next two decades, RIF and ethambutol were added to the recommended
regimen (Davies, 1994). The estimated cost to treat TB disease ranges from $17,000 per
U.S. patient with drug-susceptible TB to $430,000 per U.S. patient with extreme drugresistant TB (Fitzpatrick & Floyd, 2012; Laurence, Griffiths, & Vassall, 2015; Marks et
al., 2014). These costs include diagnostic procedures, hospitalizations, prescriptions, and
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the personnel costs associated with providing medications via DOT (Laurence, Griffiths,
& Vassall, 2015; Marks et al., 2014). Most often, these costs are extreme making the
treatment of TB, a significant burden on people and communities.
Latent Tuberculosis Infection
With 90% of TB cases in the foreign-born population in the United States being
attributed to reactivation, the impact LTBI has on the health of the public if not treated is
significant. Notably, since global TB mortality has surpassed that of HIV and Malaria
any attempt to reduce the number of persons infected with Mycobacterium tuberculosis
could result in a decrease in mortality (Petersen et al., 2017; Schmit, Wansaula, Pratt,
Price, & Langer, 2017; Semu, Fenta, Medhin, & Assefa, 2017). Community-wide LTBI
preventive therapy studies have demonstrated a long-term reduction in TB incidence in
Alaska, Greenland, and Tunisia. Latent tuberculosis infection preventive therapy has
been used to successfully avert future cases of TB disease potentially eliminating the risk
of death from active disease (Ragonnet, Trauer, McBryde, Houben, & Denholm, 2017;
Semu et al., 2017).
Treatment. The publics’ health benefits from the treatment of LTBI in high-risk
groups (Dobler, Martin, & Marks, 2015; Larson, 2000). Because early detection and
treatment of LTBI prevents reactivated transmissible disease, the entire populace’ health
is protected. Although most of the costs to treat LTBI fall onto the public sector, the
marginal $495.21 average cost per patient receiving LTBI preventive therapy has the
potential to not only improve population health, but decrease overall health care costs
when compared to the $17,000 price tag to treat TB disease (Holland, Sanders, Hamilton,

53
& Stout, 2009; Horsburgh, 2017; Marks et al., 2014). Ultimately, by preventing future
transmission as well as the potential lifelong negative impacts of TB, treating a high
percentage of persons infected with Mtb could minimize the global impact this pathogen
has on morbidity and mortality.
Latent Tuberculosis Infection Treatment Completion
The increasing emphasis being placed on ensuring successful completion of LTBI
therapy has encouraged a transition away from solely researching the factors associated
with treatment completion for active disease (CDC, 2016; Salinas et al., 2016). A
growing number of studies are available exploring those factors associated with the
noncompletion of all LTBI regimens so completion rate improving interventions can be
developed (Cook et al., 2006; Page et al., 2006; Spyridis et al., 2007; Young,
Wessolossky, Ellis, Kaminski, & Daly, 2009). Although often conducted in the
international, urban, and high-incidence TB settings, research has begun to demonstrate
setting-specific patterns in LTBI treatment noncompletion. Unfortunately, no two TB
environments are the same in the United States so a single nationally developed approach
to improving completion rates will likely not prove fruitful (Hirsch-Moverman et al.,
2008). This suggests that TB Programs must each investigate LTBI treatment completion
trends in their own jurisdictions.
Researchers in the United States have documented completion rates range from
30 to 62% for LTBI, much below the 85% national benchmark (Cook et al., 2006;
Getahun et al., 2015; Li et al., 2009; Sandgren et al., 2016). Researchers have also
concluded that the new shorter LTBI regimens promote higher completion rates however,
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some of these regimens may not reduce the risks of adverse events and may come with an
upfront increase in cost (Dobler & Marks, 2012; Goswami et al., 2012; Li et al., 2009;
Lines, Hunter, & Bleything, 2015; Menzies et al., 2004; Shepardson et al., 2013). The
documented low rate of treatment completion for LTBI highlights the need for broad
research surrounding this trend from a variety of settings. Continuing to have completion
rates below the national targets indicate the large reservoir of infected persons will persist
for many years limiting the ability of TB Control Programs to achieve elimination.
Predictors of Latent Tuberculosis Infection Treatment Completion
Describing the potential independent variables predictive of LTBI treatment
completion and noncompletion has been used to develop targeted interventions that aim
to improve completion rates. With geography potentially playing a key role in the
availability to LTBI treatment resources, exploring this localized phenomenon in all
settings is essential (Campbell, Chen et al., 2015; Getahun et al., 2015; Spyridis et al.,
2007; Varkey et al., 2007). The rural low-incidence setting has been excluded from much
of the LTBI treatment completion research in the United States. This shortfall has left TB
controllers limited in resources, challenged by geography, and bound by funding
shortfalls, to deprioritize the assessment of LTBI treatment noncompletion rates in highrisk groups, such as foreign-born migrants. As a product of this prioritization, these
setting may experience higher rates of noncompletion or may have a vague understanding
of what host, environment, and agent factors could be modified to improve completion to
reduce future morbidity.
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Host. In the epidemiologic triangle, host-related factors refer to those that make
an individual at risk for being exposed to or developing disease (Haddon, 1980). A
significant amount of research on urban-based populations in the United States, as well as
on populations from the international high-incidence TB setting has attempted to
determine whether host factors such as sex, age, birth country, and smoking history,
influence LTBI treatment completion. Findings of these research attempts have been
mixed. Some research has examined these factors for active TB disease, which may have
limited application to similar LTBI research since the treatment of disease involves
multiple medications, improves severe symptoms which may incentivize adherence and
involves taking prescribed treatment in front of a medical provider. Additional research is
essential to understanding how host related factors may influence LTBI treatment
outcomes particularly in the rural setting.
Sex. In the published research, no clear trend has emerged demonstrating whether
males or females complete LTBI treatment at higher rates. Eight identified studies
showed that females completed LTBI treatment at higher rates compared to men, four
demonstrated the opposite finding. An additional eleven studies found no significant
difference between the rates in which either sex completes LTBI treatment. However,
understanding the role sex may play in LTBI treatment completion could be of
importance in determining if disparities exist in a specific setting as these disparities are
known to exist in terms of TB disease burden (American Lung Association, 2013; CDC,
2016; Larson, 2000). The retrospective cohort design has been the most frequently
deployed method used to study the relationship between sex and LTBI treatment
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completion, followed by the prospective cohort, and the cross-sectional design.
Infrequently, randomized control trials were used to explore this phenomenon. As the
body of treatment completion research grows, systematic literature reviews are also being
conducted. Many of these studies utilized specific sample populations from specific
geographic regions, decreasing their generalizability.
Multiple retrospective cohort studies similar in design to this current research
have included sex as an independent variable for assessment against a LTBI treatment
completion outcome. Many demonstrated females were more likely to complete
treatment compared to males. LoBue and Moser (2003) and Lines et al. (2015) each
explored sex in relation to LTBI treatment completion. LoBue and Moser (2003) noted
sex as a predictor of treatment completion. In this retrospective cohort review of San
Diego county’s LTBI treatment completion database including 3,788 unique participant
records for treatment initiators between 1999 and 2002, LoBue and Moser calculated an
overall 64% treatment completion rate. Females (65%) were slightly more likely than
males (62%) to complete treatment (95% C.I. 1.0, 1.4; p < 0.01). Lines et al. (2015) when
using the retrospective cohort design to explore adherence among community health
center TB clinic attendees (n = 100), female sex appeared to be associated with higher
rates of adherence when compared to male sex (80.8% versus 73.7%, respectively;95%
C. I. 1.22, 6.18; p = 0.01). Li et al. (2009) also determined that sex was predictive of
treatment completion with a 15,000-participant sample from New York City providing
more power than the smaller study noted previously. Treatment completion was still
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suboptimal in both sexes. This study revealed a negative association between female sex
and LTBI treatment completion.
Prospective cohort studies have also been conducted to explore the relationship
between sex and LTBI treatment completion. Lavigne et al. (2006), in a prospective
cohort sample drawn from Montreal, Canada residents, determined that females were
more likely to adhere to LTBI treatment (OR = 1.9; 95% C.I. 1.1, 3.3) after controlling
for age and smoking status. Although 87% of participants were foreign-born and just over
half (56%) were male, this convenience-based sampling study does provide additional
evidence that sex may be correlated with adherence in some settings (Lavigne et al.,
2006). In the public health clinic in Tennessee, Priest, Vossel, Sherfy, Hoy and Haley
(2004) drew a similar conclusion but found that female sex was more likely to be
predictive of completion using multivariate analysis (RR = 1.70; 95% C.I.1.06, 2.75; p =
0.03) in 352 treatment completing patients. The sample was drawn from a single
employer with a recent significant TB exposure event where administrative
encouragement to complete treatment was present, potentially limiting generalization.
Nonetheless, these findings demonstrate how social support can influence LTBI
treatment completion covariates as well as how sex can act as a predictor of treatment
completion (Priest, Vossel, Shefy, Hoy, & Haley, 2004). In 2004, Tulsky et al. published
the findings of a prospective cohort including 119 homeless adults from San Francisco,
California. The study showed sex as a potential predictor of treatment completion with
males being more likely to complete (88.1%; 95% C.I. 1.36, 23.40; p = 0.02) when
compared to females (72.2%). The study was limited by a smaller sample size and also
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utilized cash incentives to demonstrate the impact on completion potentially skewing the
results. It is important to note, however, that incentives are frequently deployed in TB
control to improve completion (Tulsky et al., 2004).
Non-cohort based studies have also demonstrated a positive association between
sex as a predictor of LTBI treatment completion. A cross-sectional review of 11,963
people prescribed LTBI treatment in Italy conducted by Codecasa et al. (2013) supported
previous findings that sex could predict LTBI treatment completion. Codecasa et al.
(2013) found that female sex had a protective effect (OR = 0.81; 95% C.I. 0.73, 0.89)
against experiencing adverse treatment events. These findings suggested that females had
improved completion when looking specifically at the use of INH as preventive therapy
(Codecasa et al., 2013). From the county jail and homeless shelter setting, two
populations likely not representative of the broader population but at high risk for having
LTBI, LoBato et al. (2005), using a sample of 1,211 participants, built further upon the
notion that sex may be predictive of treatment completion. In this observational study, the
researchers found similar rates of completion in the two populations, with females being
more likely to not complete treatment (73.9%; OR = 0.35; 95% C.I. 0.23, 0.54; p < 0.001)
(LoBato et al., 2005). Conversely, the cross-sectional study conducted by Cegolon et al.
(2010) found male sex to be more predictive of treatment failure (OR = 1.53; 95% C.I.
1.37, 1.71; p < 0.001), albeit the sample not limited to the incarcerated or homeless. This
more robust sample of 12,929 participants was used to calculate a successful treatment
completion rate near 88%, but demonstrates how in a given geographical setting, sex may
be predictive of treatment completion. Lastly, in the only identified prospective,
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randomized clinical trial Pettit et al. (2013) concluded that sex was a negative predictor
of LTBI treatment completion, with females (49.9%) being less likely to complete
treatment (RR = 1.67; 95% C.I. 1.32, 2.10; p < 0.001) on account of a greater risk of
experiencing adverse medication events. Lastly, the systematic review including 62
articles that focused on the determinants of LTBI treatment initiation and completion
performed by Stuurman et al. (2016) also identified that females had a higher rate of
LTBI treatment completion although it was noted that studies focusing on specific
populations (i.e. visa holders, racial/ethnic minorities) were scarce making rates
inconsistent across all groups.
Despite a number of studies demonstrating sex as a predictor of LTBI treatment
completion, some researchers have failed to draw this conclusion. Levesque, Dongier,
Brassard, and Allard (2004) sampled 229 refugees in Canada and found no association
between sex and treatment adherence (OR = 1.0). The study findings are limited due to
the relatively small sample size of TST positive individuals (n = 49) but the even smaller
(n = 24) number of persons whom initiated treatment with which data could be analyzed.
The systematic reviews surrounding LTBI treatment adherence, conducted by HirshMoverman, Daftary, Franks, and Colson (2008), Zuñiga (2012), and Lin and MelendezTorres (2016) yielded mixed findings. Hirsch-Moverman et al. (2008) identified sex was
poorly associated with treatment adherence in a review of 78 quantitative studies that
analyzed adherence to LTBI treatment, as did Lin and Melendez-Torres (2016) in a more
recent review including 20 articles identifying risk factors associated with LTBI
treatment noncompletion. Zuniga (2016) reported sex as somewhat correlated when
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qualitative methods were used to explore the relationship beyond quantitative means; the
only systematic review drawing this conclusion. Of the two descriptive studies identified,
which focused on Latino immigrants in the United States using random medical record
chart abstraction from the urban public health clinic setting, sex failed to predict
adherence (t = -0.302; p = 0.76; and p > 0.05, respectively) (Ailinger, Black, Nguyen, &
Lasus, 2007; Ailinger, Moore, Nguyen, & Lasus, 2006).
Sex has been shown to play an inconsistent role in LTBI treatment completion
with 10 study findings identifying sex as a predictor of treatment completion and 11
indicating no association. Although frequently included as an independent variable in
LTBI treatment completion research, sex as a host factor has not been consistently
associated with adherence or completion in either a positive or negative direction. These
findings, stemming mostly from urban samples, highlight the need for rural-based
samples to be included in the published research. Inclusion of samples drawn from
various settings will provide a more comprehensive understanding of sex as a potential
predictor of LTBI treatment completion and may provide more robust evidence that this
potential host factor could be critical to understanding treatment completion.
Age. Multiple studies have demonstrated associations between age and LTBI
treatment completion but consistencies between the direction and the age groups most
commonly associated with completion or noncompletion have varied. In specific settings,
the age of the individual initiating LTBI preventive therapy may influence the likelihood
of completion in a negative way. Age was included as an independent variable of interest
nearly as frequently as sex. Of the studies identified where researchers explored the
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relationship between age and LTBI treatment completion, the cohort design is used most
frequently. As is the case when exploring the independent variable “sex”, cross-sectional
studies, systematic literature reviews, and randomized control trials are performed less
frequently. Similar to the aforementioned research on sex and LTBI treatment
completion, research surrounding age involved documenting treatment completion or
adherence, the risk of progressing from LTBI to TB disease, but also using age as a
predictor of treatment completion. In some instances where an association was found,
young adults 18 to 30 years of age were more likely to complete LTBI treatment
compared to others outside that age range however, regionally specific differences were
observed. In general, completion rates decreased with increasing age.
In 1999, Bock, Metzger, Tapia, and Blumberg conducted a prospective cohort
study exploring age as a potential predictor of LTBI treatment completion. Using a
sample of 409 persons living in inner-city Atlanta, Georgia, the study did not show age as
a consistent predictor of treatment completion across each stratified age group. Only
those 65 years old or greater could be used to predict treatment completion in this study
where participants ≥65 years old were ten times more likely to complete treatment
compared to those less than 65 years old (OR = 10.11; 95% C.I. 3.45, 29.66; p < 0.001).
Unfortunately, a low rate of LTBI diagnosis in the 409 participants as well as a low rate
of completion (20%) limits the interpretation of these findings. Hovell et al. (2003)
studied 268 adolescents from San Diego County and showed that age was again a
predictor of negative adherence in that the rate of treatment completion decreased with
increasing age (p < 0.0001). Additional research conducted by LoBue and Moser (2003)
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supported that age may predict negative LTBI treatment completion using the
retrospective cohort design of 3,788 patients initiating INH LTBI preventive therapy in
San Diego between 1999 and 2002 (Age 0 to 14 years: OR = 4.1; 95% C.I. 2.2, 7.8; p <
0.01; Age 15 to 34 years: OR = 2.1; 95% C.I. 1.1, 3.9; p = 0.02). However, the
retrospective nature of this study required researchers to use documented prescription
refill records in order to determine adherence and eventual compliance (LoBue & Moser,
2003). The 64% completion rate may have been underestimated since participants may
have obtained refill medications outside of a pharmacy reporting records (LoBue &
Moser, 2003).
A 2004 prospective study that primarily aimed to explore the rates of hepatoxicity
and treatment completion for LTBI using a newly recommended regimen, further
demonstrated that older age was associated with noncompletion (OR = 1.08 per year; p =
0.001) (Priest, Vossel, Sherfy, Hoy, & Haley, 2004). The study recruited 598 participants
from a single workplace that was experiencing an outbreak of active TB. Overall the
treatment completion rate of 83% was promising and the documentation of age as an
influencer of completion contributes to the field of knowledge since those ≥35 years were
at increased risk of treatment failure compared to those less than 35 (Priest, Vossel,
Sherfy, Hoy, & Haley, 2004). The overall application of age as a predictor of LTBI
treatment completion is limited from this research since a majority of those discontinuing
treatment did so due to severe hepatoxic events (Priest, Vossel, Sherfy, Hoy, & Haley,
2004). Instead of fully supporting the notion that age may be a negative predictor of

63
treatment completion, these researchers demonstrated that older age may be a risk factor
of hepatoxicity and may contribute to the overall negative trend in completion.
Additional cohort research has been conducted by Rennie, Bothamley, Engova,
and Bates (2007), Bieberly and Ali (2008), Morano, Walton, Zelenev, Bruce, and Altice
(2013), Spicer, Perkins, DeJesus, Wang, and Powell (2013), and Rennert-May et al.
(2016) which all demonstrated age as a potential predictor of treatment completion.
Rennie, Bothamley, Engova, and Bates (2007) prospectively followed 675 London TB
clinic attendees and estimated that a one year increase in age translated into a 1.04 greater
risk of failing to complete treatment. This study also found that providing patients with a
number of treatment regimen options of differing duration could improve completion.
This was especially true for those falling in the workforce age groups that may not
comply with preventive treatment due to pressures from other obligations (Rennie,
Bothamley, Engova, & Bates, 2007).
When looking at very specific populations, Bieberly and Ali (2008) and Spicer et
al. (2013) each concluded that age may be an important factor when hypothesizing who
may or may not complete treatment. In the retrospective study involving 380 LTBI
patients in the New Orleans area post-Katrina, those aged 19 to 34 had the highest rate of
nonadherence, while children were more likely to complete (Bieberly & Ali, 2008). The
eventual completion rate calculated at 19% further supports that those persons receiving
LTBI treatment the typically fall into the workforce age range (15 to 64 in the United
States) may be at increased risk of nonadherence or noncompletion. This research
demonstrates that those in the working age range may be an important group to target
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when recommending treatment. Opposite the working population are children, whom
Spicer et al. (2013) also concluded became at greater risk of noncompletion with aging (p
= 0.02). The 1,516 children participating in the study produced a high rate of treatment
completion, nearly 90%, in the retrospective study that aimed to explore the demographic
variables that may influence treatment completion. In this study population those not
completing treatment differed significantly by age from those that did complete (Spicer et
al., 2013) indicating that age may be useful in predicting completion.
Last of the identified cohort-based research studies that included the exploration
of age as a predictor of treatment completion, Morano, Walton, Zelenev, Bruce, and
Altice (2013) and Rennert-May et al. (2016) drew different conclusions although each
did find an association. In the prospective cohort of 357 urban city U.S. residents,
Morano, Walton, Zelenve, Bruce, and Altice (2013) determined that those in younger age
groups tended to complete treatment at higher rates (OR = 1.03; p = 0.039) which is
counter to the findings reported by Rennert-May et al. (2016) where younger age was
associated with nonadherence in a retrospective cohort of Canadian refugees (p < 0.05).
Although the studies drew somewhat different conclusions, the varying settings and
sampled populations may have contributed to these findings.
In 2016, a study conducted by Asres, Jerene, and Deressa including 790
Ethiopians being treated for active TB did demonstrate an association between age and
treatment completion (OR = 1.02; 95% C.I. 1.001, 1.022; p = 0.5). These findings may
not be relatable to LTBI treatment completion due to the often severe symptoms of active
TB which may encourage treatment completion for active disease. In 2010, Hirsch-
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Moverman, Bethel, Colson, Franks, and El-Sadr used a more robust and less homogenous
inner-city population, did find a slight correlation between age and LTBI treatment
completion (p = 0.053) along with being married, being homeless, and ever using
alcohol.
Years after research demonstrating age as a factor associated with treatment
completion became consistently published, Levesque, Dongier, Brassard, and Allard
(2004), using a prospective cohort, failed to conclude that age, when stratified for
analysis, was associated with completion in the international setting. The limited sample
size of 229 recruited and the even smaller sample of 24 that initiated and completed
preventive therapy may have influenced these findings, but the researchers did note that
age was a significant predictor of TST positivity and thus, having a diagnosis of LTBI
(Levesque, Dongier, Brassard, & Allard, 2004). Although this research did not support
age as a predictor of treatment completion, it does support the notion that older
individuals with LTBI may require greater clinical attention to ensure prompt diagnosis
and treatment of LTBI. In a prospective sample of 320 Canadians, Lavigne, Rocher,
Steensma, and Brassard (2006) aimed to test the previously identified connection
between smoking and LTBI treatment adherence, but to also test the potential influence
demographics may have. Lavigne, Rocher, Steensma, and Brassard (2006) reported that
age, region of birth, and nicotine dependence were not associated with adherence (p =
0.4, p = 0.8, p = 0.6, respectively) albeit the convenience sampling method as well as the
self-reported nature of many of the study variables may have influenced this outcome.
Also in the international setting, van Zyl et al. (2006) found no association between age
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and treatment completion in 335 South African children known to be contacts to persons
with active TB. The researchers hypothesize this may be attributed to the education
parents were provided about the potentially severe outcomes associated with childhood
TB, thus parental involvement led to greater adherence regardless of the child’s age (van
Zyl et al., 2006).
Overall, age as a host factor has been inconsistently associated with LTBI
treatment completion but multiple populations and settings have been excluded from the
published research with most studies focusing on very specific samples in very specific
locales. The rural setting often differs significantly from the urban setting highlighting
the need for age-related research in this setting to better assist rural TB Control programs
in developing targeted interventions.
Birth country. In the United States, where most active TB occurs in the foreign
born, renewed interest on preventing the progression from LTBI to infectious disease has
led to increased emphasis on examining the role birth country may play in various aspects
of TB control. Birth country, a potential host factor in the epidemiologic triangle that may
influence treatment completion, has been less extensively explored in the LTBI treatment
completion research, but trends have emerged from those studies examining this
independent variable. Of the 14 identified studies where birth country was a key variable
explored by researchers, half included findings suggesting birth country was positively
associated with treatment completion. Most of these studies suggest the underdeveloped
setting such as sub-Saharan Africa suffers from high rates of LTBI treatment
noncompletion.

67
Research has been published on the impact birth country may have on LTBI
treatment completion using retrospective methods. Parsyan et al. (2007), Spicer et al.
(2013), and Rennert-May et al. (2016) all determined that birth country was positively
correlated with LTBI treatment noncompletion. In 2007, Parsyan et al. drew this
conclusion after analyzing completion data on 1,572 TB clinic attendees from Boston.
The researchers identified a treatment completion rate below 40% with a majority of
those failing treatment being from China, Vietnam, Haiti, and the Dominican Republic
(RR = 0.74, p < 0.0001; RR = 0.68, p = 0.0001; RR = 1.33, p < 0.0001; and RR = 1.10, p
= 0.01, respectively). The researchers argued that interventions seeking to improve
completion should at a minimum, target these identified high-risk country-specific groups
(Parsyan et al., 2007). In Columbus, Ohio, Spicer et al. (2013) assessed medical record
data from 1,516 visits to Nationwide Children’s Hospital and determined that sex, history
of TB exposure, size of TST reaction, nor having LTBI learning material available in
multiple languages improved treatment completion rates in children but region of birth
did appear to be the most significant predictor of treatment completion success (p <
0.001). Similarly, Rennert-May et al. (2016) conducted analysis on a dataset from a
Canadian refugee health screening center where 265 refugees started LTBI preventive
therapy and concluded that not only was birth country predictive of treatment
noncompletion, but that sub-Saharan countries of origin were highly associated with
noncompletion (p < 0.05).
In 1999, while evaluating an inner-city tuberculin screening and INH preventive
therapy program in Atlanta, Georgia, Bock et al. concluded that only 20% of those
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intending to complete preventive treatment actually completed in a prospectively
recruited sample of 409 treatment eligible participants. An early study exploring factors
associated with LTBI treatment completion in a community-based intervention setting,
Bock et al. (1999) concluded that foreign-birth was a predictor of participant treatment
completion (OR = 2.11; 95% C.I. 1.12, 3.94; p = 0.0009). Using a sample of 496 persons
recruited from a TB Clinic in Raleigh, North Carolina, Goswami et al. (2012) determined
that birth country did have an impact on treatment completion. In this research, non- U.S.
born participants tended to complete treatment at higher rates (p = 0.04) (Goswami et al.,
2012). Fiske et al. (2014) corroborated this finding in a multi-center U.S. and Canada
study of 1,371 persons recommended for preventive therapy however, when analyzing
specific countries included in the dataset in relation to completion, no associations were
identified (p = 0.87).
A single randomized control trial was identified, conducted by Hirsch-Moverman
et al. (2010), that focused on predicting the factors associated with LTBI treatment
completion in the United States using a sample of 314 individuals drawn from inner-city
Harlem. The researchers concluded that foreign-birth was a predictor of noncompletion
(p = 0.04), however, the study did not collect information on exact birth country making
country-specific level of analysis impossible. Assuming foreign-birth to be a proxy to
specific birth country variables, the researcher’s findings may provide evidence to
support the development of completion rate improving interventions that target the
foreign-born, albeit one with a birth country level of specificity would be more ideal.

69
A single systematic literature review performed by Hirsch-Moverman et al.
(2008) was identified that included a birth country assessment on treatment completion.
Birth country was reported to not be a predictor of treatment completion however, at least
five additional studies have been published since this systematic literature review where
an association was identified. The somewhat dated nature of this review may limit its
applicability to the current time, especially as the body of research surrounding the
predictors of LTBI treatment completion grows.
Overall, although birth country has been studied somewhat regularly in relation to
LTBI treatment completion, as an independent variable it has been considered a
statistically significant predictor of completion in some studies, but a growing body of
evidence to the contrary is also present. As with many of the other variables explored
thus far, the urban, high-incidence setting is overrepresented in the research and thus,
exploring this phenomenon in the rural setting is still needed.
Visa type. The role the visa held by migrants arriving in the United States may
have on LTBI preventive treatment completion postarrival has been minimally studied.
The visa held could be a contributing factor to completion or noncompletion as an
indirect product of the requirements to change a visa holders’ status. Refugees are
thought to have a slightly greater likelihood of being exposed to Mtb and thus having
LTBI due to the poor living conditions experienced in camps prior to migration (Lim et
al., 2016) however, immigrants and other visa holders from TB endemic regions are also
at risk. Consistently, all visa-types have been associated with poor LTBI treatment
completion (Sandgren et al., 2016).
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In 2004, Coly and Morisky sought to identify the predicting variables of LTBI
treatment completion in foreign-born adolescents residing in Los Angeles. The authors
identified that not addressing barriers to treatment completion would prevent the region
from successfully combating future TB disease. In a prospective cohort involving nearly
38,000 LTBI clinic attendees from the United States and Canada, Sterling et al. (2006)
attempted to estimate the number of persons initiating treatment and to describe the types
of clinics and providers medically managing persons with LTBI. Sterling et al. sought to
accomplish this to develop interventions that improve treatment completion (2006). With
successful LTBI treatment completion decreasing future TB burden, Sterling et al. found
that in these settings, over 80% of LTBI initiators were foreign-born and the public sector
is mostly responsible for the management of these individuals. Although Sterling et al.
did not seek to quantify completion rates by visa-type, the researchers did demonstrate
that immigrant and refugee clinics, facilities serving different visa-types, accounted for
more than 92% of the providers managing LTBI patients. These facilities may be an
appropriate target for treatment completion improving interventions (Sterling et al.,
2006).
In a retrospective cohort, Lim et al. (2016) found that refugees were at greater risk
compared to immigrants for having LTBI and that treatment completion rates reached a
low of 76% in the foreign-born arriving in Alberta, Canada. In this study, LTBI was more
common in migrants 30 years of age and older, and most treatment defaulters stopped
within the first month after initiating treatment. Although not a study directly measuring
the impact visa-type may have on LTBI treatment completion, the findings of this
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research have important implications. With refugees being at greater risk of LTBI,
potentially targeting this visa-type for completion rate improving interventions may prove
advantageous. Despite the limited generalizability of this study directly related to the
small sample size of participants with LTBI (n = 49), this study demonstrated that
Tibetans tended to be a greater risk of default. Special attention to this population that
often enters industrialized countries under refugee-visas may improve treatment
completion rates in this group in other settings (Lim et al., 2016).
No systematic reviews were identified that focused solely on the literature
published surrounding the relationship between visa-type and LTBI treatment
completion. This is likely due to the limited number of studies available where visa-type
was an independent variable but some reviews did include a component of visa-type
research. In 2015, Getahun et al. published guidelines surrounding the management of
LTBI in the low-incidence TB setting. Getahun et al. drew attention to the fact that legalstatus significantly impacted LTBI treatment initiation, adherence, and completion.
Getahun et al. also noted that in general, LTBI treatment completion rates tend to be
lower than the general population in visa-holding populations, with undocumented
migrants or migrants staying past expired visas at even greater risk of failure (2015). This
research helps highlight the gaps that exist in managing the care of migrants and persons
on visas especially in settings where this population contributes significantly to the
agricultural workforce, as is the case in Idaho. In a separate systematic literature review,
Stuurman et al. (2016) sought to summarize the research surrounding LTBI treatment
completion improving interventions, with visa-type being a variable covered in a limited
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context. Stuurman et al. concluded that domestic-born persons with LTBI tended to
complete treatment at higher rates and that cultural differences in immigrants likely
influenced LTBI completion (2016). These researchers also concluded that some of the
most important factors consistently associated with LTBI treatment completion are
patient-related, such as the visa-type they arrive with after migration to a new country.
Although studied infrequently, visa-type has been shown in some capacity to have
a potential impact on the outcome of LTBI treatment completion. With most studies
indirectly referencing or measuring visa-type more work must be done to determine if
this variable is truly predictive of treatment completion especially in the rural setting.
Smoking. Only a single study was identified that considered the impact smoking
has on LTBI treatment completion. In a 2006 prospective cohort consisting of 320
convenience-sample recruited LTBI clinic attendees in Montreal, Canada, Lavigne,
Rocher, Steensma, and Brassard determined that smokers involved in the study were less
likely to complete LTBI treatment and had difficulty being compliant for the time on
treatment prior to discontinuation (p = 0.04). In further univariate analysis, the
researchers concluded that male smokers were at greater risk of noncompletion compared
to their female smoking counterparts (Lavigne, Rocher, Steensma, & Brassard, 2006).
The convenience-based sampling method may limit generalizability as those opting to
participate in the study may differ significantly from other smokers choosing to be
excluded. Additionally, the use of self-reported smoking status may bias results due to
under- or over-reporting. The limited number of studies available exploring this
phenomenon indicates interpreting these findings broadly should be done with caution.
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Environment. In the epidemiologic triangle, environment-related factors refer to
the structure surrounding the individual that interacts with characteristics of both the host
and the agent to promote pathology but also the severity and duration of disease (Haddon,
1980). As with the host variables described previously, most published research
exploring the role environmental factors may play in promoting or demoting LTBI
preventive therapy has included only those from the urban and high-incidence TB setting,
creating a gap in the understanding of this potential relationship in the rural setting.
Although it has been noted that environmental factors play a key role in promoting
treatment completion across a variety of diseases and conditions, these factors have been
less frequently studied in relation to LTBI. Some studies have focused on the distance
from the treating LTBI clinic and the patient’s home and the role this may play on
completing treatment. In the rural setting, understanding environmental factors may be
critical to promoting higher rates of treatment completion as barriers to completing may
be many and resources dedicated to improving completion limited.
Distance. The distance an individual has to travel to seek health care has been
shown to negatively influence the uptake of public health services if considered great
(Jacobs, Ir, Bigdeli, Annear, & Van Damme, 2012). Failure to complete LTBI preventive
therapy can leave individuals at risk of developing reactivated disease in the future,
promoting transmission to others. Few studies have been designed around distancerelated variables and their association with LTBI preventive therapy completion despite
guidelines recommending interventions aim to reduce distance-related barriers to achieve
high rates of completion (Getahun et al., 2015). Of the independent variables included in
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the exploration of predictors of LTBI treatment completion, distance has produced the
least heterogeneous findings.
A retrospective cohort conducted by Spicer et al. in 2013 concluded that the
pediatric patient’s location in reference to the LTBI treatment dispensing facility was
highly inversely associated with LTBI evaluation and treatment completion (p < 0.001).
Those being more remote were at greater risk of not completing treatment (Spicer et al.,
2013). Although the study had a robust sample of 1,516 participants drawn from an urban
U.S. city, the patient’s transportation options were often subject to that of their parents,
potentially biasing these findings. No in-depth analysis was done on the number of miles
a patient must travel before becoming at greater risk of treatment noncompletion. In a
prospective cohort of 1,078 children residing in Rio de Janeiro, Silva et al. (2016)
determined that the greater the distance to the health department, the more likely the
participant would fail. In this study, the distance independent variable was measured in
30 minute increments as well as in cost, with persons 30 minutes and more away from the
health department and paying greater cost being at greater risk of noncompletion (p =
0.03). In a cross-sectional study by Mindachew, Deribew, Tessema, and Sibhatu (2011)
that focused on identifying the predictors of treatment completion in the HIV-positive
population living in Ethiopia, the researchers concluded that persons living farther from
the health department had a higher number of missed LTBI treatment doses and a higher
rate of noncompletion. Although the study involved a very specific sample (n = 319 HIVpositive persons), subsequent interventions that aimed to improve adherence through
education and incentives did prove successful (Mindachew, Deribew, Tessema, &
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Sibhatu, 2011). These findings demonstrate how distance may be too difficult a barrier to
overcome without assistance (Mindachew, Deribew, Tessema, & Sibhatu, 2011).
Although few studies actually quantified the number of miles traveled before LTBI
treatment noncompletion became likely, the findings of these studies suggest that in the
rural setting, where travel to the nearest health department may be lengthy, distance may
serve as a predictor of noncompletion for those living far from the nearest treatment
dispensary.
Area of resettlement. Refugees and immigrants arriving in the United States are
typically encouraged to resettle in areas where others from their native country may
already be established (United Nations High Commissioner for Refugees [UNHCR],
2015). Many of these areas are urban localities (UNHCR, 2015). In recent years, four of
the top 10 states with the highest per capita rates of resettlement were in rural America
(Radford & Connor, 2016). This trend may influence LTBI treatment completion rates
and the eventual elimination of TB in the United States if the rural setting suffers from
low rates of completion. Although no identified studies explored the difference between
resettling in the urban region compared to the rural region and its potential impact on
LTBI treatment completion, some studies did explore how the urban setting may
influence these rates. Although not necessarily generalizable to the rural setting,
understanding LTBI treatment completion rates in the urban setting may assist in
describing the overall trend and may support the need for more thorough research in a
variety of settings.
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Ailinger, Moore, Nguyen, and Lasus (2006), and Fluegge (2015) used the crosssectional study design to each explore urban resettlement and LTBI treatment
completion. Examining data gathered from 53 Latino immigrants relocating to the urban
U.S. setting, Ailinger, Moore, Nguyen, and Lasus (2006) determined that adherence
issues are complex. Additionally, the researchers concluded that in the sampled
participants, adherence appeared especially difficult since the preventive nature of LTBI
treatment was deemed a lower priority to adjustment to their new country. As such,
completion rates tended to suffer. With the data from 552 urban TB clinic attendees,
Fluegge (2015) found that as an area’s disease burden increased, adherence dwindled
requiring more creative approaches to improve completion. Specifically, Fluegge (2015)
found that in the urban setting, persons with more frequent interactions with their Public
Health Nurse providing their preventive therapy, the likelihood of treatment completion
improved.
Dobler and Marks (2012), Morano, Walton, Zelenev, Bruce, and Altice (2013),
Wingate et al. (2015), and Juarez-Reyes, Gallivan, Chyorny, O’Keeffe, and Shah (2015)
each studied foreign-born cohorts in the urban setting to describe LTBI preventive
treatment completion. In an Australian metropolitan area, 75% of the originally recruited
216 participants in a study conducted by Dobler and Marks (2012) assigned to a sixmonth regimen of INH for treatment of LTBI dropped out during the second half of the
six-month period. This finding speaks to the negative impact the lengthy duration of
treatment can have on individuals. The following year, Morano, Walton, Zelenev, Bruce,
and Altice (2013) conducted a prospective cohort study involving 357 foreign-born
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persons residing in inner city Connecticut that also suffered from lower rates of treatment
completion albeit a mobile clinic dispatched to help improve these rates demonstrated
some success. In the rural setting, such an intervention may be feasible however, could
require the mobile clinic to travel much larger distances and thus, be more resource
intensive. Potentially addressing this issue, Wingate et al. (2015) proposed that all
international urban centers with a high incidence of TB could contribute to U.S. TB
control cost-savings if overseas TB screening was more rigorous prior to United States
entry since only 75% of those entering actually follow up for further medical evaluation.
Lastly, Juarez-Reyes et al. (2015) deployed a short course, 12-week regimen of INH and
rifapentine(3HP) to improve LTBI treatment completion rates in a prospective cohort
drawn from an urban county jail, of which foreign-born participants were numerous.
Unfortunately, the institutionalized nature of the sample may not allow for much
generalization to the non-incarcerated population, but the drastic increase in successful
LTBI treatment completion, from 18% before 3HP to 85% after, could produce some
rural-setting successes.
Although lacking findings on urban versus rural resettlement on the rate of LTBI
treatment completion, it is important to note that in the urban setting, completion issues in
the foreign-born are complex. Overall, environmental factors have been more
consistently associated with LTBI treatment completion compared to the host factors
explored however the research settings and sampled populations included are not
representative of persons outside of the urban or high-incidence setting. Additional
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research is needed in the rural setting to determine whether environmental factors play a
significant role in LTBI treatment completion rates.
Agent. The final component of the epidemiologic triangle that may be important
to determining the predictors of LTBI preventive treatment completion are those related
to the organism itself, or the agent, that may be necessary to produce the disease in
question. In the case of LTBI, where no diagnostic tool exists that detects the presence of
Mtb in a latent state, measuring immunologic response is used as a proxy for assuming
infection, barring exclusion of active disease. The TST and the IGRA measure the host’s
immunologic response to Mtb antigens which if positive, suggest past infection and not
necessarily current microbial presence (Collins, Geadas, & Ellner, 2016; Ling & Flynn,
2010). Unfortunately, the TST has limited sensitivity and specificity and may produce
false-positive results as a product of BCG vaccination or infection with other
nontuberculous mycobacteria found in the environment (Chee, Sester, Zhang, & Lange,
2013). The IGRA has improved sensitivity and specificity when compared to the TST in
BCG vaccinated persons. An individual’s positive response to a TST or an IGRA may
make them eligible for preventive LTBI therapy and potentially cured of the risk of
reactivation barring no future exposure (Chee, Sester, Zhang, & Lange, 2013). It is
unknown if the extent of TST positivity, in millimeters, or IGRA positivity are related to
LTBI treatment completion in the rural setting although some studies from the urban
setting have demonstrated an association.
Studies examining TST positivity and IGRA positivity as well as the relationship
with LTBI treatment completion are few. A limited number of studies have been
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developed to look at general positivity and the relationship to LTBI treatment completion
while many studies simply describe overall positivity trends often comparing TSTs to
IGRAs. IGRA positivity in relation to LTBI treatment completion has been even less well
studied compared to TSTs. Although specific studies examining the relationship between
TST or IGRA positivity and LTBI treatment completion are lacking, reviewing the trends
established in TST and IGRA positivity-related research is a critical step prior to
deploying further in-depth research.
TST or IGRA positivity. As described by Campbell, Krot et al. (2015), men tend
to be TST positive more frequently than women, immigrants tend to have higher rates of
positivity by TST than by IGRA, and older age groups are also more likely to be TST
positive compared to younger age groups. Levesque, Dongier, Brassard, and Allard
(2004) also determined that age was a predictor of TST positivity, with older adults more
likely to screen positive and the lifetime risk of reactivation estimated at 20% in TST
positives (Horsburgh, 2004). This study did not include a LTBI treatment completion
component so no conclusions can be drawn pertaining to a potential association. Lastly,
from the only nationally representative sample known to have TSTs placed on the general
populace, Miramontes et al. (2015) concluded that overtime, the rate of TST positivity in
the United States has not changed significantly from 1999-2000 and 2011-2012
potentially indicating that the number of persons infected with Mtb is not growing.
The measure of TST positivity, for those studies including interval levels of
measurement, was inconsistently associated with LTBI treatment completion. Two crosssectional studies have been conducted surrounding TST positivity and LTBI treatment
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completion status, with the researchers concluding that recent TST converters, persons
who went from negative to positive within two years, were more likely to complete
treatment compared to non-recent converters (Bieberly & Ali, 2008; Reichler et al.,
2002). In 2002, Reichler et al. reviewed health department records from five urban U.S.
sites for 447 individuals, 89% of whom completed treatment. Reichler et al. (2002) also
concluded that recent converters were more likely to be offered treatment compared to
their counterparts not known to recently convert potentially impacting the study findings
due to these inconsistencies in provider practice. Bieberly and Ali (2008) also reported
that recent converters had higher rates of treatment completion in their analysis of records
from 380 patients residing in New Orleans. Unfortunately, 85% of those aged 19 to 34
included in the study were lost to follow-up, limiting the analysis for this group, but these
findings are likely supported by the work reported by Reichler et al. (2002).
In a retrospective study, Çakar, Demir, Karnak, and Özkara (2014) concluded that
TST positive persons residing in Ankara, Turkey were more likely to complete treatment
however exact induration size was not available for analysis so it is difficult to conclude a
specific reaction size-association may be present or absent. The higher rate of treatment
completion, at 89% for Çakar, Demir, Karnak, and Özkara (2014) could demonstrate that
certain TST positive persons may perceive their infected status as more severe, for
example those with a larger induration, and might be more likely to complete treatment.
Overall, TST positive-related factors have been somewhat consistently associated with
LTBI treatment completion although these studies are only a minority of the number of
studies strictly looking at what kinds of people tend to be TST positive. Similarly, a
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prospective cohort designed and carried out by Fiske et al. (2014) demonstrated that those
with indurations measuring 10 to 19 millimeters were likely to not complete the full
course of LTBI treatment (p = 0.04; OR = 0.51; 95% C.I. 0.27, 0.97), characterizing this
size of positive reaction as a predictor of treatment noncompletion.
In a study stratifying analysis by size of TST reaction, the retrospective cohort
performed by Spicer et al. (2013) involving 1,516 children from urban Connecticut,
failed to reveal consistencies between TST reaction size and LTBI treatment completion.
This study was limited by the inability to verify actual treatment completion and was
reliant upon pharmaceutical records for determining whether medications were picked up
by those included in the study. This may have resulted in an underestimation of
completion if persons filled their prescriptions from different pharmacies during the study
period (Spicer et al., 2013). Interested in looking specifically at the risk of failing to
complete treatment, Chang, Eitzman, Nahid, and Finelli (2014) performed a retrospective
cohort involving 1,872 participants recruited from two different California county sites.
With an overall completion rate of 78%, Chang et al. (2014) concluded that being aged
15 to 18 years, non-Hispanic race, development of hepatitis, and symptoms of adverse
events were associated with noncompletion however, TST size of positivity was not.
No studies were identified that evaluated the relationship between IGRA
positivity and LTBI treatment completion. As only one of two diagnostic tools available
for supporting a diagnosis of LTBI, IGRA positivity is often studied in a comparative
manner to TST. To date, no gold standard exists for diagnosing LTBI prompting
researchers to continuously evaluate the sensitivity and specificity of the TST and IGRA
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to provide evidence for the recommendation of the use of one diagnostic tool over the
other. Current research indicates IGRAs are more sensitive than the TST in BCG
vaccinated persons (LoBue & Castro, 2012) however the two tools currently remain
interchangeable under most circumstances (LoBue & Castro, 2012).
Of the studies published exploring the impact the use of IGRAs have on LTBI
treatment completion, none directly compared IGRAs to TSTs. A single retrospective
study conducted by Shah et al. (2012) compared treatment initiation and completion rates
pre-IGRA implementation and post-IGRA implementation including 607 participants and
750 in Baltimore, respectively. Shah et al. (2012) concluded that there was no difference
between the rate of treatment initiation or treatment completion after the implementation
of IGRAs in the Baltimore City Health Department. However, claiming IGRA positivity
as a predictor of treatment initiation or completion was not possible due to the study’s
design which lacked the parallel arm that studied these trends with TSTs. Dewan et al.
(2006) in a prospective cohort involving 4,143 persons evaluated for LTBI at six San
Francisco clinics, attempted to evaluated the feasibility, acceptability, and cost of TB
testing by IGRA. Again, the study design prevented the researchers from determining if
IGRA positivity could predict LTBI treatment completion, but the researchers did
identify that more patients completed the LTBI medical evaluation when tested by IGRA
compared to TST. These results may indicate patients tested for LTBI via IGRA have
greater perceived risk and are more likely to complete medical evaluation and possibly
LTBI treatment; although this remains to be studied.
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Despite the limited number of diagnostic tools available for the diagnosing LTBI,
the restricted amount of research surrounding whether TST positive persons or IGRA
positive persons complete treatment at different rates may further contribute to the fact
that no gold standard exists, although agent factors such as this are likely critical. By
exploring which of the two positive groups complete treatment at higher rates, TB
Control Programs may be better equipped to implement interventions that promote
efficiency and may contribute to reducing future rates of TB disease.
The Gap
This literature review has demonstrated that the rural setting remains
underrepresented in study design, sampling, and in the overall number of publications
documenting LTBI treatment completion trends. The number of resources available to
control TB in the urban U.S. setting may differ dramatically compared to the rural
setting, greatly limiting the applicability of published urban-setting research to the rural
setting and drawing attention to this significant gap. Data on the host, environment, and
agent-related predictors of LTBI treatment completion are growing however continue to
disproportionately represent non-rural settings creating an impetus for rural setting
research. Understanding LTBI treatment trends in the foreign-born residing in all U.S.
settings will broaden the depth of understanding surrounding these persons whom are at
greater risk of being infected with Mtb and may better assist all U.S.-based TB Control
Programs move toward elimination.
The analysis of the LTBI treatment completion research is also somewhat
homogenous identifying another gap that this research intends to assist in addressing. A
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majority of the articles reviewed analyzed data using regression techniques however, this
approach does not account for censoring and ignores the element of time which may be
critical to the LTBI treatment completion trends described previously. Using survival
analysis to explore host, environment, and agent-related independent variables and the
relationship to LTBI treatment completion will help close these gaps as survival analysis
accounts for censoring as well as the time to event.
The inconsistencies identified in the host, environment, and agent variables
reviewed and their ability to predict LTBI treatment completion produces a strong call for
greater research to explore these factors across a broader setting. Additionally, these
inconsistencies may indicate that LTBI treatment completion is a localized phenomenon
likely influenced by the individuals receiving treatment (host), their area of residence
(environment), as well as their perceived severity of being infected and the risk of
developing transmissible disease along with disease-related sequellae (agent). Studying,
the factors associated with LTBI treatment completion in the rural setting could assist in
closing this gap in knowledge but may also help better target specific, necessary
treatment completion improving interventions in the rural setting.
Summary
This present literature review was conducted to determine what was currently
known about LTBI treatment completion trends in the rural U.S. setting as TB Control
Programs are increasingly pressured to address the pool of latently infected persons. To
move the United States toward elimination in the face of declining rates of active disease,
characterizing LTBI treatment completion trends in a variety of settings using a variety of
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samples will likely achieve a more thorough understanding of the gaps that exist in
practice that may prolong the move toward elimination. This literature search revealed
the rural setting is wholly underrepresented in current research leaving TB Control
Programs serving this setting reliant upon implementing treatment completion improving
interventions that have been extrapolated from research done in the urban, resource rich
setting. This dissertation research will add to the evidence currently available on the
predictors of LTBI completion from the urban setting by characterizing the rural-based
LTBI treatment completion trend.
Many host-related LTBI treatment completion factors have been explored.
Multiple studies have noted inconsistencies in using sex as predictors of LTBI treatment
completion research. Unlike sex, researchers tend to find age-related associations with
LTBI treatment completion often however, the valid research published showing no
association cannot be ignored. Birth country, also a thoroughly studied independent
variable, is frequently supported as a predictor of LTBI treatment completion. Smoking
status is understudied but too is thought to be a predictor of LTBI treatment completion.
Exploring these factors in the rural setting, as is proposed by this dissertation research,
will assist in filling the gap that currently exists surrounding this demographic.
Environment-related LTBI treatment completion factors are less well studied
however, consistent trends have emerged. Persons traveling greater distances or spending
more to travel to LTBI treatment facilities are consistently reported to be at greater risk of
delaying LTBI medical evaluation or not completing LTBI treatment compared to their
counterparts. Likely with greater distances to travel in the rural setting it is unfortunate
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that virtually no studies have been published examining this phenomenon but instead,
have focused solely on urbanites. Agent-related factors are equally less studied in relation
to LTBI treatment completion although some studies are available that describe who
tends to be TST or IGRA positive as well as compare the sensitivity and specificity of the
TST and IGRA.
A retrospective study using survival analysis to identify potential predictors of
LTBI treatment completion in the rural setting is a novel approach to addressing the gap
that currently exists in the literature. Additionally, intending to describe LTBI treatment
completion trends in the rural-based foreign-born population too is a unique approach
that has thus so far failed to be adequately covered in the literature. The rural setting
differs significantly in structure and resource availability from the urban setting and thus,
studying LTBI treatment completion trends in this context will not only add to the body
of knowledge but may also be critical to shaping appropriate public health interventions
in this setting. The methodology for addressing this gap in knowledge is detailed in
Chapter 3 where the rational for the study design, the data sources, the variables of
interest, and the planned analysis used to quantify treatment completion and identify
predictors of completion and noncompletion are described.
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Chapter 3: Research Method
Introduction
This main purpose of this research was to describe the epidemiology of LTBI
treatment completion in refugees, immigrants, and other visa holders resettling in the
rural state of Idaho. Consistently, foreign-born persons account of over 60% of the active
TB disease burden in Idaho, which is likely due to reactivation from prior overseas
exposure (IDHW, 2016; Schmit et al., 2017). Preventive LTBI therapy initiated at the
time of arrival in Idaho can reduce this risk of reactivation and may improve active TB
disease rates over time in the state (Blount et al., 2016; Pareek et al., 2016). This research
aimed to determine what independent variables predicted noncompletion for visa holders
initiating LTBI treatment. Similar research had shown LTBI treatment completion could
be influenced by host, environment, and agent factors (Coly & Morisky, 2004; HirschMoverman et al., 2008; Malangu & Yamutamba, 2016; Parsyan et al., 2007).
Identification of completion influencing variables could promote the development of
targeted interventions in the resource-limited setting like Idaho. Unfortunately, little
research had focused on the identification of these potential predictors in the rural-U.S.
setting. This retrospective cohort study was consistent in research design and had a
similar overarching goal with that of comparable work conducted in the high-incidence or
international TB setting; however, I made modifications to account for the level of data
available for testing the hypotheses in question, for making interpretations, and for
drawing conclusions (Johnson et al., 2016; Malejczyk et al., 2014; Parsyan et al., 2007).
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In this chapter I describe the study design to address the research questions, the
sample size, the source of the data, the relevant variables, data cleaning and management,
and the analytical methods. The chapter also covers any ethical concerns related to this
research.
Research Design and Rationale
This was a retrospective cohort study using a secondary dataset. When attempting
to describe the epidemiology of LTBI treatment completion and determine if certain host,
environment, and agent factors are predictive of LTBI treatment completion, the
retrospective cohort study had been demonstrated to be appropriate. Several researches
had been conducted using this method (Chang et al., 2014; Li et al., 2009; Lines et al.,
2015; Malejczyk et al., 2014; Parsyan et al., 2007; Spicer et al.; 2013). Collectively, these
studies demonstrated the value of the cohort method to investigating LTBI treatment
completion associated factors.
This retrospective cohort study identified two cohorts of LTBI subjects based on
their visa status at the time of entering the United States. The study followed the subjects
from receiving medical evaluations shortly after resettlement in Idaho to the expected
time of completing LTBI treatment, if diagnosed with LTBI, during the study period. The
primary dependent variable was LTBI treatment completion status among categories of
visa holders. Independent variables included demographic characteristics (i.e., age, sex),
visa type, smoking status, country of origin, distance from residence to LTBI treatment
facility, urban or rural resettlement, TST or IGRA positivity, and the time measured in
days between date of arrival and initial medical follow-up. The reason for selecting these
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factors was that many had been shown to influence LTBI treatment completion from
research conducted in the high-incidence TB setting, the international setting, and in the
urban U.S. setting. These independent variables were assessed individually and
collectively for their impacts on LTBI treatment completion or total time on LTBI
therapy.
Since global migratory patterns change annually, this retrospective study was
limited to a sample population completing LTBI treatment between January 1, 2012 and
December 31, 2016. In Idaho, the number of visa holders arriving fluctuates, but since
2012, arrivals from Iraq, Democratic Republic of Congo, Myanmar, Somalia, and Bhutan
have continuously represented the top five countries of origin for resettlers in the state
(CDC, 2017). The retrospective cohort design fit this research due to the limited change
in year-to-year arrivals by country in Idaho and should be useful for application to future
visa-holder arrival trends. Additionally, since TB resources are scarce in Idaho, the
retrospective nature of this study did not impose extra burden compared to other study
designs as the data for analysis had already been collected.
Data Sources
Electronic Disease Notification System
Data for this research was derived from a single surveillance system, detailed in
Figure 1. The CDC’s EDN system is the only nationwide secure platform housing
medical information for migrants arriving to the United States with notifiable conditions
(CDC, 2011). The EDN houses the electronic versions of the Department of State forms
required for migration including the results of overseas medical examinations, treatments,
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and immunizations (CDC, 2011). This information is accessible to approved public
health officials in the United States. The system allows for these state and local health
departments to enter the results of postarrival tuberculosis follow-up examinations using
a standardized TB Follow-up Worksheet for persons arriving with a TB Notification
(CDC, 2011).

Figure 1. EDN data entry process and research data set methods.
EDN sources of data. The EDN system is populated daily with the Department
of State forms collected by the U.S. Customs and Border Protection agents stationed at
airports designated to receive migrants with admissible notifiable health conditions
(CDC, 2011). These forms are sent to the CDC’s quarantine stations for upload into EDN
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shortly after new migrant arrival. The EDN program receives the collected forms from all
20 quarantine stations located at the U.S. ports of entry (CDC, 2011). Persons’ records
indicating follow-up for TB or LTBI from prearrival medical evaluations are marked with
a “TB Notification” (CDC, 2011). Persons thought to be infected with Mtb but not
infectious (e.g., latent tuberculosis) are designated with a B2 or B3 TB classification
(CDC, 2011; Lee et al., 2013). These classifications were the focus of this research. The
EDN forms are converted to electronic content and securely stored for future access by
the visa-holder receiving jurisdiction. Although EDN houses multiple aspects of new
migratory arrivals health status, the standardized TB Follow-up Worksheets currently
contained most of the necessary data elements for this dissertation research. Access to
any other EDN dataset was limited to Department of State forms 2053, 3026, and the TB
Follow-up Worksheet (CDC, 2011).
Idaho EDN sources of data. Representatives of the Idaho State TB Program are
notified via e-mail of all visa holders arriving in the state that require medical evaluation
for LTBI or TB disease. Seven agencies in Idaho are responsible for coordinating the
follow-up of these visa holders or performing these evaluations. Preliminary and final
medical follow-up records on all newly arrived visa holders requiring follow-up for TB
are submitted to the Idaho State TB Program, and I used data from records submitted
between January 1, 2012 and December 31, 2016 for this research. In Idaho, at least one
public health official or representative from each of the seven public health districts
covering Idaho’s 44 counties has record management access to EDN. This permission
setting allows end users to receive electronic notifications for new migratory arrivals
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requiring TB or LTBI follow-up, print the necessary overseas medical records, and
generate a migrant-specific TB Follow-up Worksheet. Medical TB evaluations generally
take place within 90 days postarrival. Initial findings are recorded, diagnoses made, and
when necessary, treatment recommended. All TB Follow-up Worksheets are then
submitted to the Idaho State TB Program per contractual arrangements. Submission of
these follow-up forms makes the evaluating agency eligible for reimbursement for some
of costs of these visa-holder medical evaluations from the State TB Program. Upon
receipt, staff with the Idaho State TB Program enters the TB Follow-up Worksheet
findings for electronic submission to the CDC. Visa holders recommended for TB or
LTBI therapy had an initial TB Follow-up Worksheet submitted to the state and a final
submitted at the time of treatment completion or disposition.
Access to Idaho data. The Idaho State TB Program manager and the Idaho state
TB controller, along with local-level epidemiologists and health care providers associated
with each of Idaho’s PHDs can access EDN data through a CDC portal requiring
validated credentials for log-in. Idaho EDN users can electronically download all
predeparture, postarrival, and TB follow-up records for any visa holder arriving in the
state with any classification. I accessed only B TB classifications for the purposes of this
research. Data downloaded included all necessary variables for this research; however,
matching of records was required as the data existed in three separate report exports. I
used unique “alien numbers” assigned to every arriving visa holder to match records as
this number was consistent across all EDN report exports. All matched records were
combined into a single dataset for analysis.
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To access the EDN data, I submitted an e-mail detailing the data request to the
Idaho State TB Program for forwarding on to the Idaho Division of Public Health
Institutional Review Board (IRB). This occurred before the Walden University IRB
approval process to conduct this dissertation research so as to obtain a data use agreement
(DUA) and letter of cooperation signed by an Idaho Division of Public Health
representative. Requested data was de-identified and in Excel spreadsheet format with a
single row representing the unique EDN record for a visa holder in Idaho for the
specified timeframe and each column representing a demographic factor or a research
variable. The EDN dataset included the following variables for this research, among
others: sex, date of birth, country of origin, visa type, date of arrival, date of medical
evaluation in the United States, smoking status, HIV status, address of resettlement, TST
results, IGRA results, disposition code, treatment start date, and treatment stop date. Only
a subset of the variables recorded in EDN were used in this dissertation research; they are
described later in this chapter. The dataset was obtained from the Division after Walden
IRB approval.
Instrumentation
Since this was a secondary database research, it did not have its own study
instrument for data collection. EDN data are collected using standardized, nationally
developed formal instruments (CDC, 2011). The Idaho state TB Program uses these EDN
standard forms to collect TB and LTBI medical evaluation information on visa holders
and these were used to produce the dataset for this research. The EDN TB Follow-up
Worksheet is available only through the secure CDC application but includes
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predeparture medical evaluation results, post-arrival medical evaluation findings, TB and
LTBI treatment initiation data, and treatment completion data. The EDN TB Follow-up
Worksheet has been and currently still is used nationally to ensure consistency in the
reporting of TB medical evaluation findings after the foreign-born arrive in the United
States. For this dissertation research, this instrument was not tested or further validated as
the Idaho state TB Program has been relying on this form for data collection related to
this research for over a decade. The version of the EDN TB Follow-up Worksheet used
for this research can be found in Appendix A at the end of this dissertation.
The data analyzed for this study were submitted from six different public health
departments and a single Federally Qualified Health Center (FQHC) specializing in the
diagnosis and treatment of LTBI and TB disease. All seven entities utilized the
standardized, nationally developed TB Follow-up Worksheet to record predeparture
medical findings, post-arrival screening results, treatment decision, and final disposition.
Dispositions include “no exposure, not infected”, “TB exposure, no evidence of
infection”, “TB infection, no disease”, “TB, TB disease”, and “TB, inactive disease”.
Tuberculosis Follow-up Forms from all seven entities were submitted to the Idaho state
TB Program for data entry. The dataset used for this research was derived from EDN
standard reports and exports for data entered for the “Idaho” jurisdiction.
Research Questions and Hypotheses
This study described LTBI treatment completion trends in the foreign-born
residing in the rural state of Idaho and explored potential predictors of treatment
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completion using host, environment, or agent-related factors that could influence the
outcome. The specific research questions for this research are outlined below.
RQ1: Is visa type (refugee, immigrant, parolees, asylees, or fiancés) associated
with LTBI treatment completion among permanent visa holders initiating LTBI
treatment in Idaho?
H01: There is no association between visa type and LTBI treatment
completion among permanent visa holders initiating LTBI treatment in Idaho.
Ha1: There is an association between visa type and LTBI treatment
completion among permanent visa holders initiating LTBI treatment in Idaho.
RQ2: Is the mean time distribution to last treatment for LTBI between permanent
visa holders initiating LTBI treatment in Idaho significantly different?
H02: The mean time distribution to last treatment for LTBI between
permanent visa holders initiating treatment in Idaho is not statistically
difference.
Ha2: The mean time distribution to last treatment for LTBI between
permanent visa holders initiating treatment in Idaho is statistically different.
RQ3: Is time on LTBI treatment in permanent visa holders initiating treatment in
Idaho affected by sex, age, country of origin, visa type, smoking status, distance
between residence and treatment facility, area of resettlement, time between
arrival and initial medical evaluation, TST positivity, or IGRA positivity?
H03: Time on LTBI treatment in permanent visa holders initiating treatment in
Idaho is not affected by sex, age, country of origin, visa type, smoking status,
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distance between residence and treatment facility, area of resettlement, time
between arrival and initial medical evaluation, TST positivity, or IGRA
positivity
Ha3: Time on LTBI treatment in permanent visa holders initiating treatment in
Idaho is affected by sex, age, country of origin, visa type, smoking status,
distance between residence and treatment facility, area of resettlement, time
between arrival and initial medical evaluation, TST positivity, or IGRA
positivity.
Additional Research Questions
Although not directly related to above research hypotheses, this study also
explored the potential association of the prescribed LTBI treatment regimen and
treatment completion status. In Idaho, at least one TB Clinic is known to be consistently
using the expedited 12 week LTBI treatment regimen while other clinics are known to
rely on standard LTBI treatment spanning four, six, or nine months. This research
attempted to determine if the regimen prescribed influences the likelihood of completion
as some studies have shown shorter regimens equate to higher completion rates. The role
LTBI treatment prescribing provider in Idaho may also be important to treatment
completion and was thus, a secondary research result. Research participants were
grouped by the prescribed treatment regimen during analysis of the first additional
research goal and by the prescribing provider for the second additional research goal.
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Population
This study included only visa holders in Idaho diagnosed with LTBI either by
panel physicians overseas (e.g. predeparture) or by a health care provider representing
one of Idaho’s seven PHDs after arrival and whom have met the study eligibility criteria
listed below. These visa holders arrived in Idaho through traditional United States
immigration channels and had predeparture medical records designated as Class B TB,
requiring medical follow-up upon arrival to the host jurisdiction, and had not initiated
treatment overseas. Typically, U.S. migrants do not initiate LTBI treatment prior to
arrival however, persons with active TB disease must complete treatment prior to
departure. Visa holders with non-Class B TB notification but found to have LTBI after
evaluation in Idaho were also included.
Sampling and Sampling Procedures
All visa holders that started LTBI therapy post-arrival to Idaho and whom were
eligible for inclusion were included in this study. Sampling techniques were not used to
select the study subjects. To be included in this study, the following criteria were met:
•

Visa-holder diagnosed with LTBI.

•

Clinical or laboratory findings consistent with active TB absent.

•

Initiation of preventive therapy in Idaho.

•

Preventive therapy start date on or after January 1, 2012.

•

Preventive therapy completion date on or before December 31, 2016, for those
completing treatment.
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•

Resided in Idaho at time of treatment initiation and completion, for those
completing.

•

If evaluated multiple times during the study timeframe, only the instance in
which preventive treatment is initiated was included.

A visa-holder was considered to reside in Idaho if predeparture and post-arrival
demographic EDN records indicated that individual’s physical address was associated
with an Idaho zip code. This determination was made by the Idaho state TB Program staff
at the time of research dataset creation as the Idaho state TB Program is made aware of
residence status changes and is responsible for transferring records between jurisdictions.
The criteria for study exclusion was:
•

Visa-holder diagnosed with LTBI not initiating preventive therapy.

•

Visa-holder found to have active TB disease at the time of resettlement.

•

Preventive treatment initiation outside of the timeframe specified above.

•

Preventive treatment initiation in a jurisdiction other than Idaho.

•

Visa holders initiating preventive therapy in Idaho but moving out of the state
prior to completion.

Sample Size Calculations
The sample for this research was drawn from secondary data collection using
nonprobability sampling procedure. All eligible visa holders in Idaho initiating LTBI
preventive therapy were included in the research thus randomization was not involved.
Since the rate of LTBI treatment completion in the Idaho visa-holding population was
unknown, purposive sampling was best to ensure all eligible participants during the five-
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year study period were intentionally included in the study. This sample may not be
representative of similar groups at the national level, however, likely represent the visaholding population in Idaho well.
A G*Power analysis (Faul, 2014) was used to estimate the minimum sample size
required for evaluating the first research question involving the treatment completion rate
among three study groups. The formula to calculate the degrees of freedom, a component
of the sample size calculation, was (rows -1) x (columns - 1) where treatment completion
status (yes, no) represented the rows and visa-type (refugee, immigrant, other)
represented the columns. To detect a 10% of difference among groups using chi-square
test and two degrees of freedom at an alpha level of 0.05 and a power of 0.80, assuming
the LTBI treatment completion rate is 28.5%, this study would need 841 subjects divided
across each group. To detect a 20% difference among groups using the same
aforementioned parameters and a treatment completion rate of 24.5%, this study would
need at least 229 subjects. To assess the impact of various treatment completion rates,
Table 1 shows the samples size needed for different rates.
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Table 1
Minimum Sample Size: χ² tests - Goodness-of-fit tests: Contingency tables
Treatment completion
rate in each group

Alpha

Power

Detectable difference among three
study groups

Sample size

10%

0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05

80%
90%
80%
90%
80%
90%
80%
90%
80%
90%
80%
90%
80%
90%

77%
77%
33%
33%
7%
7%
20%
20%
10%
10%
14%
14%
33%
33%

16
21
87
114
1,821
2,392
229
300
841
300
521
684
114
87

20%
30%
24.5%
28.5%
40%
50%

This study used all eligible subjects without limiting to the minimum sample size.
However, it was assumed that even if the database could only provide 76 subjects, it
would have 80% power using survival analyses to detect the 20% difference at 0.05
significance level and a hazard ratio not equal to one indicating that survival was better in
one or two of the groups.
Acquisition of the Database
A de-identified line list of the Idaho EDN data was obtained from the state TB
Program through formal electronic request. The use of the EDN data for research
purposes mandates the submission of an electronic request for the data. The data request
was submitted to the Bureau of Communicable Disease Prevention (BCDP) prior to
Walden IRB approval to establish a DUA, letter of cooperation, and the Division of
Public Health “Research Determination” process, so appropriate documentation could be
provided at the time of Walden IRB submission. At the time of this request, the IDHW
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Division of Public Heaths’ IRB process would have been initiated if the research
determination team indicated the request was for research related data. However, the
research determination team indicated the requested dataset was for public health
practice, so the Division of Public Health’s IRB was not needed to be consulted. The deidentified EDN database was requested in Excel spreadsheet format.
After Research Determination Committee approval was received from the IDHW
Division of Public Health and Walden University IRB approval, creation of the
secondary data file occurred. The Idaho TB Program removed all visa-holder names from
the dataset. The EDN data reports available for download were merged into a single
dataset using the unique alien number, which was removed prior to dissemination of the
final dataset since alien numbers could be used to identify individuals. Physical addresses
of resettlement were geocoded and miles between nearest public health department
calculated. After calculation by TB Program staff, residence numbers and street names
were deleted but zip codes retained to determine urban and rural residency. Visa-holder
dates of birth were also removed from the line list after age was calculated by the
Program staff. At the time of data analysis, ages were grouped and assigned a numerical
value (Table 3). Since the data file created by the TB Program did not include Protected
Health Information its use did not require informed consent.
Dataset Quality
The primary data entered into the EDN system for the Idaho jurisdiction is subject
to routine quality assurance. Quarterly, TB Program staff query the EDN application to
detect missing reports, arrivals transferring to out of state jurisdictions, and percentage of

102
TB Follow-up Worksheet variable completion. Arrivals missing TB Follow-up
Worksheets are brought to the attention of local public health officials and an evaluation
status determined. If the visa-holder was determined to have relocated to a non-Idaho
jurisdiction, EDN records are electronically transferred and removed from the Idaho
dataset. Missing variables associated with the TB Follow-up Worksheets are also brought
to the attention of local public health officials and if made available, entered to improve
data completion. Records are also reviewed for quality and identified fields with
erroneous or questionable data are followed-up on and corrected when necessary.
Due to the recurring data quality assurance practices of the Idaho TB Program
staff, it was hypothesized that the secondary dataset requested for this research was of
high quality. The request for the secondary dataset called for the inclusion of incomplete
records, however, none were identified by the Program and none required removal from
the dataset prior to analysis for this research. This approach assisted in determining the
percentage of data completion and thus, the potential quality of the data used in this
research. Additionally, the routine review of the primary dataset likely reduced data entry
errors, improving the quality of the secondary dataset. Missing data would have
potentially only influenced the assessment of research question one and although the
survival analysis involved in research questions two and three can handle missing data,
the covariate analysis could have been negatively impacted if missing data was high,
albeit was not. TB Program staff created variables could have introduced data entry
errors, however, data reviews conducted prior to analysis for this research promoted
improved data integrity.
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Addressing data integrity issues. Prior to data analysis, the secondary dataset
received from the Idaho state TB Program was assessed for data completion. Many of the
variables for this dissertation research were derived from EDN required data entry fields
however, not all variables, if left incomplete, would have prevented data entry staff from
submitting the EDN content. Incomplete variables were possible but it was assumed that
data would have been missing completely at random due to data quality assurance
practices in place at the program level. Prior to receiving the dataset, it was planned that
records with missing data would require deletions since the de-identified nature of the
dataset would not allow for the TB Program to collect additional information. As such,
listwise deletion had the potential to reduce the external validity of this research.
Contractual obligations that assist in ensuring a high percentage of data completion for
Idaho public health officials or health care providers evaluating newly arriving visa
holders led to the assumption that data would be missing completely at random, but many
data missing at random could have decreased the overall power of this study (Kang,
2013). This was not an issue, however. Encountering a small sample size at the start of
data analysis may have indicated pairwise deletion should have been used to maintain the
sample size, sustain power, and promote stable external validity (Kang, 2013). Again,
however, missing data was not an issue with this dissertation research so no deletion
methods were deployed.
Study Variables and Data Set Components
This research compared the treatment completion rates in categories of migrants
and explored the potential risk factors as covariates on the completion rates. For this
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research, LTBI treatment completion, or the primary endpoint, was defined as completing
90% or more of the doses originally prescribed at the time of visa-holder LTBI diagnosis
within the prescribed regimen duration. Research participants on the expedited 12-week
regimen should have completed 90% or more of doses by the twelfth week, those on four
months of RIF must have completed 90% or more of doses by the end of month four,
while those on six or nine months of INH should have completed 90% or more of doses
by the end of month six or nine. The minimum number of doses for successful treatment
completion is included in Table 2. This definition is consistent with real-world practice as
persons prescribed LTBI treatment who complete at least 90% of their doses are
considered successfully treated. This is also a standard of practice in Idaho.
Table 2
Minimum Number of Doses (≥90% of prescribed) for Completion
Age group
Adult

Regimen
Prescribed duration
INH+RPT
12 weeks
RIF**
4 months
INH**
6 months
INH**
9 months
Children
INH+RPT*
12 weeks
RIF**
4 months
INH**
6 months
INH**
9 months
Note. INH=Isoniazid, RPT=Rifapentine, RIF=Rifampin
*Children 12 and older
**Based off daily regimen
***Must be completed by end of "Prescribed Duration"

Standard doses
12
120
180
270
12
Not Recommended
Not Recommended
270

Minimum doses***
11
108
162
243
11
n/a
n/a
243

The study variables included completion status (yes or no) and subject
demographics shown in Table 3. These demographic factors are also considered hostrelated factors in this dissertation research.
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Table 3
Demographic Variables, Descriptions, and EDN Source Form
Variable

Variable description

Sex

Nominal

Age group

Nominal/Calculated

Country of origin
(collapsed into WHO
region)

Nominal

Visa type

Nominal

Smoking status

Nominal

Value
1=Male
2=Female
0=24 years
1=25-44 years
2=45+ years
1=Americas
2=European or
Eastern
Mediterranean
3=African
4=South-East Asia
5=Western Pacific
Region
1= refugee
2=immigrant
0=Nonsmoker
1=Current smoker
2=Ex-smoker

Variable data source
Form DSForm DS2053
3026
X
X

X

X
X

Environment (Table 4) and agent-related (Table 5) independent variables were
included in the dataset and were also used to determine what impact they may have on
LTBI treatment completion.
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Table 4
Environment-related Variables, Descriptions, and EDN Source Form
Variable
Distance between
residence and
treatment facility
Area of
Resettlement
Time between
arrival and initial
medical
evaluation

Variable description
Ordinal/Calculated

Value
Number of miles

Variable data source
Form DS-2053
Form DS-3026

X

Nominal/Calculated

1=Urban
2=Rural

X

Ordinal/Calculated

Number of days

X

Table 5
Agent-related Variables, Descriptions, and EDN Source Form

Variable

Variable
description

TST
positivity

Nominal

IGRA
positivity

Nominal/Binary

Value

Variable data source
Form
Form DSDS-2053 3026

0=Negative
1=Positive
2=Unknown
0=Negative
1=Positive
2=Indeterminate
3=Invalid
4=Unknown

Form Followup Worksheet

X

X

The EDN system has established a definition for each variable included in the
system as well as acceptable values for data entry. This EDN data dictionary was critical
to understanding the contents of report exports and all independent variables extracted
from EDN included in this research are detailed below.
Sex. In the EDN, “sex” is a binary variable. Currently, only categorical entries are
allowed with “M” representing male sex and “F” representing female sex. This variable is
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also a mandatory element for data entry. Upon export of EDN data, sex is represented as
“M” or “F”. For data analysis, Male=1 and Female=2.
Age. Age is not a variable included in the EDN dataset that is available for export.
Department of State variables such as date of birth are included in the EDN. Upon export,
age was calculated by the Idaho TB Program staff to the nearest year from the listed date
of birth and the date of arrival. Date of birth in EDN is reported in MM/DD/YYYY
format and are values that were excluded from the final dataset, after age as calculated,
due to the sensitive nature of this information. For the purposes of data analysis, age
categories were established (Table 3).
Birth country. Information about birth country and country of residence prior to
departure for the United States is gathered on all on visa holders in EDN. In most
instances, birth country is populated in EDN however, may be unknown for some
refugees. When unknown, prior country of residence was used as a proxy for birth
country as both variables are included in the EDN export reports that produced the
dataset for this research. Both variables in the EDN export report included a unique twocharacter code tied to the full country’s name in the system supplied data dictionary for
cross-referencing. The unique two-character country code was expanded in the dataset to
include the respective country’s full name. To further improve participant protection, the
country of origin was assigned a numerical value associated with a WHO world region.
The world regions included: Americas, European or Eastern Mediterranean, African,
South-East Asian, and Western Pacific.
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Visa type. The EDN system only stores information for permanent U.S. visa
statuses. Immigrants are represented with an “I”, Parolee with a “P”, Fiancé with a “K1”
or “V1”, Refugee with a “R”, and Asylee with an “A”. All visa holders are only granted
one status so a combination of characters is not possible in the dataset. For the purposes
of this research, refugee visas were assigned a numerical value of one in the dataset,
immigrant visas a two, and parolee, fiancé, and asylee visas assigned a three. The refugee
and immigrant visa types are the most common in Idaho. Due to their small numbers
compared to the refugee and immigrant visa types, parolee, asylee, and fiancé visas were
combined into a single group, designated by three in the dataset.
Smoking status. Current or former use of tobacco is recorded on Department of
State form 3026 in EDN. As a nominal level of measurement, a yes response, coded as a
one, prompts a skip pattern requesting information on current for former status. Current
smokers receive a one while former smokers receive a two in the EDN export dataset.
Lifetime non-smokers receive a zero when responding to current or former tobacco use
and do not initiate the skip pattern functionality.
Distance. Each visa-holder must submit a physical U.S. address prior to
resettlement. For the purposes of this research, submitted physical addresses in Idaho was
used to calculate the “Distance” variable by the Idaho TB Program staff. Using
geocoding software, the distance in miles between the visa-holder’s listed United States
address and the Idaho Public Health District (or respective health agency) where
evaluation for TB and LTBI takes place was determined. The calculated distance in miles
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was retained in the final research dataset and physical house number and street name
were excluded by the Idaho TB Program staff to assist with reducing identifiability.
Area of resettlement. Each visa-holder is assigned an Idaho public health agency
responsible for their TB and LTBI medical evaluation upon arrival based off their
physical address. Using the zip code variable in EDN, rural or urban resettlement was
determined for use in the final dataset and was coded numerically with one representing
urban resettlement and two representing rural resettlement.
Rural. In 2016, the population living in Idaho was estimated to be 1,683,140 by
the United States Census Bureau. To determine rural or urban residency the Rural-Urban
Commuting Area Code (RUCA) classification was used as developed by Morrill,
Cromartie, and Hart (2011). Zip codes associated with visa-holder’s physical Idaho
addresses were used to determine rural status. Each Idaho zip code has been assigned a
RUCA code by Morrill, Cromartie, and Hart with those codes greater or equal to five
being classified as rural for this dissertation research. Values on the RUCA scale from
one to four were classified as urban. Each record included in the research dataset was
assigned a RUCA code after receiving the datafile from the state TB Program. This
approach was consistent with urban-versus-rural classifications used in Idaho in other
research.
Arrival and medical evaluation time. The Idaho state TB Program aims to have
all newly arrived visa holders medically evaluated within 30, 60, or 90 days. In EDN, the
date of arrival is recorded by Customs and Border Protection agents and the date of
medical evaluation is recorded by Idaho public health officials using the EDN TB
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Follow-up Worksheet. Both fields are recorded in MM/DD/YYYY format and are
included in the DS-2053 export or the TB Follow-up Worksheet export. Time between
arrival and initial medical evaluation was calculated by the Idaho state TB Program prior
to release of the research dataset and the number of days populated the “Arrival and
Medical Evaluation Time” variable.
TST or IGRA positivity. After arrival and during medical evaluations, visa
holders recently migrated to the United States are tested for tuberculosis. In EDN, TB
Follow-up Worksheets record the results for TST and/or IGRAs as well as the
interpretation of the results. A TST or IGRA recording in the EDN export of zero was
indicative of a positive result and would support the diagnosis populated on the Followup Worksheet. Values of one indicated positivity but for IGRAs, values of two
represented indeterminacy, three represented an invalid IGRA result, and four
represented an unknown IGRA result.
Dataset Cleaning and Management
The creation of the dataset for this research involved preliminary cleaning by TB
Program staff to ensure participants could not be identified. After receipt of the secondary
dataset, the proportion of missing values for the study variables described above was
determined. A low proportion of missing variables would have led to listwise deletion if
the sample size is large enough, while a high proportion of missing data for the study
variables would have to pairwise deletion, however, neither was necessary.
After assessing data completion, data accuracy was reviewed for each study
variable. This included a review of the accuracy of coded elements (i.e. Male=1,
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Female=2) but also a review to ensure inappropriate coded values were excluded.
Additionally, during this review, some variables were coded per the values in Tables 3, 4,
and 5. This primarily involved the categorization of age group, country of origin
regionalization, and area of resettlement determination (e.g. rural versus urban).
Formatting of date specific variables (i.e. date of arrival, date of medical evaluation, date
of treatment initiation, date of treatment completion) was reviewed as incorrect
formatting could impact variables calculated off these values.
The secondary dataset was also reviewed to ensure participant records included
meet the inclusion criteria for this research. This included reviewing disposition codes
and removing records where visa holders were diagnosed with active disease, and
reviewing treatment status variables to ensure treatment was initiated in Idaho.
The management of this dataset involved versioning. The original dataset
received from the Idaho TB Program was preserved as the master datafile and as
incomplete data was assessed, coded values reviewed, and accuracy of the participant
records evaluated, changes to the dataset prompted the file to be saved with the
appropriate versioning nomenclature (e.g. v1). Preservation of the original master file
ensured any data cleaning errors could be corrected and the overall integrity of the
secondary dataset for this research maintained.
Data Analysis Plan
The data supporting this dissertation research were analyzed using International
Business Machines Corp (IBM) SPSS Statistics version 21 (IBM, 2012). All analysis
code and output were saved for archival purposes but also to promote study duplicability.
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A data dictionary was developed to ensure variables names, types, and manipulation of
the dataset was recorded although many variables were already defined by the EDN. The
originally planned statistical analysis for this research has been summarized in Table 6.
Table 6
Planned Statistical Analysis Tests and Measures
Research question

Independent variable

Is visa type (refugee, immigrant,
parolee, asylee, or fiancé)
associated with LTBI treatment
completion among permanent visa
holders initiating LTBI treatment in
Idaho?

Visa-type (categorical,
three levels)

Is the median time distribution to
last treatment for LTBI
significantly different in permanent
visa holders initiating LTBI
treatment in Idaho?

Visa-type (categorical,
three levels)

Is time on LTBI treatment in
permanent visa holders initiating
treatment in Idaho affected by sex,
age, country of origin, visa-type,
smoking status, distance between
residence and treatment facility,
area of resettlement, time between
arrival and initial medical
evaluation, tuberculin skin test
(TST) positivity, or interferon
gamma release (IGRA) positivity?

Sex; Age; Country of
Origin; Visa-type;
Smoking-status.
Distance from
residence to treatment
facility; Are of
resettlement; Time
between arrival and
medical evaluation.
TST positivity; IGRA
positivity.

Dependent
variable
LTBI treatment
completion
status (binary)

Statistical analysis
or measure
Pearson's chi-square
and post hoc
pairwise
comparison with
Bonferroni
corrections

Time in months
on LTBI
treatment
(interval;
censored
variable =
noncompletion)
Time in months
on LTBI
treatment
(interval;
censored
variable =
noncompletion)

Kaplan-Meier
estimator

Cox proportional
hazards regression
model

Descriptive Analysis
Initial statistical analyses included a descriptive analysis of sample-specific data
for each of the visa status groups, where continuous variable (such as age) were described
with mean, median, range and categorical variables (such as sex, birth country, smoking
status, and area of resettlement) were described with n and percent of the total. The
results were planned to be presented in a similar tabular format as shown in Table 7, as
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appropriate. Important identified participant characteristics are presented in tables in
Chapter 4.
Table 7
Sample Descriptive Analysis Results
Variable
Age in years
Age groups
<1
1-4
5-9
…….

Refugee (n =)

Immigrant (n =)

Other (n =)

Total (n =)

Gender
Female
Male
Smoking status
Never
Former
Current
…..

Research Question Data Analysis
The first dissertation research question that aimed to explore the potential
association between visa-type and treatment completion was addressed using bivariate
analysis. Latent tuberculosis infection treatment completion was the dependent variable
and visa-type was the independent variable. Treatment completion rates for visa holders
were tested using pairwise comparisons so the impact visa-type may have could be
assessed. Normality of the research population was initially assessed using histogram
distribution and analyzing skewness and kurtosis. The Shapiro-Wilk Test of Normality
was used as the numerical means to assess normality as this statistical test can handle
small sample sizes or sample sizes up to 2,000 (Field, 2013). Additionally, this was an
appropriate technique for the Chi-square analysis associated with research question one
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since non-parametric (e.g. Kaplan-Meier) and semi-parametric (e.g. Cox Proportional
Hazard) statistical techniques do not make assumptions regarding normality (Mills,
2011). Calculated Shapiro-Wilk values greater than 0.05 were indicative of normality in
this research (Field, 2013). Assuming normal distribution of the samples by visa-type,
Chi-square test were used to assess relationship between the categorical treatment
completion variable and each level of visa-type. A calculated p-value was used to
interpret the Chi-square test result against the first hypothesis. Post hoc chi-square
pairwise comparison with Bonferroni corrections was planned for statistical differences
to identify which groups differed specifically (McDonald, 2015). Since performing three
pairwise comparisons would mean there would be a 14% chance of making a type I error
(1-(0.95)3), adjusted standardized residuals were planned to produce z-scores (McDonald,
2015). The produced z-scores were to be converted to chi-square test statistics and then to
p-values if statistically significant findings were identified. For this research question, the
number of chi-square analyses performed was equal to three, resulting in a Bonferroni of
0.0167. Values less than 0.0167 were to be deemed significant. If the distribution was not
normal or if a Chi-square cell is less than five, Fisher’s exact test was an alternative
approach used (McDonald, 2015).
Nonparametric methods. Research question two, which aimed to determine if
visa type was associated with time on treatment, was assessed using the non-parametric
Kaplan-Meier (KM) statistical approach. This approach was identified a priori to be the
best technique for determining the probability research participants will not experience
the event (e.g. treatment noncompletion) at time t. This technique demonstrated if
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specific visa-types experienced greater LTBI treatment survivorship (Mills, 2011). This
approach allowed censoring to be considered, unlike other statistical techniques (e.g.
regression) (Mills, 2011).
Kaplan-Meier. In the EDN dataset, the number of months on treatment was
calculated for each eligible participant using treatment initiation indicators and treatment
completion/disposition indicators. Treatment completion was the censoring variable of
concern and the x-axis for the KM plot, representing the observation period, spanned nine
months. Additionally, the KM technique was appropriate for handling a sample that was
small (Mills, 2011). The KM analysis allowed for the counting of visa holders in Idaho
that remain at risk of treatment noncompletion prior to a specified time (e.g. an
acceptable end of treatment) (Mills, 2011). This allowed the survival probability, in terms
for treatment completion for this dissertation research, to be estimated (Mills, 2011). This
analysis was also critical to determining the mean time LTBI treatment initiators remain
on therapy.
The KM analysis was performed to compare the visa categories described
previously simultaneously after assessing all KM assumptions were met. The KM method
requires six assumptions be met for results to be valid: 1) the event status should include
two mutually exclusive and exhaustive states, 2) time to event should be clearly defined,
3) left censoring should be minimized, 4) independence should exist between the event
and censoring, 5) there should be no secular changes, and 6) a similar amount of
censorship should occur in each group (Mills, 2011). Additionally, since multiple
treatment regimens are appropriate for LTBI and no single regimen is preferred or
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superior, visa holders were grouped by prescribed treatment regimen for separate KM
analyses. Four regimens were consistently prescribed in Idaho: six months of INH, nine
months of INH, four months of RIF, or 12 weeks for INH/RPT. The KM plots were used
to visualize the survival distribution and demonstrated a difference in survivorship
(treatment noncompletion) in the analyzed groups when one function ran below another
(Mills, 2011). The calculated KM estimator was used to estimate the survival probability,
or the likelihood of not experiencing the event at time t, for each visa-type group (Mills,
2011). The median survival time was also produced when calculating the KM estimator
and was compared for the visa-type groups to assess central tendency (Mills, 2011).
Lastly, the log-rank test was used to determine whether there was a statistically
significant difference between the three survival curves. The log-rank statistic, sampling
variances, and covariances were used to produce the chi-square statistic with a p-value
less than 0.05 representing a difference in survival (Mills, 2011).
Cox Proportional Hazards Regression. This research hypothesized covariates
influence the rate of LTBI treatment completion in Idaho visa holders making Cox
Proportional Hazards (CPH) appropriate as a mechanism of statistical analysis to assess
this hypothesis. Additionally, since many of the covariates in this research remained fixed
over time the use of CPH for time-fixed variables was further supported (Mills, 2011).
Cox proportional hazard is also useful when the baseline hazard for a phenomenon is
unknown (Mills, 2011) as was the case in the rural setting for this LTBI treatment
completion research. Since extrapolating a baseline hazard from research conducted on
samples drawn from the high-incidence or urban setting may be flawed, the CPH analysis
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planned was appropriate. Additionally, CPH generally fits data well which is
advantageous when the shape of the probability distribution is unknown (Mills, 2011), as
was the case in this dissertation research.
For this research, LTBI treatment initiation were defined as picking up the first
months’ supply of medication from the managing clinic while completion was defined as
having documented pickup for at least 90% of refills as appropriate for the prescribed
regimen. In Idaho, these dates are recorded on the EDN TB Follow-up Worksheet as
“Treatment start date” and “Treatment end date”, respectively. In the event a visa-holder
is lost to follow-up during treatment, discharge diagnoses reflect this and the last known
date of medication adherence was recorded as “Treatment end date”. A participant was
determined to not have completed LTBI treatment completion if treatment was
terminated earlier than acceptable for their prescribed regimen. In some instances,
receiving at least 90% of the prescribed doses constitutes treatment completion. These
scenarios were apparent when examining discharge diagnoses for persons that had shorter
durations of treatment than planned during their initial regimen documentation.
For this survival analysis, treatment completion status was the censor indicator
and month on treatment was the time variable. Prior to conducting CPH analysis, meeting
the assumption of proportional hazards was assessed using graphical methods (Mills,
2011). Since none of the covariates were time-dependent, no statistical analysis, such as
scaled Schoenfeld residuals, were performed to assess the assumption of proportional
hazards was met (Mills, 2011). Graphically, parallelism of the curves was assessed for fit
of the proportional hazards assumption (Mills, 2011).
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Since this research hypothesizes that host, agent, or environment-related factors
influence LTBI treatment completion, multiple covariates were incorporated into the
CPH analysis. This includes sex, age group, country of origin, visa-type, smoking status,
distance between residence and treating facility, area of resettlement, time between
arriving in Idaho and the time of initial clinical evaluation for LTBI, and TST positivity
or IGRA positivity. The CPH formula for fixed covariates used in this research was hi(t)
= h0(t){exp(β1xil +…+βkxik)} with x representing a covariate (Mills, 2011). Each
covariate was added into the model for analysis against the event. To be included in the
model, covariates needed to pass the proportionality of hazards assumption (Mills, 2011).
The results of the CPH models included hazard ratios (HRs), the 95% confidence
interval, and the Wald test p-values (Mills, 2011). The hazard ratio is often reported in
statistical output as the exponential coefficient and if greater than one, indicated the
analyzed covariate was associated with an increased hazard of experiencing the event of
interest (Mills, 2011). The likelihood-ratio test was used to determine significance at
p<0.05.
Additional Exploratory Analysis
An additional goal of this research was to determine if the prescribed LTBI
treatment regimen also influenced completion by visa-type. Since it was suspected that
the independent variables, in this case six or nine months of INH, or four months of RIF,
or 12 weeks of INH and RPT, effect the treatment completion dependent variable, Cox
Proportional Hazard Regression was used to suggest which of the independent variables
had a major effect on time until LTBI treatment completion. To explore this additional
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phenomenon, it was assumed that each observation was independent (Field, 2013). The
produced p-value was used to determine significance at p < 0.05. Cox Proportional
Hazard Regression was also used to assess whether prescribing provider influenced LTBI
treatment completion. For this additional analysis, LTBI treatment completion remained
the dependent variable, while prescribing provider became the independent variable.
Again, it was assumed that each observation was independent and significance was
determined if p < 0.05.
Threats to Validity
Threats to External Validity
The dataset used for this dissertation research was dependent upon health care
provider interpretation of diagnostic, radiologic, and risk-factor evaluations on visa
holders intending to migrate to the United States. Since tools used to diagnose latent
tuberculosis infection only detect the presence of an immune response to Mycobacterium
tuberculosis (Ling Lin & Flynn, 2010), differences in diagnosis patterns may exist. In the
EDN system, this is potentially mitigated by post-arrival health care medical evaluations
following review of visa-holder’s predeparture medical evaluation as prearrival LTBI
diagnoses may be validated. An additional threat to external validity was related to the
relatively new application of IGRAs. Historically, the TST was the only tool available to
help determine Mtb exposure however false positives are common among those
vaccinated with bacille Calmette-Guerin (BCG) (Chee, Sester, Zhang, & Lange, 2013).
As such, visa holders evaluated toward the beginning of the study period with a TST only
may have been misdiagnosed.
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Threats to Internal Validity
The conclusions drawn in this research may be threatened by inconsistencies in
the implementation of LTBI treatment recommendations across jurisdictions in Idaho.
Additionally, although completing at least 90% of prescribed doses of LTBI treatment
may be deemed successful completion, health care provider discretion may also be used
to determine treatment completion potentially impacting this research by producing
variance in discharge diagnoses. Other unmeasured factors may also influence treatment
completion in the study population and will likely not be captured directly by this
research. For example, persons with known direct contact to someone with tuberculosis
may be more likely to accept and complete treatment due to their experiences (Priest,
Vossel, Shefy, Hoy, & Haley, 2004). Also, persons under the age of 18, the legal age in
Idaho to make independent medical decisions, may be forced to complete treatment by
their parents or guardians which may mask true effects of age on completion. Lastly,
familial support and other household factors may too influence LTBI treatment
completion as persons with greater support have been shown to complete treatment at
higher rates (Priest, Vossel, Shefy, Hoy, & Haley, 2004) however, these potential data
points are not collected in the EDN system.
The internal validity of this research may also be influenced by the secondary
nature of the data being analyzed. The data in this study was collected for a different
purpose and only the previously collected data will be available for analysis. Although
the Idaho state TB Program does perform data quality checks at the time of data entry, for

121
the purposes of this research, the data cannot be validated nor can additional follow-up
information be collected.
To detect a true effect and avoid low statistical power, using a large enough
sample for this research was essential (Ellis, 2015). The sample size estimates discussed
previously are the smallest possible recommended for analysis which, if larger, the
sample should have produced sufficient effects and avoided problems with low statistical
power.
Since no gold standard exists for the diagnosis and treatment of LTBI (LoBue &
Castro, 2012), variations in who got tested, who got diagnosed, and who was
recommended for treatment may have influenced this research. It was assumed that those
visa holders initiating LTBI treatment in Idaho were truly infected with Mtb and were
receiving treatment appropriately. Routine dataset cleanup may help ensure this was
accurate. Overseas medical screening results were influential in the determination of
whether a visa-holder was assigned a B TB Notification (Lee et al., 2013). Occasionally,
foreign-born persons with LTBI enter Idaho without a B TB Notification but EDN allows
for these records to be included in data export. To ensure persons without B TB
Notifications but who are identified as having LTBI after arrival in Idaho, the EDN
discharge diagnosis variable was reviewed for all visa holders that entered Idaho during
the timeframe of interest. This approach helped ensure that visa holders arriving with a B
TB Notification but determined to not be infected upon arrival in Idaho were excluded
from the dataset. This would have left only those visa holders appropriately
recommended LTBI treatment in the dataset.
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Missing data and selection bias was addressed in the data cleanup process. Visaholder records missing any of the identified necessary variables for analysis were to be
excluded from this research however, this was not necessary due to high variable percent
completion. True infection status was verified by reviewing EDN records and post-arrival
TB Follow-up Worksheets for each visa-holder included in the study sample to ensure
each was appropriate for inclusion.
Retrospective cohort studies inherently have threats to internal validity. This
study design lacks a comparison or control group, includes subjects that may mature
overtime influencing analyzed variables and participant outcomes, and may suffer from
high rates of attrition (Gordis, 2008). Although no control group was used in this
research, comparisons were made between visa-types, prescribed LTBI treatment
regimens, and area of residence potentially assisting in overcoming this limitation.
Maturation was also likely not an issue in this research due to the relatively small
window of time each person had to experience the event. With the longest available LTBI
treatment duration spanning nine months, it was anticipated that participant
characteristics did not change greatly during this time in such a way that influenced the
outcome. Lastly, high rates of attrition may have occurred in this research however,
would help demonstrate why this research was necessary. High rates of LTBI treatment
noncompletion may indicate that a large reserve of persons latently infected with Mtb
remain at risk of developing active TB and possibly transmitting disease to others. A
large number of visa holders initiating treatment with a subsequently large number
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dropping out may assist in demonstrating that greater attention needs to be paid to
ensuring these individuals complete treatment.
Ethical Considerations
Information and data related to this research was not requested until after Walden
University IRB and IDHW Division of Public Health approval was sought and obtained.
Despite the requested dataset being de-identified, its original proximity to health
information protected under the Health Information Portability and Accountability Act
(HIPAA) heightened measures to protect the data. Although the EDN database in which
the research dataset was derived contained Protected Health Information, Idaho state TB
Program staff were asked to remove potentially identifiable information from the
research dataset. This approach ensured research participants were not identifiable from
the research data file. All data collected for this research were stored in an electronic
manner that required security-only access such as a password to the storage device and
data file.
Beyond the small possibility of a data breach, participation in this research came
with no known risk. A data breach would likely only take place if the de-identified
dataset associated with this research was linked back to the original EDN data source
from which dataset producing reports were run. Although the EDN platform is accessed
through secure networks and this dataset was stored on a separate encrypted, backed-up
secure laptop, in the event of a data breach, all participants included in the dataset were to
be notified and contact procedures carried out to the full extent possible as defined by the
policies and procedures of Walden University and the IDHW. No breaches were

124
identified, however. To add greater security, the research dataset was only accessible to
the dissertation research principal investigator and the dissertation research committee, if
needed, and passwords to the laptop and the Excel file were not shared with others nor
were the passwords the same to access the laptop or file.
Summary
This dissertation study made the same assumptions of those consistent with
performing time to event analysis. It was also assumed that the foreign-born arriving in
Idaho under permanent visas were representative of the true population infected with Mtb
since surveillance data suggests that more than 60% of the TB cases in Idaho are foreignborn (IDHW, 2016). This study was limited in terms of design and data specificity. The
retrospective nature of this study involved no control group for comparison. Data related
to treatment initiation and completion were recorded in month, day, and year format
however, persons initiating LTBI treatment in this sample were likely only monitored for
treatment adherence monthly. This approach limited the time to event analysis units of
measurement to months instead of the more ideal unit in days or weeks. Regardless,
findings from this study may inform Idaho public health officials of the potential LTBI
treatment noncompletion predictors which may promote intervention development to
improve rates and decrease future active disease burden.
The aim of this study, the design, and data analysis was to describe the
epidemiology of LTBI treatment completion in the visa-holding population residing in
Idaho. By determining if low treatment completion rates can be improved in selected
persons through public health intervention, the Idaho TB Program may more
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appropriately deploy limited resources that promote the greatest impact. Identifying the
factors associated with LTBI treatment noncompletion may better position the program to
respond to the threat of untreated LTBI in the face of further declining TB resources,
ultimately improving the population’s health and prompting social change. The results of
this research, the management of the database received from the Idaho state TB Program,
and the analysis are presented in Chapter 4 and discussed in further detail in Chapter 5.
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Chapter 4: Results
Introduction
In this chapter I discuss the results of the analysis of this retrospective cohort
exploring LTBI treatment completion rates in permanent visa holders residing in Idaho as
well as the potential factors that may contribute to mean time on treatment. I obtained the
data used in the analysis from the Idaho State Tuberculosis Program. Data downloaded
from the Idaho jurisdiction on the CDC’s EDN platform consisted of a combination of
overseas medical evaluation data, postarrival TB evaluation medical data, and
demographic information reported to the Idaho State TB Program by permanent visaholder evaluating agencies voluntarily or through contractual obligation. Six of the seven
agencies providing data were located in the public sector while the seventh agency, a
Federally qualified health center, functioned on behalf of a public agency previously
responsible for collecting some of the data used in this analysis.
This study received Walden IRB approval under approval number 01-09-180538791. The IDHW’s Division of Public Health IRB waived their requirement for IRB
submission after proof of Walden’s IRB approval was submitted to the agency’s
Research Determination Committee. Software used for analysis was SPSS version 24
(IBM, 2016). Differences in observed treatment completion rate by visa type were
evaluated using Pearson’s chi-square test to determine if a variance occurred by chance. I
assessed the association between the mean time on treatment and independent variables
using Kaplan-Meier and Cox Proportional Hazard Regression. I selected independent
variables based off availability of data but also from a previously conducted literature
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review that highlighted relationships in the nonrural setting. This chapter includes the
results of detailed statistical analysis that addresses LTBI treatment completion trends
and possible contributing factors to noncompletion in permanent visa holders arriving in
the rural State of Idaho from 2012 through 2016 using univariate and multivariate
statistical techniques.
Research Questions and Hypotheses
Research questions under study focused on the association between visa type and
LTBI treatment outcome as well as the potential contributing factors to LTBI treatment
noncompletion. Via the analyses determined during study design I aimed to explore LTBI
treatment completion rates in permanent visa holders, typical duration on treatment, and
variables important to LTBI treatment noncompletion. Throughout this chapter, the
results of data analysis for each specific research question are discussed.
RQ1: Is visa type (refugee, immigrant, parolee, asylee, or fiancé) associated with
LTBI treatment completion among permanent visa holders initiating treatment in
Idaho?
H01: There is no association between visa type and LTBI treatment
completion among permanent visa holders initiating LTBI treatment in Idaho.
Ha1: There is an association between visa type and LTBI treatment
completion among permanent visa holders initiating LTBI treatment in Idaho.
RQ2: Is the mean time distribution to last treatment for LTBI between permanent
visa holders initiating LTBI treatment in Idaho significantly different?
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H02: The mean time distribution to last treatment for LTBI between
permanent visa holders initiating treatment in Idaho is not statistically
difference.
Ha2: The mean time distribution to last treatment for LTBI between
permanent visa holders initiating treatment in Idaho is statistically different.
RQ3: Is time on LTBI treatment in permanent visa holders initiating treatment in
Idaho affected by sex, age, country of origin, visa type, smoking status, distance
between residence and treatment facility, area of resettlement, time between
arrival and initial medical evaluation, TST positivity, or IGRA positivity?
H03: Time on LTBI treatment in permanent visa holders initiating treatment in
Idaho is not affected by sex, age, country of origin, visa type, smoking status,
distance between residence and treatment facility, area of resettlement, time
between arrival and initial medical evaluation, TST positivity, or IGRA
positivity.
Ha3: Time on LTBI treatment in permanent visa holders initiating treatment in
Idaho is affected by sex, age, country of origin, visa type, smoking status,
distance between residence and treatment facility, area of resettlement, time
between arrival and initial medical evaluation, TST positivity, or IGRA
positivity.
Data Cleaning
The dataset required minimal cleaning as routine data quality checks performed
by the Idaho TB Program ensured accuracy and a high percentage of variable completion.
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Coding of variables was required for text fields including visa type, birth country, and
treatment regimen as described in Chapter 3. I collapsed age into three categories and
calculated time between medical evaluation and original date of arrival using Excel
formulas to quantify the number of days between these aforementioned points in time. I
created and populated area of resettlement using Idaho zip codes, also as outlined in
Chapter 3. I kept all other variables either in their original EDN coding form or TB
Program coding form. I ran frequencies for missing values for all study variables yielding
100% completion for all data elements.
Study Sample
Between January 1, 2012 and December 31, 2016, 5,042 permanent visa holders
arrived in Idaho. Only a subset of 455 (9%) arrivals required evaluation for tuberculosis
after reaching Idaho. Over 81% (370) of those requiring postarrival medical evaluation
completed a full evaluation, whilst nine (2%) initiated but failed to complete, and 76
(17%) did not initiate evaluation. Of those fully medically evaluated, 163 (44%) were
recommended treatment, with six being excluded after receiving a diagnosis of active TB
disease. Of the remaining 157 recommended for LTBI treatment, 140 (89%) initiated
treatment and were included in this study (Figure 2).
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Figure 2. Count of permanent visa-holder arrivals, medical evaluation, and treatment statuses.

The final dataset obtained from the Idaho State TB Program included no missing
values due to existing data quality practices at the time of medical evaluation record
submission. For records submitted on arrivals relocating to Idaho from 2012 through
2016, none were removed due to incomplete variables. Annually and on average, the
State of Idaho resettles 1,008 permanent visa holders, with 91 each year requiring
medical evaluation for tuberculosis. The 9% of arrivals from 2012-2016 included in this
study was consistent with the rate of arrivals requiring TB evaluation annually and thus,
this study population was likely representative of the Idaho permanent visa-holding
population.
Permanent visa holders included in this study held only refugee and immigrant
visas. Although persons holding asylee, parolee, and fiancé visas arrived in Idaho during
the study, none met the study inclusion criteria and were excluded. No arrivals resettling
in North Central Health District were eligible for inclusion, thus this jurisdiction is not
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represented in the study. All remaining six Idaho public health jurisdictions were
represented, however. The excluded jurisdiction receives very few foreign-born arrivals
annually under normal circumstances.
Power Analysis
Prior to conducting the analysis necessary to explore the study research questions,
I performed a power analysis using G*Power (Faul, 2014). The lack of asylee, fiancé, and
parolee visas in this analysis changed previously calculated degrees of freedom from two
to one. After making this adjustment and conducting post-hoc power analysis, the
analyzed data from the unique 140 participants had 80% power to detect a 23.6%
difference in treatment completion between the groups at 0.05 significance. Although a
more robust sample would have improved power, considering the makeup of Idaho’s
foreign-born population, the study sample should have been representative of the broader,
foreign-born, EDN TB notification audience and should have detected important
differences.
Descriptive Epidemiology
Among 140 participants, 109 were refugees and 31 were immigrants. As shown in
Figure 3, 88 (80.7%) refugees and 23 (74.2%) immigrants completed LTBI treatment.
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Figure 3. Study participants by visa-type and treatment completion status.
Demographics and characteristics of study subjects are presented in Table 8. I
performed a chi-square test for independence to evaluate if the variables included were
related or whether their distributions differed. I found no observed distributions to be
statistically significant suggesting the variables were not highly related. However, I found
notable differences between the participant visa types included in the study. Sixty one
percent (61%) of refugee study participants were male compared to only 41% of
immigrants. The study included more refugees in the 45 years of age and older (45+)
group compared to the other age categories, while more immigrants were found to be in
the zero to 24 years age group. The median age for refugee treatment completers was just
slightly older than immigrants at 27.5 years of age and 28.0 years of age, respectively.
For noncompleters, a wider age difference was noted between the two visa-types with the
median age of refugee noncompleters being 38.0 years and immigrant noncompleters
26.0 years. More of the refugees included in the study originated from Southeast Asia
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(41%) compared to other WHO regions, while 45% of immigrants originated in the
Americas WHO Region. Denying current or former tobacco use was consistent across
both visa types and LTBI treatment completion statuses.
Table 8.
Demographic and characteristics of study subjects

Covariate
Sex
M
F
Age (median in years)
0-24
25-44
45+
Birth Country
Americas
Europe or EM*
Africa
SEA
WP
Tobacco use
Never
C or F
Distance to treatment facility
(median in miles)
0-10.9
11-20.9
21+
Resettlement Area
Urban
Rural
Time between arrival and
evaluation (median in days)
<30
30-59
60+
TST result
Positive
Negative
Not done

Complete
N=88
n
%

Refugee
Incomplete
N=21
n
%

54
34
27.
5
29
22
37

61.36
38.64

12
9

57.14
42.86

32.95
25.00
42.05

38.0
2
7
12

9.52
33.33
57.14

0
20
30
36
2

0.00
22.73
34.09
40.91
2.27

0
4
8
9
0

0.00
19.05
38.10
42.86
0.00

pa
0.72

0.10

Complete
N=23
n
%

Immigrant
Incomplete
N=8
n
%

10
13

43.48
56.52

3
5

37.50
62.50

28.0
16
1
6

69.57
4.35
26.09

26.0
4
3
1

50.00
37.50
12.50

10
0
2
1
10

43.48
0.00
8.70
4.35
43.48

4
1
1
0
2

50.00
12.50
12.50
0.00
25.00

0.05

0.88

0.42

0.11
75
13

85.23
14.77

16
5

76.19
23.81

3.1
18
69
1

20.45
78.41
1.14

3.1
2
19
0

9.52
90.48
0.00

100.0
0
0.00

21
0

100.0
0
0.00

78.41
17.05
4.55

21.0
18
3
0

85.71
14.29
0.00

40.91
6.82
52.27

12
0
9

57.14
0.00
42.86

0.62

0.28
20
3

86.96
13.04

8
0

100.0
0
0.00

5.9
0
13
10

0.00
56.52
43.48

3.1
0
5
3

0.00
62.50
37.50

0.82

-88
0
20.
5
69
15
4

0.56

0.94
14
9

60.87
39.13

5
3

62.50
37.50

21.0
7
9
7

30.43
39.13
30.43

22.0
3
2
3

37.50
25.00
37.50

13
0
10

56.52
0.00
43.48

4
1
3

50.00
12.50
37.50

0.77

0.25
36
6
46

pa
0.77

0.23

(table continues)
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Complete
N=88
n
%

Refugee
Incomplete
N=21
n
%

Complete
N=23
n
%

Immigrant
Incomplete
N=8
n
%

Covariate
pa
IGRA result
0.76
Positive
16
18.18
5
23.81
6
26.09
2
25.00
Negative
1
1.14
0
0.00
0
0.00
0
0.00
Not done
71
80.68
16
76.19
17
73.91
6
75.00
Note. achi-square test of independence (χ2);.*Abbreviations: EM=Eastern Mediterranean, SEA=South-East Asia,
WP=Western Pacific; C=Current smoker, F=Former smoker.

pa
0.95

Study participants with a refugee visa had a lesser distance between their
residence and LTBI treatment facility compared to immigrants. For refugee treatment
completers and non-completers, the mean distance to travel in miles was 3.1 whilst
immigrant treatment completers traveled 5.9 miles to their treatment facility. The time
between arrival and medical evaluation was also different across visa-type and treatment
completion status. Over three quarters of refugees completing treatment received medical
evaluation within 30 days after arrival, while only just over a third of immigrant
treatment completers did. For treatment non-completers, 85.7% of those holding refugee
visas were still evaluated within 30 days after arrival but nearly two thirds of immigrants
were evaluated more than 30 days after arrival. The median days between arrival and
medical evaluation for refugee treatment completers and non-completers, and immigrant
treatment completers and non-completers varied minimally at 20.5 days, 21.0 days, 21.0
days, and 22.0 days, respectively.
Tuberculosis medical evaluation. All 140 study participants received evaluation
for LTBI and TB both prior to departure and after arrival. Due to potential variations in
the overseas screening process, postarrival medical TB screening findings are described.
Administration of TST or IGRA varied with 72 (51.4%) study participants and 30
(21.4%) study participants having a TST placed or an IGRA drawn, respectively (Table
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8). For refugees and immigrants where a TST was placed and treatment was not
completed, the rate of positivity was higher in refugees and immigrants (57.1%, 50.0%).
For IGRAs in participants not completing treatment, immigrants had a higher rate of
positivity at 25.0% compared to the refugee positivity rate of 23.8%. A large number of
study participants did not have a TST or IGRA performed.
LTBI treatment regimen trends and completion. Four LTBI regimens were
prescribed throughout the study period to treat infection with Mycobacterium
tuberculosis (Table 9). Due to the small number of participants prescribed 3HP and 4RIF,
these regimens were combined into one “Expedited” regimen category for chi-square
analysis but remained as separate regimens for survival analysis. This approach was
taken due to the difference in treatment duration between the two regimens which, if left
combined, would not produce accurate survival analysis results. Overall, more than 66%
of LTBI treatment initiators were prescribed nine months of INH. It is important to note
that 3HP became a recommend treatment for LTBI near the beginning of the study period
potentially impacting the early lower rate of use observed. Visa-type-based differences in
the LTBI regimen used were also observed in this study. No immigrants included in this
study were prescribed 3HP and only one was prescribed four months of RIF. Typically,
immigrants were prescribed INH regimens. Over 90% of immigrants were prescribed
nine months of INH, compared to 59% of refugees.
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Table 9.
LTBI Treatment Regimen Trends by Visa-type and Completion Status
Complete
N=88
n
%

Refugee
Incomplete
N=21
n
%

Complete
N=23
n
%

Immigrant
Incomplete
N=8
n
%

pa
pa
0.23
0.56
Prescribed
Expedited
32 36.36%
4
19.05%
1
4.35%
0
0.00%
LTBI
treatment
6INH
7
7.95%
1
4.76%
2
8.70%
0
0.00%
regimen
9INH
49 55.68% 16 76.19%
20 86.96% 8 100.00%
Note. aFisher’s exact test; Expedited: 12 weeks of Rifapentine/Isoniazid (3HP) or 4 months of rifampin (RIF);
6INH: 6 months of isoniazid; INH: 9 months of isoniazid.

Null Hypothesis 1: Visa Type Is Not Associated with Latent Tuberculosis Infection
Treatment Completion
Chi-Square Assumptions
The purpose of this hypothesis was to answer the research question whether LTBI
treatment completion status was influenced by visa-type of study participant. Given both
the dependent variable of treatment completion status and independent variable of visatype were categorical, the Pearson’s chi-square test was used to test this hypothesis.
Overall, 79.3% of LTBI treatment initiators completed therapy. Refugees completed
LTBI treatment at a slightly higher rate than their immigrant counterparts, 80.7% versus
74.2% respectively. However their difference is not statistically significant (χ2 = 0.63, p
= 0.43) (Table 10).
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Table 10.
Pearson Chi-square Analysis of Visa-type and LTBI Treatment Completion Status
Treatment completion

n
% within Visa
Visa
n
Immigrant
% within Visa
Note. achi-square test.
Refugee

Yes

No

88
80.7%
23
74.2%

21
19.3%
8
25.8%

χ2
0.63

pa
0.43

The categorical variables visa-type and treatment completion status included cell
frequencies greater than five and the two variables were independent of one another,
making the use of chi-square valid. Additionally, no extreme values were identified, there
were no overlaps in variables, data discrimination was not an issue, data were not
analyzed after sorting, and the data were not structured in a manner that allowed for many
processes to approach the natural limit (Buthman, 2018).
Null Hypothesis 2: Mean Time Distribution to Last Treatment Is Not Different by
Visa Type
The purpose of this hypothesis was to determine if the mean time distribution to
last LTBI treatment was different by visa-type. Kaplan-Meier (KM) survival analysis was
used to assess this relationship. All six KM assumptions described in chapter 3 were
satisfied supporting the use of KM survival analysis.
As shown in Table 11, the mean time that refugees remained on LTBI treatment
during the study was 7.85 months compared to the mean time of 7.51 months for
immigrants. However, the difference in mean treatment duration is not statistically
significant (p-value from Log Rank was 0.74). The null hypothesis that no difference in
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mean time on LTBI treatment between two types of visa holders was not rejected
suggesting the mean times on treatment were similar.
Table 11.
Kaplan-Meier Time on Treatment by Visa-type
Mean time on
treatment (months)

Visa

Refugee
7.85
Immigrant
7.51
Note. aLog Rank (Mantel-Cox).

Std. Error
0.24
0.49

95% Confidence interval
Lower bound Upper bound
7.39
6.56

pa
0.74

8.31
8.46

However, the survival curves show some separation between the two groups early
in the months on treatment, particularly around months 2 through 4 (Figure 4). The rate
of cumulative survival for immigrants dropped earlier compared to refugees. This
suggests that non-completers in immigrants would stop the treatment sooner than their
refugee counterparts. This is reflected in the survival tables (data not shown) for the
cumulative probability of survival at time t with immigrants having a cumulative survival
at month six of 0.74 and refugees, 0.82. As more time passed during the study, the
difference between the probabilities of cumulative survival of the two visa groups began
to narrow suggesting the number of treatment non-completion events were similar at this
stage. The final cumulative survival probabilities for refugees was 0.75 and 0.74 for
immigrants.
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Figure 4. Cumulative Survival Curve for Refugee and Immigrant Study Participants.

Null Hypotheses 3: Time on Latent Tuberculosis Infection Treatment Is Not
Affected by Covariates
Cox Proportional Hazard Regression Assumptions
The purpose of this hypothesis was to address whether potential covariates
influenced the mean time on LTBI treatment until noncompletion of visa holders in the
rural Idaho setting. To evaluate this question, Cox Proportional Hazard Regression was
used to compare the estimated mean time on treatment in study participants after
adjusting for sex, age, birth country, visa-type, history of tobacco use, distance between
residence and LTBI treatment facility, area of resettlement, time between arrival and
medical evaluation for LTBI or TB, TST positivity, or IGRA positivity. Subjects who had
completed LTBI treatment were censored at the last dose date as determined by Idaho
public health nurses. Cox Proportional Hazard Regression (CPHR) assumption of
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independent observations was satisfied using goodness-of-fit test performed on each
covariate explored as a potential predictor of mean time on treatment and thus influencer
of treatment completion (Table 12).
Table 12.
Test of Proportional Hazard Assumption for Covariates
Variable
chi2 df p-value
Sex
0.33
1
0.57
Age (years)
4.55
2
0.16
Birth Country
5.02
5
0.42
Visa-type
0.69
1
0.43
History of tobacco use
0.61
2
0.67
Distance to treatment facility (miles)
0.31
2
0.89
a
Area of resettlement
0.70
1
0.70
Time between arrival and evaluation
0.27
2
0.73
TST result
1.17
2
0.323
IGRA result
0.50
2
0.67
Note. aNo refugees resettled in the rural setting so pooled analysis
unavailable.

The assumption of a constant hazard over time was upheld by producing the loglog plots found in Appendix D. Time-dependent Cox regression was not performed for
this analysis as no variables were time-dependent.
Normal CPHR was performed to test covariates against LTBI treatment
completion status using 140 study participants. The CPHR analysis examined LTBI
treatment completion status as the survival endpoint. Survival curves for categorical
variables of more than two levels were generated for visual interpretation (Appendix E).
Hazard ratios were calculated to assess if participants experienced LTBI treatment
noncompletion over time while considering the included independent variables. P-values
and 95% confidence intervals were also calculated and interpreted to determine statistical
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significance of analysis. In situations where the categorical variable had greater than two
levels, the reference group was set as the last strata of the categorical variable being
assessed. The reference groups by categorical variable strata can be found in Appendix F.
Findings
The null hypothesis that covariates do not influence LTBI treatment completion
was not rejected as the model overall was not statistically significant (p = 0.64).
However, when examining covariate strata impact on time until treatment noncompletion,
age subcategory for those zero to 24 years (HR = 0.18, p = 0.01) had a statistically
significant relationship with LTBI treatment noncompletion status (Table 13). Study
participants less than 25 years old experienced LTBI treatment noncompletion less
frequently compared to the reference study participants who were 45 years of age and
older. Under one fifth of study participants less than 25 years of age experienced LTBI
treatment noncompletion compared to the older reference group. Alternatively stated,
being less than 25 years reduced the risk of LTBI treatment noncompletion by 82%
compared to study participants who were 45 years of age and older based on the observed
survival hazard ratio of 0.18. This also suggests study participants in this age group had a
greater mean time on LTBI treatment compared to other study participants.
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Table 13.
Covariates Associated with Time until LTBI Treatment Noncompletion in Cox Model
95% CI
Variable(s)
HR
SE
p-value
Lower
Upper
Sex)
Male
0.99
0.42
0.99
0.44
2.27
Female (RG)
Age‡
Age (1: 0-24 years)‡
0.18
0.69
0.01
0.05
0.68
Age (2: 25-44 years)
0.96
0.48
0.93
0.37
2.46
Age (3: 45+ years) (RG)
Birth Country
Birth Country (1: Americas)
4.07
1.01
0.17
0.56
29.57
Birth Country (2: Europe or Eastern
2.24
1.09
Mediterranean)
0.46
0.27
18.88
Birth Country (3: Africa)
2.85
1.11
0.35
0.32
25.18
Birth Country (4: South-East Asia)
1.30
1.15
0.82
0.14
12.53
Birth Country (5: Western Pacific) (RG)
Visa
Refugee
0.50
0.78
0.38
0.11
2.32
Immigrant (RG)
Time to Evaluation
Time to Evaluation (0: <30 days)
0.34
0.89
0.22
0.06
1.94
Time to Evaluation (2:30-59 days)
0.36
0.92
0.27
0.06
2.18
Time to Evaluation (3: 60+ Days) (RG)
Area of Resettle
Urban (1)
0.00
137.21
0.95
0.00
5.32E+112
Rural (2) (RG)
Distance to Treatment Facility
Distance to Treatment Facility (1:0-10.9
137.21
miles)
21,853.49
0.94
0.00
1.36E+121
Distance to Treatment Facility (2: 11184.87
20.9 miles)
0.00
0.96
0.00
1.11E+153
Distance to Treatment Facility (3: 21+
miles) (RG)
History of Tobacco Use
Yes (1: Current or former)
1.07
0.57
0.91
0.35
3.24
No (2: Never) (RG)
TST Result
Positive (0)
2.03
0.53
0.19
0.71
5.78
Negative or Not Done (1) (RG)
IGRA Result
Positive (0)
1.60
0.54
0.38
0.56
4.57
Negative or Not Done (1) (RG)
Note. Abbreviations: HR = Hazard Rate, SE = Standard Error; RG = reference group. ‡denotes statistically
significant at p<0.05.

The hazard for treatment noncompletion in study participants 25 to 44 years was
similar to those 45 years and older. For male study participants, the hazard of
noncompletion was comparable to females but those study participants hailing from the
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America WHO Region had an increased hazard of noncompletion versus those from the
Western Pacific WHO Region. Refugee study participants as well as those being
medically evaluated less than 30 and less than 60 days after arrival had decreased hazards
compared to immigrants or those medically evaluated more than 60 days after arrival,
respectively. Participants resettling in the urban setting had a decrease hazard of
noncompletion compared to those resettling in the rural setting while those current or
former tobacco users had a comparable hazard to non-users. Those needing to travel up to
10.9 miles from their residence to the nearest LTBI treatment facility had a higher hazard
of noncompletion but those traveling no more than 20.9 miles, a lower hazard compared
to those traveling more than 21 miles. Lastly, study participants with a TST positive
result had a higher hazard but those with a positive IGRA had a comparable hazard for
noncompletion compared to participants testing negative or not having a TST or IGRA
performed.
Despite a lack of statistical significance across all covariates individually,
important survival curve trends did emerge. Across all covariates, participants prescribed
9INH experienced the most events and had the lowest cumulative survival. This trend
suggests poor overall mean time on treatment and poor completion on this regimen.
Final Model Interpretation
The third null hypothesis for this study was that mean time on LTBI treatment in
permanent visa holders initiating treatment in Idaho was not affected by sex, age, country
of origin, visa-type, smoking status, distance between residence and treatment facility,
area of resettlement, time between arrival and initial medical evaluation, TST positivity,
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or IGRA positivity. The analyses performed on the effect covariates may have on time on
LTBI treatment until noncompletion found age to be the only statistically significant
potential influencer of time until noncompletion when compared to reference groups.
This finding provides evidence that the age covariate was associated with time on
treatment until noncompletion but the null hypothesis should not be rejected overall.
Ad Hoc Analyses
To further explore the potential factors on the time until LTBI treatment
noncompletion, the following additional analyses were performed as ad hoc.
1. The interactive impact of sex, age, country of origin, smoking status, distance
between residence and treatment facility, area of resettlement, time between
arrival and medical evaluation, TST positivity, or IGRA positivity on time on
LTBI treatment until noncompletion.
2. The impact of sex, age, country of origin, smoking status, distance between
residence and treatment facility, area of resettlement, time between arrival and
initial medical evaluation, TST positivity, or IGRA positivity on time on
LTBI treatment after stratifying by visa-type.
3. The impact of prescribed treatment regimen on time on LTBI treatment.
4. The impact of medical co-morbidities on time on LTBI treatment.
5. The impact of the prescribing medical provider on time on LTBI treatment.
6. The interactive impact of the prescribing provider and treatment regimen on
mean time on LTBI treatment.
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7. The interactive impact of distance and regimen on mean time on LTBI
treatment.
The first ad-hoc analysis involved performing CPHR to test whether the
interactive effect of study variables influenced mean time on treatment until
noncompletion. The purpose of this ad hoc analysis was to explore if the interaction of
any study variables influenced the participant time until noncompletion since published
research indicates treatment completion can be impacted by many complicated,
overlapping host, environment, and agent factors (Coly & Morisky, 2004; HirschMoverman et al., 2008; Malangu & Yamutamba, 2016; Parsyan et al., 2007). The
interactions performed can be viewed in Appendix G. All corresponding statistically
significant interaction hazard ratios, p-values, and the 95% confidence interval bounds
are summarized in Table 14.
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Table 14.
Ad Hoc Analysis 1: Statistically Significant Covariate Interactions using Cox
Proportional Hazard Regression
95 % CI
Variables
HR
SE
p
Lower
Upper
CPHR with levels of Age interacting with levels of Visa-typea
Age (1: 0-24 years)
1.31
1.12
0.81
0.15
11.82
Age (2: 25-44 years)
8.27
1.16
0.07
0.85
80.50
Age (3: 45+ years)
Visa (Refugee)
2.26
1.05
0.44
0.29
17.51
Visa (Immigrant)
Age (1: 0-24 years) in Visa (1: Refugee)‡
0.23
0.74
0.04
0.05
0.97
Age (2: 25-44 years) in Visa (1: Refugee)
0.96
0.44
0.94
0.41
22.29
CPHR with levels of Age interacting with levels of Distance to LTBI Treatment Facilityb
Age (1: 0-24 years)
12,646.67
103.79
0.93
0.00
2.80E+92
Age (2: 25-44 years)
1.15
0.42
0.74
0.50
2.64
Age (3: 45+ years)
Distance to Treatment Facility (1: 0-10.9 miles)
13,553.08
103.79
0.93
0.00
2.99E+92
Distance to Treatment Facility (2: 11-20.9 miles)
0.00
179.77
0.96
0.00
8.2E+148
Distance to Treatment Facility (3: 21+ miles)
Age (1: 0-24 years) in Distance to Treatment Facility
(1:0-10.9 miles)‡
0.25
0.63
0.03
0.07
0.86
Age (2: 25-44 years) in Distance to Treatment Facility
(1:0-10.9 miles)
1.25
0.4
0.58
0.57
2.75
Age (1: 0-24 years) in Distance to Treatment Facility (2:
11-20.9 miles)
0.58
490.06
0.98
0
-CPHR with levels of Age interacting with levels of IGRA positivityc
Age (1: 0-24 years)
0.35
0.59
0.08
0.11
1.14
Age (2: 25-44 years)
1.45
0.48
0.45
0.57
3.70
Age (3: 45+ years)
IGRA Result (0: Positive)
1.46
0.67
0.57
0.39
5.37
IGRA Results (1: Negative or Not Done)
Age (1: 0-24 years) in IGRA (0: Positive) ‡
0.35
0.59
0.05
0.12
1.03
Age (2: 25-44 years) in IGRA (0: Positive)
1.24
0.74
0.77
0.29
5.32
Note. Abbreviations: HR = Hazard Rate; SE = Standard Error. aReference Group = 45+ years, Immigrant. bReference Group
= 45+ years, 21+ miles from treatment facility. cReference Group = 45+ years, IGRA negative or not done. ‡ Denotes
statistically significant at p<0.05.

For the analysis of interactive predictors of mean time on LTBI treatment until
noncompletion, the overall model significance of p = 0.03 suggests the null hypothesis
should be rejected. Additionally, the Log-likelihood was reduced in the second block
where interaction terms are included compared to the first block where main effects are
assessed suggesting the accuracy of the model improves when interaction terms are
included. The interactive effect of some study covariates appeared to influence the mean
time until treatment noncompletion.
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The age (zero to 24 years) and visa-type (refugee) interaction term suggested the
effect of age on time until LTBI treatment noncompletion was different by visa-type (HR
= 0.23, p = 0.04). The main effect of the age variable for those less than 25 years, if
statistically significant, would have suggested the risk of LTBI treatment noncompletion
was 31% higher than those 45 years of age and older in the reference group (p = 0.81).
However, this would be exclusive of visa status as the visa-type term was held at zero.
Likewise, the risk of noncompletion would have increased by a rate of 2.26 when age
was held at zero in refugees compared to immigrants (p = 0.44) but again, only if this
finding were statistically significant. In terms of interaction, the hazard of 0.23 indicates
that for study participants zero to 24 years of age who held a refugee visa, the risk of
noncompletion was 77% lower than the comparator group indicating a greater mean time
on treatment.
When assessing the age (zero to 24 years) and distance from study participant
residence and LTBI treatment facility (zero to 10.9 miles) interaction term, this study
identified the effect of age on time until LTBI treatment noncompletion differed by
distance (HR = 0.25, p = 0.03). The hazard associated with the interaction term indicates
that those zero to 24 years of age living less than 11 miles away from their LTBI
treatment facility experienced a rate of LTBI treatment noncompletion 75 times less than
the comparator group. Furthermore, the somewhat wide confidence interval around this
interaction term hazard ratio estimate did not cross one and suggests the true risk of LTBI
treatment noncompletion in this group was 93% less than the comparator group.
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The interaction between age (zero to 24 years old) and IGRA result (positive) also
appeared to be a predictor of time on treatment until noncompletion (HR = 0.35, p =
0.05). The main effect for age (zero to 24 years) while all other variables were held
constant, resulted in a decreased hazard of LTBI treatment noncompletion by 65%
compared to the 45 years of age and older reference group (p = 0.08). The main effect for
IGRA result (positive) however, resulted in a 46% increase in the risk of experiencing
noncompletion compared to the reference group that tested IGRA negative or did not
have an IGRA performed (p = 0.57). For this interaction term, being in the study
participant group less than 25 years old who were IGRA positive reduced the likelihood
of LTBI treatment noncompletion by 65% when compared to study participants 45 years
of age and older and IGRA negative or who did not have an IGRA performed. Notably,
the 95% confidence interval for this interaction crosses one, suggesting the true risk of
noncompletion reported could be due in part by chance.
The second ad-hoc analysis involved stratifying the dataset by visa-type prior to
analysis. CPHR analysis was performed to assess variable interaction terms by visa-type
as study participants may differ according to visa. Statistically significant interactions can
be found in Table 15 in Appendix H.
For refugees, the following interactive effects were identified:
•

Age (zero to 24 years) and visa-type (Refugee) (HR = 0.21, p = 0.04).

•

Age (zero to 24 years) and distance (less than 11.0 miles between residence
and LTBI treatment facility) (HR = 0.21, p = 0.05).
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•

Age (zero to 24 years) and history of tobacco use (having a current or former
history of tobacco use) (HR = 0.22, p = 0.05).

•

Age (zero to 24 years) and area of resettlement (urban) (HR = 0.21, p = 0.04).

All interaction terms above were associated with experiencing less treatment
noncompletion events at specific age categories and a longer duration on LTBI treatment
when compared to the reference group. Ultimately, for this model, the null hypothesis
that the mean time on LTBI treatment for study participants with a refugee or immigrant
visa was not influenced by select covariates was not rejected (Refugee model p = 0.74,
Immigrant model p = 0.22).
More specifically, the age (zero to 24 years) and visa-type (Refugee) interaction
term in this analysis suggested these participants experienced LTBI treatment
noncompletion 79% less often compared to refugees who were 45 years of age and older
(p = 0.73). For the interaction between visa (refugee) and distance (<11 miles) only one
fifth of those study participants experienced LTBI treatment noncompletion compared to
the reference study participants. Additionally, for the interaction term in the same less
than 25-year age category reporting current or former tobacco use, being in this grouping
reduced the likelihood of LTBI treatment noncompletion by 78% compared to older (45+
years), non-smoking refugee study participants (p = 0.05). Finally, the interaction
between belonging to the refugee group less than 25 years and resettling in the urban
Idaho environment corresponded with a 79% reduction in the likelihood of experiencing
LTBI treatment noncompletion when compared to study participants reference groups (p
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= 0.04). At the conclusion of the study period, refugees less than 25 years of age
frequently experienced a greater mean time on treatment.
For immigrants, two interaction terms that were found to be statistically
significant influencers of mean time on LTBI treatment until noncompletion included: (a)
age (25 to 44 years) and birth country (Africa WHO Region) (HR = 12.20, p = 0.05), and
(b) age (25 to 44 years) and area of resettlement (urban) (HR = 4.42, p = 0.05). For the
interaction of immigrant study participants aged 25 to 44 years hailing from the Africa
WHO region, participants were at significantly elevated risk for experiencing treatment
noncompletion compared to immigrant study participants 45 years of age and older and
who were from the Western Pacific WHO Region. Specifically, these participants
experienced LTBI treatment noncompletion at a rate 12.2 times higher than the
aforementioned reference group indicating mean time on treatment was low. The very
wide confidence interval around this estimate indicates the true risk of LTBI treatment
noncompletion for this group compared to reference study participants was in excess of a
rate 140 times higher.
For the interaction term of this same 25 to 44 years old age category and area of
resettlement (urban), those resettling in the urban-Idaho setting were 4.4 times more
likely to experience noncompletion compared to immigrant study reference group
members who were 45+ years old resettling in the rural-Idaho setting signifying these
participants had a decreased mean time on LTBI treatment. Interpretation of the 95%
confidence interval, however, suggests chance may have been a contributing factor to this
finding as one was included in the range.
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The third ad-hoc analysis was performed because multiple treatment regimen
options exist potentially influencing the time until treatment noncompletion (Dobler &
Marks, 2012; Goswami et al., 2012; Li et al., 2009; Lines et al., 2015; Menzies et al.,
2004; Shepardson et al., 2013). Data were analyzed by controlling for treatment regimen
and no statistically meaningful relationship was identified between visa-type and mean
time on LTBI treatment (Appendix H, Table 16). For this model, the null hypothesis that
the mean time on LTBI treatment was not influenced by the regimen prescribed could not
be rejected (p = 0.89).
Study participant medical co-morbidity influence on mean time on LTBI
treatment was also assessed. The null hypothesis for ad-hoc analysis model four
suggested the mean time on LTBI treatment was not influenced by the presence of a
medical comorbidities and this hypothesis was not rejected (data not shown). Medical comorbidities were assessed individually and for interaction. Finally, to improve the
medical comorbidity sample size, a new “any comorbidity” variable was created for
analysis that included all study participants with at least one medical comorbidity
recorded in the dataset. The results of this analysis were statistically non-significant
(Table 17, Appendix H) (p = 0.84). These findings suggest the medical co-morbidities
recorded in the dataset did not influence mean time on LTBI treatment for the study
participants.
The fifth and sixth ad-hoc analysis assessed the impact the prescribing provider
may have had on mean time on LTBI treatment until completion. When the impact
between provider and mean time on LTBI treatment was assessed (ad hoc analysis five),
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the null hypothesis that health care provider did not influence mean time on LTBI
treatment was not rejected (data not shown). The interactive effects assessed in ad-hoc
analysis six suggest that an interaction between provider and prescribed treatment as an
influencer of mean time on LTBI treatment until noncompletion also did not exist and the
null was not rejected (p = 0.59) (Appendix H, Table 18). Provider specific patterns did
emerge, however. As seen in Table 18 in Appendix H, Provider 18, when prescribing 4
months of RIF had study participants experience treatment noncompletion at a rate over
11 times more frequent compared to the study reference group receiving 9 months of INH
as prescribed by provider 23 (HR = 11.21, p = 0.02). This finding suggests that the
interactive effect of prescribing provider and prescribed regimen are not widespread but
provider-specific predictors of mean time on treatment may exist.
Lastly, the interaction term of distance between study participant residence and
LTBI treatment facility and the regimen was assessed. For this seventh ad-hoc model, the
null hypothesis was that the interaction between distance to LTBI treatment facility and
the prescribed regimen did not influence mean time on LTBI treatment. This hypothesis
was not rejected (p = 0.89) and the analytic findings are reported in Table 19 found in
Appendix H. Hazards for study participants prescribed 3HP, 4RIF, or 6INH having less
than 20.9 miles between residence and LTBI treatment facility were comparable to those
prescribed 9INH having more than 21 miles between residence and LTBI treatment
facility.
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Summary
The purpose of this retrospective cohort study was to document LTBI treatment
completion and noncompletion rates in visa holders arriving in Idaho and initiating
treatment. The study also aimed to determine whether an association existed between the
type of permanent visa held and LTBI treatment completion for foreign-born individuals
resettling in the rural U.S. Additionally, the study sought to determine if the mean time
on LTBI treatment was influenced by selected factors in these permanent visa holders. A
single dataset derived from the Idaho jurisdiction on the CDC EDN platform was used to
test the following null hypotheses:
H01: There is no association between visa type and LTBI treatment completion
among permanent visa holders initiating LTBI treatment in Idaho.
H02: The mean time distribution to last treatment for LTBI is not significantly
different between permanent visa holders initiating LTBI treatment in Idaho.
H03: Time on LTBI treatment in permanent visa holders initiating treatment in
Idaho is not affected by sex, age, country of origin, visa-type, smoking status,
distance between residence and treatment facility, area of resettlement, time
between arrival and initial medical evaluation, TST positivity, or IGRA positivity
The findings from this analysis suggests none of the null hypotheses should be
rejected at a significance level of 0.05. Chi-square analysis conducted to answer research
question one suggests an association between visa-type and LTBI treatment completion
status does not exist and the alternative hypothesis should not be accepted. Kaplan-Meier
survival analysis demonstrated the difference in mean treatment duration was not
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statistically significant across visa-types and the null hypothesis that no difference in
mean time on LTBI treatment between two types of visa holders was not rejected.
The impact of sex, birth country, visa-type, smoking status, distance from
residence to LTBI treatment facility, area of resettlement, the time between arrival and
medical evaluation, TST positivity, or IGRA positivity were not statistically significant
however, age was statistically significant. Specifically, being aged less than 25 years was
associated with a longer mean time on treatment and higher treatment completion rate.
However, overall, the CPHR model assessing the impact covariates have on mean time
until treatment noncompletion was not statistically significant.
Ad-hoc analysis examining the interactions between covariates did produce
statistically significant findings, however. The mean time to last LTBI treatment for study
participants was influenced by the (a) interactions of age (group one, zero to 24 years)
and visa-type (refugee), (b) age (group one, zero to 24 years) and distance between
residence and LTBI treatment facility being less than 11 miles, and (c) age (group one,
zero to 24 years) and being IGRA positive in Idaho when compared to study reference
groups.
Greater, in-depth interpretation of the findings outlined here will be provided in
chapter 5. This will also be accompanied by the current limitations surrounding this
research and recommendations for further research. The positive social change
implications for this research will also be discussed in chapter 5 as the findings
mentioned above highlight potentially important areas for public health practice change.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Annual U.S. tuberculosis surveillance data for 2017 suggest more than 80% of the
9,093 cases of active TB reported were due to reactivation of untreated LTBI likely
acquired outside of the United States (Stewart, Tsang, Pratt, Price, & Langer, 2018).
Providing increased opportunities for appropriate, risk-based screening and preventive
treatment for LTBI may have averted the progression from infection to active disease in
many of these individuals, minimizing the risk of transmission and improving the health
of those infected and the health of their contacts. Tuberculosis elimination experts
continue to urge that U.S. TB control programs devote more resources to the prevention
of disease through detecting and treating LTBI whilst continuing to reduce transmission
through early detection of those with active disease (Stewart et al., 2018).
In the face of decreasing TB control-related resources, including funding, a
skilled workforce, and research seeking out innovative preventive short-course regimens,
the ability to increase LTBI screening and treatment efforts broadly in the public sector
seems unlikely (Bayer & Castro, 2017). In the rural setting, which is already
disproportionately negatively impacted by resource limitations, renewed emphasis on
LTBI preventive strategies will likely have to take advantage of existing infrastructure to
be successful. Placing greater emphasis on ensuring high rates of preventive treatment
completion of those already being screened and initiating LTBI treatment in the rural
setting may be one approach to moving closer to TB elimination. However, there exists a
paucity of findings from LTBI interventions deployed in the rural U.S. setting. This gap
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leaves TB control officials serving rural populations reliant upon the extrapolation of
findings from potentially dissimilar research settings.
This retrospective cohort study was undertaken to quantify the LTBI treatment
completion rate in rural Idaho for permanent visa holders, determine the mean time on
treatment, and identify potential predicting variables of noncompletion. These efforts had
the potential to promote more targeted treatment completion thus improving public health
interventions. The epidemiologic triangle underpinned this research with multiple host,
environment, and agent-related variables extracted from review of similar published
research materializing in this study. De-identified pre- and postarrival medical evaluation
records from the CDC EDN system were used to establish the dataset analyzed to address
the study areas of inquiry. Study participant LTBI treatment completion estimates were
produced, Kaplan-Meier survival curves generated and interpreted, and Cox Proportional
Hazard Regression was used to calculate hazard ratios using sex, age, birth country, visa
type, history of tobacco use, distance from residence to treatment facility, area of
resettlement in Idaho, time to medical evaluation after resettlement, TST positivity, or
IGRA positivity as study covariates.
In this chapter, the key study findings are summarized, an interpretation of these
findings in the context of the epidemiologic triangle and existing body of knowledge are
provided, and the limitations of this research study are acknowledged. This chapter will
also provide recommendations for further research as well as the social change
implications of the current research findings.
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Interpretation of Major Findings
This study used three research questions to assess the impact of the immigration
status of visa holders arriving in Idaho on the treatment completion status for LTBI:
RQ1: Is visa type (refugee, immigrant, parolee, asylee, or fiancé) associated with
LTBI treatment completion among permanent visa holders initiating LTBI
treatment in Idaho?
RQ2: Is the mean time distribution to last treatment for LTBI between permanent
visa holders initiating LTBI treatment in Idaho significantly different?
RQ3: Is time on LTBI treatment in permanent visa holders initiating treatment in
Idaho affected by sex, age, country of origin, visa type, smoking status, distance
between residence and treatment facility, area of resettlement, time between
arrival and initial medical evaluation, TST positivity, or IGRA positivity?
Visa Type and Latent Tuberculosis Infection Treatment Completion
This study showed that immigrants had a higher treatment noncompletion rate
than refugees, 25.8% versus 19.3%, although, the difference was not statistically
significant. However, the nonsignificant finding may be caused by a few sample-related
factors. First, this study sample contained mostly refugees (n = 109) and fewer than 35
immigrants. Although the numbers of refugees included was somewhat robust, the
number of immigrants included was small. This small number equated to a small number
of recorded events which may have contributed to this finding. Second, immigrants were
disproportionately prescribed longer regimens compared to refugees in this study. With
longer treatment regimens having been shown to be associated with poorer completion in
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the urban setting (Juarez-Reyes et al., 2015; McClintock et al., 2017; Shepardson et al.,
2013; Wingate et al., 2015), immigrants in this study were not provided an equal
opportunity to gain access to expedited regimens that may have influenced treatment
completion status. Although their overall percent of noncompletion was just slightly less
than refugees, having a more evenly distributed treatment prescribing pattern across all
visa types in this study may have highlighted important differences.
A higher noncompletion rate in immigrants is different than that reported by Lim
et al., (2016) which identified Tibetan refugees had a greater risk of noncompletion than
immigrant visa holders in the urban Canadian setting. Such difference may be caused by
the study setting and demographic characteristics of the study subjects. The study by Lim
et al. (2016) included more refugees (n = 180) albeit from a single country of origin. All
refugees in this study were privately sponsored by Canadian citizens, potentially making
more resources available for medical evaluation and treatment completion compared to
Canadian migrants not sponsored. Typically, in Idaho, refugees are sponsored by
resettlement agencies and not private citizens.
Although visa type alone did not have a statistically significant impact on the
completion rate, it is important to note that a quarter of immigrants failed to complete
LTBI treatment compared to less than 20% of refugees. This difference may still be
critical to public health practice. Though the results deviated from trends established
using samples drawn from urban settings, it may show the trend of treatment completion
in the rural setting with more refugees. Additionally, these findings bring attention to
treatment completion rates for a rural population and support previous findings that no
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two environments are the same. Completion rate improving interventions should be
targeted after considering rural or urban-setting-specific characteristics (HirschMoverman et al., 2008).
Mean Time Distribution to Last Latent Tuberculosis Infection Treatment by Visa
Refugees and immigrants may be inherently different, so assessing differences in
mean time on LTBI treatment until noncompletion was necessary. This study showed that
immigrants had an average time on LTBI treatment of 7.51 months compared to an
average of 7.85 months for refugees, though the difference was not statistically
significant. It is worth noting that for this research question analysis, average time was
calculated without factoring the differing treatment regimen durations, which varied from
3 months to 9 months. Additional ad-hoc analysis was performed to address this with the
mean time in months for 3HP, 4RIF, 6INH, and 9INH being 2.96 months, 3.83 months,
5.4 months, and 7.7 months, respectively. Although few studies have been published
surrounding this phenomenon, a previous study by Parsyan et al. (2007) had identified
similar population group-specific differences in mean time on LTBI treatment. Parsyan et
al. (2007) reported that when Haitian (refugees) and the Dominican Republicans
(immigrants) resettled in Boston, they experienced less time on treatment and a higher
rate of noncompletion compared with U.S.-born Bostonians and Boston residents hailing
from other foreign countries. Unlike this current research, though, when compared to
each other, Parsyan et al. (2007) found Haitian refugees to have higher odds of
noncompletion and thus a lesser mean time on LTBI treatment compared to Dominican
Republic immigrants. Considering this published finding and the findings of this current
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study, the visa type held by LTBI treatment initiators may be an important factor to
consider when estimating mean time on treatment. However, more work in this area is
needed to draw this conclusion.
Despite the relatively small number of noncompletion events in this study sample,
notable trends potentially influential to public health practice emerged related to
treatment noncompletion in participants. Immigrants experienced all events within the
first 6 months of treatment initiation with no events being recorded in months 7, 8, or 9.
This meant immigrants had a final estimated cumulative proportion of survival at month
6 and until the end of the study of 0.738. Considering this, treatment completion
improving interventions for immigrants should target this 6-month window when the
number of noncompletion events is greatest. Refugees, however, experienced a majority
of events between months 3 and 6 but had the last recorded event just after the start of
month 8. This difference between when noncompletion events are experienced by visa
type may influence public health interventions, although additional studies drawing
similar conclusions would help support this notion.
Reasons for the difference in mean time on LTBI treatment could not be
determined from the data available; however, these findings represent a real actionable
difference between the two groups in practice. Additionally, reasons for regimen-specific
noncompletion events could not be determined. With immigrants failing to complete
treatment shortly after initiation and refugees failing to complete later in the course, the
two populations may benefit from separate completion improving interventions.
Predictors of Time on Latent Tuberculosis Infection Treatment
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The two previous research questions only examined visa type as a sole factor
influencing treatment completion and time on treatment. However, it is known that other
factors can impact treatment completion status and time on treatment. Known risk factors
impacting LTBI treatment completion status and overall time on treatment in the urban
and international setting are age (Bieberly & Ali, 2003; Bock et al., 1999; Hovell et al.,
2003; Lobue & Moser, 2003; Spicer et al., 2013), birth country (Fiske et al., 2014;
Parsyan et al., 2007; Spicer et al., 2013), visa-type (Lim et al., 2016; Sandgren et al.,
2016), and distance to health care facility (Getahun et al., 2015; Silva et al., 2016; Spicer
et al., 2013). Cox proportional hazard regression used in this study showed that as a
model overall, the covariates of age, sex, history of tobacco use, area of resettlement,
birth country, distance to health care facility, time between arrival and medical
evaluation, TST positivity, or IGRA positivity were not influencers of time on LTBI
treatment until noncompletion.
Among all the covariates, age may be an important factor to consider when
predicting risk for LTBI treatment noncompletion using Cox Proportional Hazard
Regression, however. Participants zero to 24 years of age, regardless of visa-type,
experienced the least number of treatment noncompletion events compared to study
participants 25 years of age and older. This translated into a higher cumulative survival
and an 82% reduced risk of experiencing noncompletion. Participants in this age group
were thus expected to have a longer mean time on treatment and were less likely to
experience LTBI treatment noncompletion. Although the exact reason why being less
than 25 years old in this study was associated with a greater mean time on treatment and
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higher completion is unknown, this finding supports those in published literature
surrounding minority migrant populations in San Diego, migrant TB clinic attendees
from San Diego County, post-Katrina survivors from urban New Orleans, and patients
referred to a large metropolitan health care facility in Columbus, Ohio (Bieberly & Ali,
2003; Lobue & Moser, 2003; Hovell et al., 2003; Spicer et al., 2013). Possibilities are
likely not due to confounding as tests for confounding were negative, however, could be
due to parental or guardian involvement during younger ages (van Zyl et al., 2006).
Alternatively, younger persons infected with Mtb and not successfully treated have more
years of lifetime risk ahead of them possibly leading to greater provider education
surrounding the benefit of treatment.
Birth country, visa-type, and distance to treatment facility were not predictors of
mean time on treatment until noncompletion in this study as they were for other
published work (Fiske et al., 2014; Getahun et al., 2015; Lim et al., 2016; Parsyan et al.,
2007; Sandgren et al., 2016; Silva et al., 2016; Spicer et al., 2013). The assessment of
birth country in this study may have been influenced by the use of WHO Regions instead
of specific countries of origin. This use of the WHO Region was deployed to increase
factor strata sample size for analysis however, may have masked country specific LTBI
treatment noncompletion trends. The analysis of visa-type as a predictor may have been
influenced by the relatively small number of immigrants included in this study compared
to refugees. Additionally, differences in the prescribed regimen were present based on
visa-type with no immigrants being prescribed the 3HP expedited regimen. This pattern
produced a study participant pool where it was more likely that immigrants would be
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prescribed longer treatment durations despite longer treatment durations having
documented lower rates of completion in various urban-based populations (Juarez-Reyes
et al., 2015; McClintock et al., 2017; Shepardson et al., 2013; Wingate et al., 2015).
Lastly, with no refugees resettling in the rural Idaho setting, the mean distance to the
nearest LTBI treatment facility was smaller than immigrants since refugees tended to
resettle less than five miles from their treatment facility. This resettlement pattern
excluded the analytic comparison of rural refugee resettlement and rural immigrant
resettlement, possibly hiding a true phenomenon observed in urban U.S. city-based
research that showed the greater the distance traveled, the less likely treatment
completion would be achieved (Getahun et al., 2015; Spicer et al., 2013).
Interactive Terms, Comorbid Conditions, and Provider Impact
Ad-hoc Cox Proportional Hazard Regression analyses were conducted to identify
the interactive covariate terms potentially influencing time on LTBI treatment. The
interaction between (a) age and visa-type, (b) age and distance to LTBI treatment facility,
and (c) age and IGRA positivity were found to be important influencers of the time on
treatment until noncompletion.
The assessment of interaction between age and visa-type identified that LTBI
noncompletion differed by visa-type. Refugees zero to 24 years of age had a 77% lower
risk of experiencing noncompletion compared to immigrants 45 years and older. This
finding suggests younger refugees experienced a longer time on treatment in contrast to
their older immigrant counterparts. Supporting this finding are the results of a study from
an inner-city Atlanta sample where Bock et al. (1999) identified older study participants,
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defined as those 45 years of age and older, had a higher rate of noncompletion and thus,
younger participants a lower. Similarly, in San Diego, Hovell et al. (2003) determined
that as study participant age increased, LTBI treatment completion decreased. Although
visa-type was not assessed by factors of age in either of these studies, it has been shown
to be an important component in determining LTBI treatment completion.
The assessment of interaction between the host factor age and the environmental
factor distance between residence and LTBI treatment facility revealed noncompletion
also differed by distance. Visa holders 45 years and older living more than 21 miles away
from their LTBI treatment facility had a risk of experiencing noncompletion 75 times
higher than persons zero to 24 years of age living less than 11 miles from their treatment
facility. This finding suggests that being younger than 25 years old and being treated for
LTBI in combination with living closer to their treatment facility, equated to a higher
mean time on treatment and a lower risk of noncompletion. This finding is corroborated
by the research conducted in urban Brazil where younger study participants traveling
further or taking longer to reach their treatment facility experienced higher rates of
noncompletion (Silva et al., 2016). Spicer et al. (2013) also found age and distance to be
inversely related to treatment completion but an increase in both factors resulted in a
decrease in completion.
Finally, the assessment of interaction between the host factor age and the agent
factor IGRA result indicates noncompletion differed by IGRA result. The risk of
experiencing LTBI treatment noncompletion was reduced by 65% in IGRA positive, zero
to 24-year-old persons. Utilizing IGRAs to diagnose LTBI are a helpful, yet nonessential
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tool, however, studies suggest these blood tests increase perceived severity and improve
the likelihood of treatment completion (Alsdurf, Hill, Matteelli, Getahun, & Menzies,
2016). Although this study could not validate this specific conclusion, being IGRA
positive and of a younger age potentially could support these claims if investigated
further. The assessment of age and IGRA positivity from this study may be the first
amongst its kind with no similar studies being identified.
Visa-specific interactive term findings. Visa-type specific predictors of LTBI
treatment noncompletion were also found. The interactive impact of age and visa-type
highlighted that persons zero to 24 years of age holding a refugee visa were 79% less
likely to experience LTBI treatment noncompletion; that refugees of the same less than
25 age group also living less than 11 miles from their treatment facility were 79% less
likely to experience noncompletion; that persons less than 25 years old reporting current
or former tobacco use were 78% less likely to experience noncompletion; and refugees
less than 25 years old resettling in the urban setting were 78% less likely to experience
noncompletion. Individually, most of these findings have been demonstrated in similar
research from urban-setting drawn samples however, these studies did not address
interaction (Parsyan et al., 2007; Rogo et al., 2017).
For immigrants, the interactive impacts of age and birth country, and age and area
of resettlement resulted in a greater risk of noncompletion. Immigrants aged 25 to 44
years hailing from the Africa WHO Region, experienced noncompletion at a rate 12
times higher than the 45 year old and older reference group hailing from the Western
Pacific. Additionally, immigrants of this same 25 to 44-year age group resettling in the
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urban environment experienced noncompletion four times more often compared to
persons 45 years and older from the rural setting. These findings suggest immigrants aged
25 to 44 years may be at heightened risk of experiencing noncompletion and in the
resource limited setting, may benefit from targeted interventions. Each of these findings
are similar to those demonstrated in research from urban-setting drawn samples however
these similar studies did not address the interactive impact as this study on the rural
population did (Ailinger, Black, Nguyen, & Lasus, 2007; Hirsch-Moverman et al., 2010;
Shieh et al., 2006).
Study Limitations
Given this was a study based on a secondary database, there were some
limitations related to:
•

The intent of the original data collection;

•

Data availability and the inability to collect additional data;

•

Results not being generalizable to the urban setting or areas with a different
makeup of visa holders; and

•

The sampling methods used, the small sample size, and the subsequent small
number of events that may have impacted statistical power.

Original Intent of Data
Components of chapter 1 highlighted the purpose of the CDC’s EDN system from
which the data for this study were derived suggesting that data were not originally
collected to address the current research questions. This may have provided opportunity
for important variables related to LTBI treatment completion and this current research to
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be excluded since they were not collected in the first place. Furthermore, the CDC EDN
system only houses data for U.S. permanent visa-holding migrants so this study was
unable to include similar data from the general, non-migrant U.S. population potentially
making these findings less generalizable to a broad population. Additionally, the reason
for LTBI treatment noncompletion was not well documented and was thus, excluded
from the study dataset. Reasons for noncompletion may be due to other variables not
included in this research so these study findings should likely not be considered the only
important factors when assessing noncompletion risk. Lastly, treatment completion has
been shown to be a complicated phenomenon with this study including no social support
variables which have been documented to influence adherence.
Data Availability, Collection of Additional Data, and Generalizability
This study did not include visa holders seeking care in the private market making
data on this group unavailable for comparison. This limits the extent to which these study
findings can be applied to this private-care seeking population. Additionally, one Idaho
jurisdiction did not have visa holders represented in this study possibly limiting the
generalizability of these findings to that jurisdiction. Power analyses performed suggest
this study obtained a sufficient sample size to be representative, however, the exclusion
of a jurisdiction is unfortunate. Furthermore, unlike treatment for active disease,
treatment for LTBI is not mandated in Idaho law potentially influencing patient
perception of disease severity and influencing treatment initiation however this could not
be validated due to a lack of data. Lastly, the de-identified dataset did not allow for
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additional information to be collected on study participants that may have been useful
variables to include in this research to justify noncompletion events.
Sampling and Sample Size
This study did not deploy formal sampling techniques to select participants as to
include the highest number of eligible visa holders. However, nearly 20% of visa-holding
arrivals with a B TB notification possibly suggestive of LTBI were automatically
excluded due to a lack of medical follow-up information. It is unknown if these
individuals had LTBI, but if that were the case, their contributions to the overall sample
size may have improved statistical power and decreased further the likelihood that some
of the major findings were less likely to have occurred due to chance. Additionally, the
lack of medical information collected on these individuals reduced study generalizability.
Given the considerable number of B TB Notifications received by Idaho public
health officials, the sample size for this study, representing only 9% of those arrivals, is
relatively small. The small sample likely lead to the small number of events recorded and
may have influenced the ability to perform multivariate analysis since some of the
variable strata approached or became zero. Additionally, the study population is likely
not representative of entire Idaho population infected with Mtb, limiting extrapolation of
these findings only to newly arriving refugee and immigrant visa holders and not U.S.born Idahoans.
The sample size issues described provide opportunity for improvement. This
study had very strict inclusion criteria that decreased B TB notification evaluation result
data availability from visa-holding arrivals to Idaho. By excluding visa holders diagnosed

169
with LTBI who were recommended treatment but failed to initiate treatment within the
first month, by excluding visa holders on LTBI treatment moving from non-Idaho
jurisdictions, and by excluding visa holders who may have been evaluated and accepted
LTBI treatment in subsequent years after arrival but still during the study timeframe, the
number of visa holders included in this study was decreased and the visa-type diversity
restricted to refugees and immigrants. This reflection highlighted it may be advantageous
in the future to include these abovementioned visa holders to increase the sample,
diversify the types of visas held by participants, and to improve overall study power and
generalizability to a broader visa-holding population.
Recommendations for Further Research and Public Health Practice
This current study was the first of its kind for the rural Idaho-setting, but does
present additional opportunities for further research. With the rural-setting in general
being underrepresented in the published literature, there is a need to further explore the
factors that contribute to the urban versus rural differences identified between this work
and the published work from the urban setting. Additionally, increasing the sample size
for research focused on the rural setting would also be beneficial as this study suffered
from a relatively small sample. The proactive collection of more socioeconomic and
familial support factors in the rural setting could also contribute to explaining the
differences noted between urban and rural jurisdictions.
In this study, data were not available for why a participant did not complete LTBI
treatment, likely related to the retrospective nature of this study design. This highlights an
important area for future prospective rural-setting research. Persons who fail to complete
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LTBI treatment for medical reasons may differ from those failing to complete by choice
and these potential differences need to be explored. Since some medical reasons for
stopping LTBI treatment may be unavoidable, future prospective research in this arena
could take this into account. Furthermore, potential spurious correlations possibly the
product of unassessed factors could be taking place in this retrospectively designed study.
Public health interventions developed for the rural setting may have greater success in
improving LTBI treatment completion when targeting non-medically related modifiable
noncompletion risk factors.
Due to the complex nature of treatment completion, additional research into the
interaction between factors is needed especially in the rural setting. Although costlier and
labor intensive, a prospective cohort, as discussed above, involving visa holders
diagnosed with LTBI in Idaho would allow for data to be collected on additional
variables of interest, would potentially allow for documentation of reasons for noncompletion, and may allow for a greater number of participants to be enrolled for sample
size improvement. Alternatively, an additional retrospective study with less restrictive
inclusion criteria or possibly spanning a timeframe greater than five years may also
contribute to the body of knowledge surrounding this phenomenon and may support the
findings of this research.
This study consistently demonstrated that refugees under the age of 25
experienced higher rates of treatment completion when acting interactively with visatype, distance to treatment facility, history of tobacco use, and area of resettlement
however, some of these findings have not yet been described in published works.
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Additionally, the interactive relationship between holding an immigrant visa and birth
country as well as being an immigrant and resettling in the urban setting needs further
exploration as this study included a very small number of immigrants.
Lastly, no immigrant study participant was prescribed the expedited LTBI
treatment regimen lasting the shortest duration of 12 weeks. Although a number of
refugees were prescribed the expedited regimen, this study may have been improved if
comparison between visa-types on the expedited regimen could have been performed. As
the use of the expedited regimen expands, future research should focus on the differences
between treatment completion status by visa-type when a broader variety of visa-types
are available for analysis.
Recommendations for improving public health practice may be derived from this
study. As demonstrated by the regimen-specific time on treatment analysis, nine months
of INH likely should not be as heavily relied on in the rural setting as completion rates
were inferior to shorter regimens. The use of expedited regimens, when appropriate, for
treating LTBI should be improved. Also, providing all visa-types greater access to non9INH regimens should be a focus of public health practitioners as this study
demonstrated mostly refugees were prescribed expedited regimens. Furthermore,
although more resource intensive for the rural setting, visa holders at higher-risk of
noncompletion in Idaho may benefit from more frequent interactions with public health
practitioners. This may help ensure adherence and continuously promote LTBI treatment
completion. Additionally, more frequent interactions may be beneficial in the early stages
of treatment for immigrants or the mid- to later-stages of treatment for refugees as these
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areas were where the largest number of noncompletion events took place. Finally, a more
thorough assessment of clinic-based completion rates may inform LTBI treatment
prescribing practitioners which regimens are garnishing the highest completion rates in
their clinics. The outcome of such a clinic-based assessment may provide evidence for
the utilization of the most appropriate LTBI regimen for the clinic patient population.
Social Change Implications
The results of this study can fundamentally be used to assist the TB control
workforce serving geographically large, rural states understand LTBI treatment
completion in likely the population at greatest risk of being infected with Mtb. In the rural
setting, public health resources for TB control are scarce and information potentially
driving public health intervention development may stem from research findings using
samples drawn from the urban setting where TB disease is more abundant. This research
identified some rural-jurisdiction specific LTBI treatment noncompletion trends and
predictors but also correlated with some findings from the urban setting suggesting
geographic variation was present. This research may promote social change in the rural
setting by providing actionable, rural-population specific information for the
prioritization of visa holders at increased risk of experiencing LTBI treatment
noncompletion. Furthermore, with visa holders being a focus of this research, findings
may help scope state-based Refugee Health Screening Program priorities.
Ensuring high rates of LTBI treatment completion can prevent future cases of
active disease reducing health care costs and hospitalizations, improving individual
quality of life, preventing transmission, and improving community health. In the clinical

173
context, this study has reaffirmed other work that longer courses of LTBI treatment have
lower rates of completion indicating a shift in TB control narrative is needed to promote
broader use of expedited regimens. As this study, and others have demonstrated, host,
environment, and agent factors are important considerations in the development of
successful public health interventions. This study has highlighted that age, visa, birth
country, and history of tobacco use are important interactive host factors, distance to
treatment facility and area of resettlement important interactive environment factors, and
IGRA positivity interactive agent factors to consider when assessing risk of LTBI
noncompletion. Lastly, this study adds to the incredibly limited body of knowledge
surrounding LTBI treatment completion in the rural setting potentially making these
findings available to other rural jurisdictions with limited TB control resources.
Conclusion
This research attempted to address the identified gap surrounding the
quantification of LTBI treatment completion rates in the non-urban setting, the mean time
on treatment in the rural setting, and the predictors of noncompletion. The study found
noncompletion in immigrants approached 26% whilst noncompletion remained below
20% in refugees. Though the difference was not statistically significant, the rates of
noncompletion in both groups remains of concern.
The refugee study participants had a mean LTBI treatment time of 7.85 months
compared to 7.51 months for immigrants. Across both visa-types, study participants
prescribed nine months of INH had the lowest mean time on treatment compared against
the recommended duration. This finding suggests other shorter regimens should be

174
considered before nine months of INH, when clinically appropriate, for this rural
population.
Age had a significant impact on the probability of time on treatment until
noncompletion in this study. Specifically, being aged less than 25 years of age equated to
an 82% less likelihood of experiencing LTBI treatment noncompletion. When age
interacting with visa (refugee), or distance to LTBI treatment facility (<11 miles), or
being IGRA positive, study participants zero to 24 years of age had a 77%, 75% and 65%
less likely chance of experiencing noncompletion, respectively. A finding of this nature
suggests public health interventions that target refugees and immigrants older than 25
years may result in an increased rate of completion, although more work is needed to
draw this conclusion.
Although this research has important implications for the rural Idaho TB-control
setting, further research, potentially with a more robust sample size drawn from the rural
setting, would assist in validating these findings. The inclusion of more diverse visa-types
may promote broader finding applicability as this research only included refugees and
immigrants. Additionally, more effort to explore the interaction terms described in this
study is needed as these factors are rarely described in the published literature in an
interactive sense. Regardless, the findings presented add to the body of literature on LTBI
treatment completion and potentially arm TB controllers in the rural, resource limited
setting with evidence for setting and visa-type specific treatment completion improving
interventions.
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For Idaho, the results of this study provide TB control leadership with the first
documented estimates of LTBI treatment completion for this vulnerable population.
Additionally, this study provides potential risk factor-related information for the
development of actionable interventions targeting those at increased risk of LTBI
noncompletion. Lastly, the dissemination of these results to Idaho public health and TB
control officials will help those entities prioritize communication to partners, scope
recommendations, and place greater emphasis on the observed differences between
refugee and immigrant LTBI treatment completion rates without solely relying on
findings from urban setting research.
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214

215
Appendix C: Department of State Form 3026

216

217
Appendix D: Log-Log Functions for Covariates

Figure D1. Log-log curve for age.

Figure D2. Log-log curve for sex.
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Figure D3. Log-log curve for visa-type.

Figure D4. Log-log curve for history of tobacco use.

219

Figure D5. Log-log curve for distance between residence and treatment facility.

Figure D6. Log-Log Curve for Area of Resettlement.
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Figure D7. Log-log curve for time between arrival and Medical Evaluation.

Figure D8. Log-log curve for TST.
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Figure D9. Log-log curve for IGRA.
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Appendix E: Cox Proportional Hazard Regression Survival Curves

Figure E30. Survival function for male participants.

Figure E31. Survival function for participants on 3HP by age group.

223

Figure E32. Survival function for participants on 4RIF by age group.

Figure E33. Survival function for participants on 6INH by age group.
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Figure E34. Survival function for participants on 9INH by age group.

Figure E35. Survival function for participants on 3HP by birth country
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Figure E36. Survival function for participants on 4RIF by birth country.

Figure E37. Survival function for participants on 6INH by birth country.
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Figure E38. Survival function for participants on 9INH by birth country.

Figure E39. Survival function for participants on 3HP by smoking status.
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Figure E40. Survival function for participants on 4RIF by smoking status.

Figure E41.Survival function for participants on 6INH by smoking status.
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Figure E42. Survival function for participants on 9INH by smoking status.

Figure E43. Survival function for participants on 3HP by treatment facility distance.
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Figure E44. Survival function for participants on 4RIF by treatment facility distance.

Figure E45. Survival function for participants on 6INH by treatment facility distance.
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Figure E46. Survival function for participants on 9INH by treatment facility distance.

Figure E47. Survival function for participants on 3HP by time between evaluation.
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Figure E48. Survival function for participants on 4RIF by time between evaluation.

Figure E49. Survival function for participants on 6INH by time between evaluation.

232

Figure E50. Survival function for participants on 9INH by time between evaluation.

Figure E51. Survival function for participants on 3HP by TST positivity.
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Figure E52. Survival function for participants on 4RIF by TST positivity.

Figure E53. Survival function for participants on 6INH by TST positivity.
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Figure E54. Survival function for participants on 9INH by TST positivity.

Figure E55. Survival functions for participants on 3HP by IGRA positivity.
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Figure E56. Survival functions for participants on 4RIF by IGRA positivity.

Figure E57. Survival functions for participants on 6INH by IGRA positivity.
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Figure E58. Survival functions for participants on 9INH by IGRA positivity.
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Appendix F: Cox Proportional Hazard Reference Groups
Cox Proportional Hazard Analysis Reference Groups Without Visa-stratification
Variable(s)*
TxRegimen
TxRegimen (1: 3HP)
TxRegimen (2: 4RIF)
TxRegimen (3: 6INH)
TxRegimen (4: 9INH)
Sex
Male (1)
Female (2)
Age
Age (1: 0-24 years)
Age (2: 25-44 years)
Age (3: 45+ years)
BirthCountry
BirthCountry (1: Americas)
BirthCountry (2: Europe or E. Mediterranean)
BirthCountry (3: Africa)
BirthCountry (4: South-East Asia)
BirthCountry (5: Western Pacific)
Visa
Refugee (1)
Immigrant (2)
TimeEval
TimeEval (1: <30 days)
TimeEval (2: 30-59 days)
TimeEval (3: 60+ days)
AreaResettle
Urban (1)
Rural (2)
TxDistance
TxDistance (1: 0-10.9 miles)
TxDistance (2: 11-20.9 miles)
TxDistance (3: 21+ miles)
HistoryOfTobaccoUse
No (1)
Yes, current or former (2)
TSTPos
Positive (1)
Negative or not done (2)
IGRAResult
Positive (1)
Negative or not done (2)
Note. *Bold font signifies Reference Group.

Number in Stratum (N
= 140)
24
13
10
93
79
61
51
33
56
14
25
41
46
14
109
31
97
29
14
129
12
126
1
13
119
21
65
75
29
111
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Cox Proportional Hazard Analysis Reference Groups: Count by Visa-type
Variable(s)*
TxRegimen
TxRegimen (1: 3HP)
TxRegimen (2: 4RIF)
TxRegimen (3: 6INH)
TxRegimen (4: 9INH)
Sex
Male (1)
Female (2)
Age
Age (1: 0-24 years)
Age (2: 25-44 years)
Age (3: 45+ years)
BirthCountry
BirthCountry (1: Americas)
BirthCountry (2: Europe or E. Mediterranean)
BirthCountry (3: Africa)
BirthCountry (4: South-East Asia)
BirthCountry (5: Western Pacific)
TimeEval
TimeEval (1: <30 days)
TimeEval (2: 30-59 days)
TimeEval (3: 60+ days)
AreaResettle
Urban (1)
Rural (2)
TxDistance
TxDistance (1: 0-10.9 miles)
TxDistance (2: 11-20.9 miles)
TxDistance (3: 21+ miles)
HistoryOfTobaccoUse
No (1)
Yes, current or former (2)
TSTPos
Positive (1)
Negative or not done (2)
IGRAResult
Positive (1)
Negative or not done (2)
Note. *Bold font signifies Reference Group.

Refugee (N=109)

Immigrant (N=31)

24
12
8
65

0
1
2
28

66
43

13
18

31
29
49

20
4
7

0
24
38
45
2

14
1
3
1
12

87
18
4

10
11
10

109
0

19
12

108
0
1

18
1
12

91
18

28
3

48
61

17
14

21
88

8
23
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Appendix G: Cox Proportional Hazard Regression Models
Model
1

Variable(s)
TxRegimen
TxRegimen (3HP)
TxRegimen (4RIF)
TxRegimen (6INH)

2

Sex
Sex*Age
Sex*BirthCountry
Sex*Visa
Sex*HistoryOfTobaccoUse
Sex*TxDistance
Sex*AreaResettle
Sex*TimeEval
Sex*TSTPos
Sex*IGRAResult

3

Age
Age*BirthCountry
Age*Visa
Age*HistoryOfTobaccoUse
Age*TxDistance
Age*AreaResettle
Age*TimeEval
Age*TSTPos
Age*IGRAResult

4

BirthCountry
BirthCountry*Visa
BirthCountry*HistoryOfTobaccoUse
BirthCountry*TxDistance
BirthCountry*AreaResettle
BirthCountry*TimeEval
BirthCountry*TSTPos
BirthCountry*IGRAResult

5

Visa
Visa*HistoryOfTobaccoUse
Visa*TxDistance
Visa*AreaResettle

(table continues)
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Model
5, continued

Variable(s)
Visa*TimeEval
Visa*TSTPos
Visa*IGRAResult

6

HistoryOfTobaccoUse
HistoryOfTobaccoUse*TxDistance
HistoryOfTobaccoUse*AreaResettle
HistoryOfTobaccoUse*TimeEval
HistoryOfTobaccoUse*TSTPos
HistoryOfTobaccoUse*IGRAResult

7

TxDistance
TxDistance*AreaResettle
TxDistance*TimeEval
TxDistance*TSTPos
TxDistance*IGRAResult

8

AreaResettle
AreaResettle*TimeEval
AreaResettle*TSTPos
AreaResettle*IGRAResult

9

TimeEval
TimeEval*TSTPos
TimeEval*IGRAResult
TSTPos
TSTPos*IGRAResult

10
11

IGRAResult
Sex*Age*BirthCountry*Visa*HistoryOfTobaccoUse*TxDistance*AreaResettle*TimeEva
l*TSTPos*IGRAResult
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Appendix H: Ad Hoc Analyses Result Tables
Table H1
Ad Hoc Analysis 2: CPHR with Visa-type Stratification and Covariate Interactions
Visa
Refugee

Variables
CPHR with levels of Age interacting with levels of Visa-typea

Age (1: 0-24 years)
Age (2: 25-44 years)
Age (3: 45+ years)
Visa (Refugee)
Visa (Immigrant)

Immigrant

HR

SE

p-value

0.67
1.14
0.33
1.44
Age (1: 0-24 years) in Visa ‡
0.21
0.77
Age (2: 25-44 years) in Visa
0.90
0.48
CPHR with levels of Age interacting with levels of Distance to LTBI Treatment Facilityb
Age (1: 0-24 years)
0.67
1.14
Age (2: 25-44 years)
0.33
1.44
Age (3: 45+ years)
Distance to Treatment Facility (1: 0-10.9 miles)
0.73
373.48
Distance to Treatment Facility (3: 21+ miles)
Age (1: 0-24 years) in Distance to Treatment Facility
(1:0-10.9 miles) ‡
0.21
0.77
Age (2: 25-44 years) in Distance to Treatment Facility
(1:0-10.9 miles)
4.11
0.77
Age (1: 0-24 years) in Distance to Treatment Facility
(2: 11-20.9 miles)
0.00
1,242.96
CPHR with levels of Age interacting with levels of History of Tobacco Usec
Age (1: 0-24 years)
0.67
1.14
Age (2: 25-44 years)
0.33
1.44
Age (3: 45+ years)
History of Tobacco Use (1: Yes)
0.53
0.65
History of Tobacco Use (2: Never)
Age (1: 0-24 years) in History of Tobacco Use (1: Yes) ‡
0.22
0.77
Age (2: 25-44 years) in History of Tobacco Use (1: Yes)
1.00
0.49
CPHR with levels of Age interacting with levels of Area of Resettlementd
Age (1: 0-24 years)
0.67
1.14
Age (2: 25-44 years)
0.33
1.44
Age (3: 45+ years)
Area of Resettlement (1: Urban)
Area of Resettlement (2: Rural)
Age (1: 0-24 years) in Area of Resettlement (1: Urban) ‡
0.21
0.77
Age (2: 25-44 years) in Area of Resettlement (1: Urban)
0.90
0.48
*CPHR with levels of Age interacting with levels of Birth Countrye
Age (1: 0-24 years)
0.67
1.14
Age (2: 25-44 years)
0.33
1.44
Age (3: 45+ years)
6,189.
Birth Country (1: Americas)
81
137.51
12,694
Birth Country (2: Europe or Eastern Mediterranean)
.36
137.51
15,379
Birth Country (3: Africa)
.85
137.51
Birth Country (5: Western Pacific)
Age (1: 0-24 years) in Birth Country (1: Americas)
1.96
0.82
Age (1: 0-24 years) in Birth Country (3: Africa)
0.00
1,208.45

95 % CI
Lower
Upper

0.73
0.44
0.04
0.83

0.73
0.02
0.05
0.35

6.22
5.57
0.96
2.31

0.73
0.44
0.99
-

0.73
0.02
0.00
-

6.22
5.57
-

0.05

0.05

0.98

0.07

0.91

18.61

0.99

0.00

--

0.73
0.44
0.33
0.05
0.99

0.73
0.02
0.15
0.05
0.38

6.22
5.57
1.89
0.99
2.65

0.73
0.44
0.04
0.83

0.73
0.02
0.05
0.35

6.22
5.57
0.96
2.31

0.73
0.44
-

0.73
0.02
-

0.95

0.00

0.95

0.00

0.94
0.41
0.99

0.00
0.39
0.00

6.22
5.57
6.9E+1
20
1.4E+1
21
1.7E+1
21
9.77
--

(table continues)

242

Visa

Variables
HR
Age (2: 25-44 years) in Birth Country (2: Europe or
Eastern Mediterranean)
5.70
Age (2: 25-44 years) in Birth Country (3: Africa) ‡
12.20
CPHR with levels of Age interacting with levels of Area of Resettlementf
Age (1: 0-24 years)
0.67
Age (2: 25-44 years)
0.33
Age (3: 45+ years)
Area of Resettlement (1: Urban)
Area of Resettlement (2: Rural)
Age (1: 0-24 years) in Area of Resettlement (1: Urban)
Age (2: 25-44 years) in Area of Resettlement (1: Urban)

0.00
0.42

95 % CI
Lower
Upper

SE

p-value

1.17
1.25

0.14
0.05

0.58
1.06

56.54
140.36

1.14
1.44
-

0.73
0.44
-

0.73
0.02
-

146.14
1.12

0.96
0.44

0.00
0.05

6.22
5.57
3.4E+1
21
3.77

‡
4.42
0.77
0.05
0.98
20.05
Note. Abbreviations: HR = Hazard Rate; SE = Standard Error. aReference Group = 45+ years, Immigrant. bReference Group = 45+
years, 21+ miles from treatment facility. cReference Group = 45+ years, No history of tobacco use. dReference Group: 45+ years,
Rural. eReference Group: 45+ years, Western Pacific. fReference Group: 45+ years, Rural. ‡ Denotes statistically significant at
p<0.05. *Analysis excluded when sample = 0 in categorical variable subgroup.

Table H2
Ad Hoc Analysis 3: Treatment Regimen and Mean Time on LTBI Treatment
Visa
Refugee

Immigrant

Variable
Regimen
Regimen (3HP)
Regimen (4RIF)
Regimen (6INH)
Regimen
Regimen (4RIF)
Regimen (6INH)

95% CI
Lower
Upper

HR

SE

p-value

1.16
1.11
0.69

0.83
0.77
1.04

0.86
0.89
0.72

0.23
0.25
0.09

5.88
5.07
5.31

0.04
0.04

11.17
6.01

0.78
0.60

0.00
0.00

1.35E+08
5603.88

Note. Abbreviations: HR = Hazard Rate; SE = Standard Error; HP = Isonaizid/Rifapentine; RIF =
Rifampin; INH = Isoniazid.

Table H3
Ad Hoc Analysis Model 4: Medical Co-Morbidities by Visa-Type
Visa
R
109

Variable

Angina Pectoris
Hypertension
Chronic Obstructive Pulmonary Disorder

No
Yes
No
Yes
No
Yes

n
108
1
103
6
108
1

%
99.08%
0.92%
94.50%
5.50%
99.08%
0.92%

I
31
n
31
0
27
4
30
1

%
100.00%
0.00%
87.10%
12.90%
96.77%
3.23%

p-value
0.79a
0.43a
0.63a

(table continues)
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Visa
R
109

Variable

History of TB
History of Stroke
Seizure Disorder
Sexually Transmitted Disease
Diabetes Mellitus
Any Comorbidity

No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes

n
105
4
107
2
107
2
108
1
108
1
94
15

%
96.33%
3.67%
98.17%
1.83%
98.17%
1.83%
99.08%
0.92%
99.08%
0.92%
86.24%
13.76%

I
31
n
29
2
31
0
31
0
31
0
30
1
26
5

%
93.55%
6.45%
100.00%
0.00%
100.00%
0.00%
100.00%
0.00%
96.77%
3.23%
83.87%
16.13%

p-value
0.64a
0.63a
0.63a
0.79a
0.79a
0.93b

Note. aFischer's Exact; bChi-square

Table H4
Ad Hoc Analysis 6: Interaction Between Provider and LTBI Treatment Regimen

Variables

HR

SE

p-value

95 % CI
Lower
Upper

*CPHR with levels of LTBI Treatment Regimen interacting with levels of Prescribing Providera
Treatment Regimen (1: 3HP)
1.00
2.19
1.00
0.01
73.11
Treatment Regimen (2: 4RIF)
1.00
3.51
1.00
0.00
967.07
Treatment Regimen (3: 6INH)
1.00
2.13
1.00
0.02
64.42
Treatment Regimen (4: 9INH)
Provider(1)
2.30
Provider(2)
1.00
2.66
1.00
0.01
90.82
Provider(3)
1.00
2.10
1.00
0.01
182.44
Provider(4)
1.00
1.94
1.00
0.02
61.32
Provider(5)
1.00
2.66
1.00
0.02
45.01
Provider(6)
1.00
4.67
1.00
0.01
182.44
Provider(7)
1.00
2.66
1.00
0.00
9406.45
Provider(8)
1.00
2.66
1.00
0.01
182.44
Provider(9)
1.00
2.82
1.00
0.01
182.44
Provider(10)
1.00
1.90
1.00
0.00
252.18
Provider(11)
1.00
3.53
1.00
0.02
41.54
Provider(12)
1.00
2.92
1.00
0.00
1009.73
Provider(13)
1.00
2.60
1.00
0.00
302.95
Provider(14)
1.00
2.66
1.00
0.01
161.65
Provider(15)
1.00
2.06
1.00
0.01
182.44
Provider(16)
1.00
2.66
1.00
0.02
56.44
Provider(17)
1.00
3.57
1.00
0.01
182.44

(table continues)
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95 % CI
Variables
HR
SE
p-value
Lower
Upper
Provider(18)
1.00
2.12
1.00
0.00
1084.58
Provider(19)
1.00
3.86
1.00
0.02
63.95
Provider(20)
1.00
2.66
1.00
0.00
1913.83
Provider(21)
1.00
3.53
1.00
0.01
182.44
Provider(22)
Provider(1)*Treatment Regimen(1: 3HP)
1.68
1.06
0.62
0.21
13.39
Provider(3)*Treatment Regimen(1: 3HP)
0.00 1,387.84
0.99
0.00
-Provider(4)*Treatment Regimen(1: 3HP)
1.46
1.06
0.72
0.18
11.64
Provider(13)*Treatment Regimen(1: 3HP)
0.00 1,962.70
1.00
0.00
-Provider(18)*Treatment Regimen(1: 3HP)
0.00 1,602.54
0.99
0.00
-Provider(3)*Treatment Regimen(2: 4RIF)
0.00 1,980.31
1.00
0.00
-Provider(4)*Treatment Regimen(2: 4RIF)
0.00
897.17
0.99
0.00
-Provider(6)*Treatment Regimen(2: 4RIF)
0.00 1,980.31
1.00
0.00
-Provider(10)*Treatment Regimen(2: 4RIF)
1.59
1.03
0.66
0.21
12.03
Provider(17)*Treatment Regimen(2: 4RIF)
0.00 1,980.31
1.00
0.00
-Provider(18)*Treatment Regimen(2: 4RIF)‡
11.21
1.06
0.02
1.41
89.08
Provider(1)*Treatment Regimen(3: 6INH)
0.00 1,208.87
0.99
0.00
-Provider(3)*Treatment Regimen(3: 6INH)
0.00 1,191.13
0.99
0.00
-Provider(4)*Treatment Regimen(3: 6INH)
3.53
1.03
0.22
0.47
26.36
Provider(10)*Treatment Regimen(3: 6INH)
0.00 1,684.52
0.99
0.00
-Provider(11)*Treatment Regimen(3: 6INH)
0.00 1,684.52
0.99
0.00
-Provider(17)*Treatment Regimen(3: 6INH)
0.00 1,735.83
0.99
0.00
-Provider(21)*Treatment Regimen(3: 6INH)
0.00 1,684.52
0.99
0.00
-Note. Abbreviations: HR = Hazard Rate; SE = Standard Error; HP = Isonaizid/Rifapentine; RIF =
Rifampin; INH = Isoniazid. *Analyses excluded when Provider did not prescribe Regimen subgroup.
a
Reference Group: Provider 24, 9INH. ‡Denotes statistically significant at p<0.05.
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Table H5
Ad Hoc Analysis 7: Interaction Between Distance and Prescribed Regimen
95 % CI
Variables
HR
SE
p-value Lower
Upper
*CPHR with levels of LTBI Treatment Regimen interacting with levels of Distance Between Residence
and LTBI Treatment Facilitya
Treatment Regimen (1: 3HP)
0.00 184.94
0.97
0.00
8.5E+153
Treatment Regimen (2: 4RIF)
0.92
0.76
0.92
0.21
4.06
Treatment Regimen (3: 6INH)
0.45
1.03
0.44
0.06
3.34
Treatment Regimen (4: 9INH)
1.06
0.62
0.93
0.32
3.55
Distance to Treatment Facility (1: 0-10.9 miles)
Distance to Treatment Facility (2: 11.0-20.9
miles)
0.00 103.44
0.94
0.00
3.64E+84
Distance to Treatment Facility (3: 21+ miles)
Regimen (1: 3HP)*Distance (1: 0-10.9 miles)
0.96
0.78
0.96
0.21
4.43

(table
continues)
Regimen (2: 4RIF)*Distance (2: 11.0-20.9 miles)
0.95
0.75
0.94
0.22
4.13
Regimen (3: 6INH)*Distance (1: 0-10.9 miles)
0.46
1.03
0.45
0.06
3.44
Note. Abbreviations: HR = Hazard Rate; SE = Standard Error; HP = Isoniazid/Rifapentine; RIF =
Rifampin; INH = Isoniazid. *Analyses excluded when Regimen not prescribed for study participant in
Distance subgroup = 0. aReference Group: Regimen 9INH, Distance 21+ miles; Denotes statistically
significant at p<0.05.

